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Abstract 
 
Mesenchymal Stem Cells (MSCs) are multipotent stromal 
cells that can self-renew and differentiate into cells from the 
mesodermal cell lineage. Under specific conditions, MSCs 
are known to transdifferentiate into the neuronal cell 
lineage.  The aim of this study was to investigate if specific 
microRNAs (miRNAs) are responsible for neural induction, 
differentiation and fate specification and if they can induce 
MSCs to commit to a neuroblast and/or mature neuron cell 
lineage. The selected miRNAs were miR-107, miR-124 and 
miR-381, which respectively are known to promote 
neurogenesis, neural differentiation and neural proliferation. 
Targeting protein expression by transiently destroying the 
messenger RNA using miRNAs is an alternative to destroying 
the gene permanently and, being a transient process, the 
cells being differentiated should not retain any permanent 
evidence of this process. The objectives of this study were 
to culture MSCs from the Wharton’s Jelly, transform these 
MSCs into neural-like cells using the spent medium from the 
neuroblastoma cell line SH-SY5Y, and further treat these 
 ix 
 
conditioned cells with retinoic acid to induce further 
maturation. MSCs were characterised by trilineage 
differentiation and all three cell types were tested for a 
series of CD and neural markers. Once characterised, the 
three cell types were transfected with one of the three 
selected miRNAs and a target gene for each miRNA was 
analysed but results were sub-optimal. The MSCs and 
neural-like derivatives were then tested for a selection of 
neural markers. Once again results provided limited 
information, however it was observed that miR-107 and 
miR-124 have the potential to induce MSCs to differentiate 
into neural-like cells and that these miRNAs may also induce 
intermediate neural progenitors and immature neuron cell 
types to differentiate further.  
x 
 
Table of Contents 
 
List of Tables         xiv 
List of Figures         xv 
List of Abbreviations        xvii 
 
Chapter 1: Introduction      1 
 
1.1. Stem Cells         2 
 
1.2. Mesenchymal Stem Cells     5 
1.2.1. Characterisation of Mesenchymal Stem Cells  8 
1.2.1.1. Cluster of Differentiation Markers     8 
1.2.2. Mesenchymal Stem Cells differentiation and  13 
therapeutic potential   
1.2.2.1. Mechanism of differentiation     18 
 
1.3. Neurogenesis       22 
1.3.1. Neural cells        22 
1.3.2. Neural differentiation      23  
1.3.2.1. Neural Progression and Characterisation   28 
1.3.3. MicroRNAs        29 
1.3.3.1. Nomenclature of microRNAs     31 
1.3.3.2. Mechanism of action of microRNAs    32 
1.3.3.3. The role of microRNAs in the regulation of    33 
neurogenesis  
1.3.3.4. MiRNA modulation of stem cell commitment  36 
1.3.4. MiRNA involved in stem cell to neuroblast to  37 
mature neuron differentiation  
1.3.4.1. Rationale for the selection of microRNAs    39 
 
1.4. Rationale and Aims      40 
 
 
xi 
 
Chapter 2: Materials and Methods    43 
 
2.1. Ethical Approval       44 
  
2.2. Experimental Design      44 
 
2.3. Cell Culturing       47 
2.3.1. Medium for cell culturing      47 
2.3.2. Fibrin clots        48 
2.3.3. Culturing of Human Mesenchymal Stem Cells  51 
2.3.3.1. Collection of cord sample     51 
2.3.3.2. Isolation of Human Mesenchymal Stem Cells  52 
2.3.4. Culturing of conditioned Mesenchymal Stem Cells 54 
2.3.4.1. Preparation of spent medium from     54 
SH-SY5Y cells 
2.3.4.2. Conditioning of Mesenchymal Stem Cells   55 
2.3.4.3. Culturing of mature neural-like cells    56 
 
2.4. MSC functional identification     57 
2.4.1. Von Kossa staining       58 
2.4.2. Oil-red-O staining       59 
2.4.3. Alcian Blue staining      60 
 
2.5. RNA extraction and cDNA synthesis   60 
2.5.1. mRNA extraction       61 
2.5.1.1. Cell lysate preparation      61 
2.5.1.2. mRNA extraction procedure     62 
2.5.1.3. Determination of mRNA concentration   63 
2.5.1.4. mRNA cDNA synthesis      64 
2.5.1.4.1. mRNA cDNA synthesis procedure    65 
 
2.6. Polymerase Chain Reaction     66 
2.6.1. Real Time Quantitative Polymerase Chain Reaction 66 
2.6.2. House-keeping Gene       67 
2.6.3. Primers        68 
2.6.3.1. Primer Design       68 
2.6.3.2. Primer preparation       71 
xii 
 
2.6.4. RT-qPCR procedure       71 
2.6.4.1. Interpretation of RT-qPCR data    72 
 
2.7. Transfection       74 
2.7.1. Transfection reagent      75 
2.7.2. Antagomirs and negative controls    75 
2.7.3. Transfection Procedure      76 
 
2.8. Green Fluorescent Protein     78 
2.8.1. Bacterial transformation and plating    78 
2.8.2. Plasmid extraction       79 
2.8.3. Gel electrophoresis      80 
2.8.4. Transfecting Green Fluorescent Protein   82 
 
2.9. Statistical Analysis      82  
2.9.1 Neurite length analysis      82 
2.9.2. RT-qPCR analysis       83 
 
Chapter 3: Results       84 
 
3.1. Cell Culture        85  
3.1.1. Isolation of Mesenchymal Stem Cells    85 
3.1.2. Mesenchymal Stem Cell Trilineage differentiation 87 
 
3.2. Neuronal differentiation of cultured   94 
Mesenchymal Stem Cells 
3.2.1. Conditioned Cells        94 
3.2.2. Conditioned Cells treated with Retinoic Acid  97 
3.2.2.1. Comparing neurite growth between Conditioned  99 
Cells and Retinoic Acid Treated Conditioned Cells 
 
3.3. Characterisation by cluster of differentiation 100 
cell surface markers  
 
3.4. Cell Characterisation by Neural Markers  105 
 
3.5. Transfection of microRNA antagonists   112 
xiii 
 
3.5.1. Transfection Efficiency      112 
3.5.2. The effect of microRNA antagonist transfection on 125 
target genes  
3.5.3. Neural marker RNA expression post-transfection  131 
with microRNA antagonists   
 
Chapter 4: Discussion       146 
 
4.1. Project development      147 
 
4.2. Mesenchymal Stem Cells isolated from   151 
Wharton’s Jelly maintain multipotency 
 
4.3. Mesenchymal Stem Cells can differentiate into 153 
neural-like cells   
 
4.4. Mesenchymal Stem Cells express Neural Markers 157 
 
4.5. MicroRNAs may induce transdifferentiation of  161
 Mesenchymal Stem Cells  
 
4.6. Neural Markers may also be affected by   164
 microRNAs 
 
4.7. Knowledge Contribution     171 
4.7.1. Contributing to the Professional Biomedical Practice 171 
4.7.2. Future investigations of microRNA transdifferentiation 177  
 
4.8. Conclusion        181 
 
References         183 
 
Appendix I: Ethical Approval     214 
Appendix II: Kit Insert      218 
Appendix III: Raw Data      222 
Appendix IV: Statistical Analysis    255
xiv 
 
List of Tables 
 
Table 1.1 Mesenchymal Stem Cells sources and cell surface 11 
markers 
Table 1.2 Neural Markers indicating the stage of neural  29 
differentiation 
Table 1.3 MicroRNA involvement in neuronal development 35  
Table 2.1 Experimental Layout      46 
Table 2.2 RNA and Primer mixture      65 
Table 2.3 Reverse transcription mix     66 
Table 2.4 cDNA synthesis reaction temperatures and duration 66 
Table 2.5 List of Primers       70 
Table 2.6 RT-qPCR reaction volumes     72 
Table 2.7 RT-qPCR set-up       72 
Table 2.8 Antagomirs used for transfection     76 
Table 2.9 Volumes required for transfection    77 
Table 2.10 Volumes required for GFP transfection   82 
Table 3.1 Neurite Length       99 
Table 3.2 Characterisation by CD Marker RNA expression  101 
Table 3.3 Neuronal Markers RNA expression    107    
Table 3.4 Gene Target RNA Expression     127 
Table 3.5 Neural Marker RNA expression post antagonist  132 
transfection  
 
xv 
 
List of Figures 
 
Figure 1.1 Stem cells to neural cell lineage Transdifferentiation 24 
Figure 3.1 Isolation of Mesenchymal Stem Cells from cord 86 
samples 
Figure 3.2 Osteogenic differentiation      88 
Figure 3.3 Adipogenic differentiation     90 
Figure 3.4 Chondrogenic differentiation     92 
Figure 3.5 Conditioning of Mesenchymal Stem Cells to   96 
 Neural-like cells  
Figure 3.6 Morphological appearance of Conditioned Cells with 98 
and without Retinoic Acid treatment 
Figure 3.7 Fold change in CD marker RNA expression between 103 
MSCs and CCs 
Figure 3.8 Fold change in CD marker RNA expression between 104 
CCs and CC-RA 
Figure 3.9 Fold change in Neural marker RNA expression  109 
between MSCs and CCs 
Figure 3.10 Fold change in Neural marker RNA expression  111 
between CCs and CC-RA Cells 
Figure 3.11 Transfection of Cord 9 Mesenchymal Stem Cells  116 
Figure 3.12 Transfection of Cord 11 Mesenchymal Stem Cells  117 
Figure 3.13 Transfection of Cord 5 Conditioned Cells   118 
Figure 3.14 Transfection of Cord 6 Conditioned Cells   119 
Figure 3.15 Transfection of Cord 13 Conditioned Cells   120 
Figure 3.16 Transfection of Cord 5 Retinoic Acid treated  121 
Conditioned Cells 
Figure 3.17 Transfection of Cord 6 Retinoic Acid treated  122 
Conditioned Cells 
Figure 3.18 Transfection of Cord 13 Retinoic Acid treated  123 
Conditioned Cells  
Figure3.19 Transfection of Green Fluorescent Protein  124 
Figure 3.20 Fold change in the Target Gene Marker RNA  130 
expression post miRNA antagonist transfection  
Figure 3.21 NES RNA expression post miRNA antagonists  137 
transfection  
xvi 
 
Figure 3.22 TUBB3 RNA expression post miRNA antagonists 139 
transfection  
Figure 3.23 ND1 RNA expression post miRNA antagonists  141 
transfection   
Figure 3.24 MAP2 RNA expression post miRNA antagonists  143 
transfection   
Figure 3.25 NEU RNA expression post miRNA antagonists  145 
transfection   
 
xvii 
 
List of Abbreviations 
 
AgNP  Silver nanoparticles  
AKT2  V-akt murine thymoma viral oncogene homolog 2 
BDNF  Brain-derived Neurotrophic Factor  
BM  Bone Marrow  
BMP  Bone Morphogenetic Proteins 
CaCl2  Calcium Chloride 
CC  Conditioned Cells  
CD  Cluster of differentiation 
cDNA  Complementary DNA 
CNS  Central Nervous System  
CPP  Cryo Poor Plasma  
Cq  Quantification cycle 
dlx-2  Distal-less Homebox 2 
DMEM/F-12 Dulbecco's Modified Eagle Medium: Nutrient Mixture 
F-12 
DMSO  Dimethyl Sulfoxide 
E2F3  E2F Transcription Factor 3 
EDTA Ethylenediaminetetraacetic acid disodium salt 
dihydrate  
EGF Epidermal Growth Factor 
EPHB2  Ephrin type-B receptor 2 
FBS  Foetal Bovine Serum  
FGF  Fibroblast Growth Factor 
FLNA  Filmin Alpha 
FOXO  Forkhead Transcription Factor Family O 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase,  
GFP   Green Fluorescent Protein 
GO  Graphene Oxide 
HES1  Hairy and Enhancer of Split 1  
HES1/3  Hairy and Enhancer of Split 1/3 
HNF4A  Hepatocyte Nuclear Factor 4 Alpha 
HSC  Haematopoietic Stem Cells 
IGF  Insulin-like Growth Factor 1  
iPSCs  Induced Pluripotent Stem Cells 
ISCT  International Society for Cellular Therapy  
LB  Luria Broth 
KCNQ2 Potassium Voltaged-Gated Channel Subfamily Q 
Member 2 
MAP2  Microtubule-associated protein 2 
xviii 
 
MASH-1  Mammalian Achaete-Scute Homolog-1  
MiRNAs  MicroRNAs  
mRNA  Messenger RNA 
MSC  Mesenchymal Stem Cell 
ND1  NeuroD1 
NEFM  Neurofilament Medium Polypeptide 
NES  Nestin 
NEU  Neuronal-specific Nuclear Protein 1 
NGF  Neural Growth Factor 
NSCs   Neural Stem Cells 
NTC  Non-Template Control 
OCT4   Octamer-binding Transcription Factor 4  
P/S  Penicillin/streptomycin  
PAX 6   Paired-box Protein 6  
PBS  Phosphate buffer saline 
PCR  Polymerase Chain Reaction 
Pre-miRNA  Precursor miRNA  
PSD95  Postsynaptic Density Protein 95 
PTP1B  Polypyrimidine Tract-Binding Protein 1 
RA  Retinoic Acid 
RA-CCs  RA-treated CCs 
REST  RE-1 silencing transcription factor 
RT  Reverse Transcription 
RT-qPCR  Real Time Polymerase Chain Reaction 
Runx2  Runt-related Transcription Factor 2 
SCNBA Sodium Channel Protein Type 1 Subunit Alpha 
SCP1  Small C-terminal domain Phosphatase 1 
Shh   Sonic Hedgehog 
SiRNA/SiR  MicroRNA antagonist 
SOX10  Sex Determining Region Y-Box 10 
SOX2  Sex Determining Region Y-Box 2 
SOX9  Sex Determining Region Y-box 9 
SYN2  Synapsin II 
TAE  Tris-acetate-EDTA 
TB Fix  Tokuda-Baron Fixative 
TBR1  T-box brain protein 1 
TBR2  T-box brain protein 2 
TGF  Transforming Growth Factor 
TGF-β  Transforming Growth Factor- beta  
Th  Tyrosine hydroxylase 
TUBB3  Beta III Tubulin 
Wnt   Wingless-type MMTV integration site  
ZIC   Zinc Finger Marker  
1 
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Introduction 
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1.1. Stem Cells  
Stem cells are undifferentiated cells with the unique 
property to become specific cells that make up tissues and 
organs. The term “Stem Cell” is a generalised terminology 
for cells displaying two fundamental characteristics defined 
as stemness properties i.e. self-renewal, where cells create 
identical copies of themselves; and differentiation, during 
which these cells become specialised and are then 
committed to one specific cell lineage.  Stemness markers 
such as Nanog a transcription factor which regulates stem 
cell pluripotency (Allouba et al., 2015), Octamer-binding 
Transcription Factor 4 (OCT4) a gene essential for somatic 
cell reprogramming (Zeineddine et al., 2014) and Sex 
Determining Region Y Box 2 (SOX2), a transcription factor 
that plays an important role in the maintenance of 
pluripotency (Park et al., 2012), also characterise these cells 
(Yu et al., 2016). Stem cells maybe (i) totipotent  and so 
may give rise to any type of cell; (ii) pluripotent meaning 
that they may become any cell type apart from those of 
extraembryonic origin; (iii) or multipotent, which may 
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develop into cell types of a specific lineage (Singh et al., 
2016). Cells which pertain to the stem cell category include: 
 Embryonic Stem Cells which originate from the 
blastocyte and appear only during the early stages of 
development. These are termed as pluripotent stem 
cells since they lack the ability to differentiate into  
non-embryonic cells such as placenta (Singh et al., 
2016). 
 Tissue Specific Stem Cells or adult stem cells 
consisting of more specialised cells such as 
Hematopoietic Stem Cells (HSCs). These cells are 
multipotent stem cells (Cheng, Zheng and Cheng, 
2020). They have a limited differential potential and 
are normally committed into becoming a predefined 
cell type and do not differentiate into other cell types. 
 Mesenchymal Stem Cells (MSCs) which are 
traditionally found in the bone marrow (BM) stroma. 
These cells are considered to be multipotent stem cells 
(Caplan, 2017) and may differentiate into cells of the 
mesodermal germ layer but may also 
transdifferentiate into cell types pertaining to 
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endodermal and ectodermal origin. 
Transdifferentiation is when a cell type pertaining to 
one particular tissue or organ is able to convert itself 
into a cell of a completely different tissue or organ 
without the need of reverting back to a pluripotent 
stage (Mollinari et al., 2018).  MSC cells were first 
isolated and described in 1976 by Friendenstrein et 
al., as fibroblast-like cells belonging to the 
hematopoietic group of cells that functioned as 
supportive cells of the BM (Zhang et al., 2018). MSCs 
were subsequently isolated from BM cultures as plastic 
adherent stromal cells capable of differentiating into 
mesoderm-derived cells.  
 Induced Pluripotent Stem Cells (iPSCs) are in-vitro 
modified somatic cells which have reverted to their 
embryonic stage. As the name implies these cells are 
of the pluirpotent type. 
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1.2. Mesenchymal Stem Cells 
MSCs are multipotent stromal cells that are capable of self-
renewal and may differentiate into a variety of cell types 
which include osteoblasts, chondrocytes, myocytes and 
adipocytes (Ullah, Subbarao and Rho, 2015). Originally, 
these cells where thought to originate from the BM as a sub-
population which supports the function of BM cells. 
However, these stromal cells are today recognised as multi-
linage cells which are also found in adipose tissue, amnion, 
synovial fluids, muscles, dermis, teeth pulp and umbilical 
tissue (Lv et al., 2014). The functions of MSCs are related to 
immunomodulation and regeneration (Caplan and Hariri, 
2015), and involves both the paracrine and endocrine 
systems (Hoogduijn and Dor, 2013). 
 
Isolation of MSCs from BM samples is met with reluctance in 
terms of ethical approval, availability and collection, since 
sampling may result in pain, bleeding or infection 
(Berebichez-Fridman and Montero-Olvera, 2018). 
Furthermore, in Malta, it is very difficult to obtain BM 
samples for research purposes and most of the donated are 
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in the form of a few grams of BM scrapings. These samples 
are obtained by scrapping off some BM from the thorax 
during open heart surgery and mainly consist of bone which, 
in conjunction with the small amount collected, are not 
suitable for cell culture. Due to the limitation of securing 
adequate BM samples, for this project Wharton’s Jelly was 
chosen as the source for the isolation of MSCs.  
 
Non-foetal derived MSCs may also differentiate into several 
cell lineages (West et al., 2016) and this differentiation 
method provided an alternative solution to somatic cell 
transfection with the added advantage of having both a 
lower tumorigenic risk and a lower risk of grafting rejection 
(Cortés-Medina et al., 2019). In this project, once MSCs 
were isolated from the Wharton’s Jelly, transdifferentiation 
of these cells into neural-like cells was induced by a 
selection of microRNAs (miRNAs). Transdifferentiaiton of 
MSCs is the result of the combined effort of several factors. 
Knowing whether miRNAs directly involved in neurogenesis 
may induce such a change would help better elucidate such 
mechanisms.  In a similar study conducted by Cortés-
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Medina et al. (2019), MSCs cultured from BM, umbilical cord 
and placenta, dental tissue and skin were induced to 
transdifferentiate into neural-like cells by supplementing cell 
culture medium with ICFRYA, a small molecule cocktail. 
Transdifferentiation of the MSCs was then confirmed via 
neuronal morphology and function, neuronal marker 
analysis and downregulation of CD90 and CD105. The 
transdifferentiation of adult-derived MSCs is, however, very 
limited. Although Cortés-Medina et al., demonstrated that it 
is possible to induce the neural differentiation of MSCs, they 
were not able to induce this change from all the different 
sources tested. A full differentiation was achieved in MSCs 
isolated from BM and umbilical cord blood and a partial 
differentiation was seen with the cells derived from the 
dental tissue and skin sources. No differentiation was 
reported from MSCs isolated from Wharton’s Jelly. This 
demonstrated that although MSCs have the potential to 
transdifferentiate not all sources are ideal. 
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1.2.1. Characterisation of Mesenchymal Stem Cells 
The standardised attributes defining MSCs were declared by 
the International Society for Cellular Therapy (ISCT) 
(Dominici et al., 2006) and these are: 
1. plastic adherence 
2. expression of CD105, CD73 and CD90, and lack of 
expression of CD45, CD34, CD14, CD79alpha and 
HLA-DR surface molecules.  
3. in vitro differentiation into osteoblasts, adipocytes 
and chondrocytes.  
 
1.2.1.1. Cluster of Differentiation Markers  
Cluster of differentiation (CD) molecules perform a variety 
of cellular functions but are commonly referred to in terms 
of being membrane proteins found on the cell surface that 
identify the cell, monitor differentiation stages and sort cell 
sub-populations. These markers have been used both in 
research and diagnosis and recently have been employed in 
the treatment of several malignancies and autoimmune 
diseases (Engel et al., 2015). More than 400 CD markers 
have been identified and each is assigned a number which 
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identifies a group of surface antibodies (Dawson and 
Lunney, 2018).  
 
In their position paper, Domenici et al. do not indicate how 
the ISCT establish how the selected CD markers may or 
may not identify a cell as an MSC in terms of a specific 
cellular function. However, CD73 expression regulates the 
phenotypes of T and Natural Killer Cells and also acts as a 
cell marker for progenitor stem cells (Monguió-Tortajada et 
al., 2017). CD105 is a component of the receptor complex 
of transforming growth factor-beta (TGF-β) which is 
involved in cell proliferation, differentiation and migration 
(Maleki et al., 2014). The role of CD90 in MSCs is still 
unknown (Moraes et al., 2016), however it is postulated 
that this is a marker for MSC progenitors (Michelis et al., 
2018). CD45 and CD34 are markers of HSC and progenitor 
cells, and MSCs are not hematopoietic cells (Sidney et al., 
2014). CD14 acts as a co-receptor expressed mainly by 
macrophages, neutrophils and dendritic cells (Jiang et al., 
2019). CD79 is a B-cell marker, and MSCs are not members 
of this family (Healy et al., 2015); since one of the 
10 
 
properties of MSCs is their immune modulatory effect, these 
cells should be HLA-DR negative.  
 
MSCs may be isolated from different sources and different 
species, so a wider range of CD markers are now being 
used, which allows for further cell differentiation. The CD 
marker characterisation established by the ISCT was based 
on BM-derived MSCs and does not take into consideration 
the source of origin or the isolation technique used 
(Okolicsanyi et al., 2015). However, identification of MSCs 
should not be limited to these CD markers since MSCs 
derived from other sources possess less defined 
characteristics (Ullah, Subbarao and Rho, 2015) and most 
importantly, no CD marker is specific for MSCs (Davies et 
al., 2015). Table 1.1 categorises the use of CD markers 
according to the source from where the MSCs were 
originally obtained. 
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Source Positive Markers Negative Markers Source 
Bone marrow CD73, CD90, CD105, STRO-1 CD14, CD34, CD45, HLA-DR 
  
Pittenger et al., 1999; Mamidi et al., 2012; 
Otsuru et al., 2013; Gronthos et al., 1994 
Adipose tissue CD73, CD090, CD29, CD44, 
CD71, CD105, CD13, CD166, 
STRO-1 
CD14, CD31, CD34, CD45 Wagner et al., 2005; Zhang et al., 2011; 
Pendleton et al., 2013; Gronthos et al., 2001; 
Baglioni et al., 2009 
Amniotic fluid 
and membrane 
CD29, CD44, CD90, CD105, 
SH2, SH3, HLA-DR 
CD10, CD14, CD34, HLA-DR In ’t Anker et al., 2003; Tsai et al., 2004;  
Cai et al., 2010 
Dental tissue CD29, CD44, CD90, CD105 CD14, CD34, CD45 Huang, Gronthos and Shi, 2009;  
Seifrtová et al., 2012; Kadar et al., 2009 
Endometrium CD73, CD90, CD105, CD146 CD34, CD45 Schüring et al., 2011 
Limb bud CD13, CD29, CD90, CD105, 
CD106 
CD3, CD4, CD14, CD15, CD34, 
CD45, HLA-DR 
Jiao et al., 2012 
Peripheral blood CD44, CD90, CD105, HLA-ABC CD45, CD133 Ab Kadir et al., 2012 
Placenta and 
foetal membrane 
CD29, CD73, CD90, CD105 CD34, CD45 Raynaud et al., 2012 
Salivary gland CD13, CD29, CD44, CD90, 
STRO-1 
CD34, CD45 Rotter et al., 2008; Riekstina et al., 2008 
Skin and 
Foreskin 
CD44, CD73, CD90, CD105, 
CD166, SSEA-4, Vimentin 
CD34, CD45, HLA-DR Bartsch et al., 2005 
Sub amniotic 
umbilical cord 
lining membrane 
CD29, CD44, CD73, CD90, 
CD105 
CD34, CD45 Wagner et al., 2005; Kita et al., 2010;  
Moretti et al., 2010 
Synovial fluid CD44, CD90, CD105, CD147, 
STRO-1 
CD31, CD34, CD45, CD106 Morito et al., 2008 
Wharton’s jelly CD73, CD90, CD105 CD14, CD34, CD45, CD79, HLA-
DR 
Hou et al., 2009; Kuznetsov et al., 1997 
Table 1.1: Mesenchymal Stem Cells sources and cell surface markers (adapted from Ullah, Subbarao and Rho, 2015) 
12 
 
In this project, MSCs were characterised by tri-lineage 
differentiation, followed by a panel of CD markers. As 
illustrated in Table 1.1, MSCs isolated from Wharton’s Jelly 
are characterised as being positive for CD73, CD90, CD105 
and negative for CD14, CD34, CD45 and CD79. All three 
recommended positive markers, that is, CD73, CD90 and 
CD105 were tested in this project. CD73 was chosen in view 
that neural cells are negative for CD73 and this would 
indicate that MSCs would have tansdifferentiaiton into 
neural-like cells. Both CD90 and CD105 are expressed by 
neural cells. Two negative markers, CD34 and CD45, were 
selected out of the recommended panel of negatives 
because CD34 may also be expressed by neuroblastoma and 
neural cells that are not fully mature, while CD45 is the 
most commonly used negative CD marker for the 
characterisation of MSCs and is also not expressed by neural 
cells. 
 
As previously discussed, these markers do not pertain 
exclusively to the characterisation of the MSC lineage: CD73 
is an ecto-enzyme and a key molecule that regulates cancer 
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progression (Buisseret et al., 2018); CD90 is a glycoprotein 
marker highly associated with brain, kidney and pancreatic 
tumours (Sauzay et al., 2019); CD105 is a marker for 
tumour-related vascular endothelial cells (Kasprzak and 
Adamek, 2018); CD34 a transmembrane 
phosphoglycoprotein that acts as a marker for different cell 
progenitors including muscle satellite cells, corneal 
keratocytes, interstitial cells, epithelial progenitors, and 
vascular endothelia progenitors but used primarily for 
the selection and enrichment of HSCs for BM transplants 
(Sidney et al., 2014); and CD45 is a protein tyrosine 
phosphatase enzyme expressed by lymphoid cells 
responsible for cell proliferation and postulated to be a 
potential target for cancer drug treatment (Perron and 
Saragovi, 2018). 
 
1.2.2. MSC differentiation and therapeutic potential 
The three germ layers arise during the early stages of the 
embryonic development during the process of gastrulation.  
After an egg has been fertilised, the zygote eventually 
becomes a blastocyst. The blastocyst contains an inner cell 
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mass which eventually will develop into the organism. The 
outside of the blastocyst contains trophoblast cells and the 
inside contains an inner core known as the blastoseal. This 
inner core contains a fluid which nourishes the inner cells of 
the inner cell mass. As the blastocyst develops the 
trophoblasts differentiate into syncytial-trophoblasts and 
cyto-trophoblasts. The syncytial-trophoblasts become 
invasive and release digestive enzymes allowing the 
blastocyst to implant into the endometrium of the uterus. 
The syncytial-trophoblasts embedded in the endometrium 
lining will later develop into the placenta. Eventually the 
blastocytes will enter the endometrium of the uterus where 
the inner cell mass will begin to differentiate into two layers, 
which are composed of the epiblast (the lower layer) and 
the hypoblasts (the upper layer) cells. The two layers will 
continue to develop forming cavities within each other but 
will remain connected to the rest of the cells via the 
connecting stalk. The epiblast cells migrate into the midline 
to form the primitive streak. Some of the epiblast cells will 
migrate into the primitive streak and enter the hypoblast 
layer creating the endoderm. The epiblast cells which do not 
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migrate will differentiate and become the ectodermal layer. 
At this stage the majority of epiblast cells would be 
occupying the space between the epiblast and hypoblast 
layers. These cells will differentiate and form the 
mesodermal layer. The ectoderm layer will give rise to the 
outer cells of the body such as skin and hair but will also 
develop into the nervous system and the neural crest which 
eventually structures the face and brain. The endoderm is 
responsible for the development of the inner organ cells, 
while the mesoderm will form muscles and bones (Solnica-
Krezel and Sepich, 2012). 
 
MSCs differentiate into cells pertaining to the mesodermal 
germ layer, but under certain conditions, these cells may be 
induced to differentiate into cells belonging to the 
ectodermal and endodermal linages. This mechanism of 
transdifferentiation led to the development of promising 
cell-based therapies for the treatment of both neurological 
and endocrine disorders.  
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Ectoderm MSC differentiation produces cells of the nervous 
system and epidermis. MSCs are known to transdifferentiate 
into the cells of the ectodermal cell linage when treated with 
growth factors such as hepatocyte growth factor, Fibroblast 
Growth Factor (FGF) and Epidermal Growth Factor (EGF) 
(Datta et al., 2011). Other studies postulate that a 
combination of the transcription factor neurogenin-1 and 
LIM homoeobox transcription factor 1 (Barzilay et al., 
2009), β-Mercaptoethanol and nerve growth factor (Naghdi 
et al., 2009), and factors like insulin and retinoic acid (RA) 
enhance the differentiation of MSCs into neural-like cells 
(Ullah, Subbarao and Rho, 2015).  
 
Endodermal differentiation causes MSCs to 
transdifferentiated into either pancreocytes or hepatocytes. 
The possibility of differentiating MSCs into pancreocytes has 
successfully resulted in the culturing of insulin producing -
cells (Tang et al., 2012) which is intended to replace the 
standard drug therapeutic approach to Diabetes with a more 
tailored cell-based therapy. To a lesser degree of success, 
hepatocytes have also been obtained from MSCs, however 
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their ability to differentiate and thus be used for therapeutic 
applications requires further elucidation (Ullah, 
Subbarao and Rho, 2015). 
 
Two properties of MSCs - their multipotentiality and ease of 
isolation - show the potential of using these cells for tissue 
engineering and therapeutic applications for ischemic, 
inflammatory, and immunological disorders such as sclerosis 
(Fellows et al., 2016). The therapeutic effectiveness of MSCs 
is associated with their unique characteristic of homing to 
the site of tissue injury or inflammation after systemic 
administration (Kariminekoo et al., 2016), their ability to 
differentiate into various cell types, stimulate the recovery 
of damaged cells and inhibit inflammation by secreting 
multiple bioactive molecules such as cytokines, growth 
factors, and chemokines (Taran et al., 2014; Wang, Yuan 
and Xie, 2018) and the absence of immunogenicity, which 
makes performing immunomodulatory functions possible 
(Mukonoweshuro et al., 2014). 
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1.2.2.1. Mechanism of differentiation 
MSC differentiation entails (i) lineage commitment, during 
which MSCs transform into lineage-specific progenitors, and 
(ii) maturation, where the progenitors become specific cell 
types. Several signalling pathways regulate the lineage 
commitment of MSCs, including TGFβ/bone morphogenetic 
protein (BMP) signalling, Wingless-type MMTV integration 
site (Wnt) signalling, Sonic Hedgehog (Shh), Notch, and 
FGFs (Chen et al., 2016). These pathways are activated via 
the interaction of MSCs and the microenvironment which is 
composed of various extracellular matrix components, 
growth factors, cytokines, and chemokines that 
consequently activate or inhibit cell lineage commitment. 
Transdifferentiation is the result of a change in the 
expression of a master regulator gene which is responsible 
for the normal development of one specific tissue (Li et al., 
2005). This change is finely regulated by cellular signalling 
pathways which are in turn dependent on key transcription 
factors (Chen et al., 2016). Transcription factors responsible 
for cell fate determination in MSCs are: PPARγ for the 
adipocyte commitment; and Runt-related transcription 
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factor 2 (Runx2) for osteogenesis and chondrogenesis 
differentiation. The osteo/adipocyte balance is dependent on 
the expression of these factors where an increased PPARγ 
expression will inhibit osteogenesis (Moerman et al., 2004). 
In vivo this imbalance is mostly seen in osteoporosis 
patients and is described as an increase in BM adiposity. 
Similarly, an increased expression of Runx2 will sustain 
osteogenesis and suppress the production of adipocytes 
(Huang et al., 2010).  
 
To be able to differentiate into the desired cell lineage, stem 
cells are required to undergo several progression stages 
(Lee, Abdeen and Kilian, 2014). In vivo, transdifferentiation 
is a natural process. It is a vital mechanism during the 
development of the new cell lineage and plays a critical role 
during the developing and regenerative processes since 
functional cells of different lineages need to be formed from 
distinct stem cells (Sisakhtnezhad and Matin, 2012). During 
development, cell fate specification is determined by a 
complex set of transcription factors and epigenetic 
networks. This process is no longer considered as 
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irreversible and in vitro it is now possible to bring about 
transdifferentiation of certain cells by inserting lineage-
specific transcription factors into these cells. However 
although highly efficient results have been seen, unlike 
iPSCs, transdifferentiaiton can be unstable and cells may 
lose their pluripotent properties.  
 
There are two ways in which a cell may transdifferentiate. 
The first is a direct differentiation where the cell 
differentiates completely into a new cell type. The other 
method is known as a two-stage differentiation. In this case 
during transdifferentiation the cell will undergo partial 
differentiation. At this stage, the cell cycle is stopped so that 
the chromatin may be modified. This modification alters the 
cell-specific transcription and causes both epigenetic and 
chromosome architecture modifications. Once cell fate is 
committed, the cell will continue to differentiate into the 
desired cell lineage (Sisakhtnezhad and Matin, 2012). These 
transition intervals permit progenitors, which are not yet 
committed to a specific cell lineage, to be reprogrammed 
back to the multipotent stem cell state (Zhang and Kilian, 
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2013). Early differentiation in vitro is generally triggered by 
specific media formulations of small molecules and proteins, 
such as in the case of the tri-lineage characterisation of the 
MSCs, in which cells are forced to differentiate into 
osteocytes, adipocytes and chondrocytes using induction 
(differentiating) media. Synthetic matrices that modify the 
microenvironment have also been used to bring about cell 
differentiation (Bloom and Zaman, 2014); for example, 
culturing MSCs on scaffolds creates a 3D environment which 
mimics that found in vivo thus preserving their pluripotent 
gene expression (Zhou et al., 2017). This cell modulation is 
possible through signalling pathways responsible for cell 
specificity which are triggered by extracellular signals which 
activate transduction cascades that regulate gene 
expression and cell fate (Zhang and Kilian, 2013).  In fact, 
early markers for osteogenesis and neurogenesis, such as 
Runx2 and Beta III Tubulin (TUBB3) respectively, are more 
likely to respond to the microenvironmental change than 
later markers like osteopontin and Microtubule-associated 
protein 2 (MAP2) (Lee, Abdeen and Kilian, 2014). 
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The changes seen during this transformation may not be the 
result of a true transdifferentiation but may be a 
consequence of external factors such as cell fusion. To 
determine that transdifferentiation has actually occurred the 
cells must satisfy two important criteria which are (i) the 
differentiation stage of the cell before and after 
transdifferentiaiton and, (ii) demonstrate the cell lineage of 
the two cells types (Li et al., 2005). 
 
1.3. Neurogenesis 
1.3.1. Neural cells   
The neural cell lineages evolve from neuroectodermal 
progenitor cells which become Neural Stem Cells (NSCs) 
(Kessaris, Pringle and Richardson, 2008). Neuronal 
progenitors undergo an additional differential stage and 
subdivide into neurones and glia (Shenoy and Blelloch, 
2014).   
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1.3.2. Neural differentiation 
The in vitro transition from stem cells to neural cells (Figure 
1.1.), involves several complex procedures including, but 
not limited to: cell proliferation, fate specification, 
differentiation and maturation. To proceed to ectodermal 
differentiation, stem cells need to lose their original 
characteristic feature markers such as Nanog, OCT4 and 
SOX2. This loss of stemness is brought about by inducing 
agents such as BMP signalling inhibitors Noggin and 
dorsomorphin, and TGFβ inhibitor SB431542 (Madhu et al., 
2016).  
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Figure 1.1: Stem cells to neural cell lineage Transdifferentiation 
(Mishra, Derynck and Mishra, 2005) 
Stem cells differentiate into neuroectodermal progenitors in the 
presence of Noggin, SB431542 and dorsmorphin and subsequent 
interference of the TGF-β/Activin/NODAL pathways. FGF and Shh 
signalling pathways together with RA further differentiate these 
progenitors into NSCs which are influenced in turn by the reactivation of 
the TGF-β pathways that promote NSC proliferation and by the Wnt 
signalling pathway which determines cell specification.  
Legend: OCT4 - Octamer-binding transcription factor 4, SOX2 - Sex 
determining region Y-Box 2, BMP - Bone Morphogenetic Proteins, ZIC – 
zinc finger marker, FOX - Forkhead transcription factor, FGF – Fibroblast 
Growth Factor, RA – Retinoic acid, Shh – Sonic Hedgehog, Pax6 - Paired 
box protein 6, NGF – neural growth factor, BDNF - Brain-derived 
neurotrophic factor, TGF – Transforming Growth Factor, PAX6 - paired-
box protein 6 . 
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SB431542, a selective and potent inhibitor of the TGF-
β/Activin/NODAL pathway (Taïhi et al., 2019), replaces 
SOX2 during reprogramming (Zheng et al., 2018), and in 
conjunction with Noggin, a protein responsible for neural 
growth, it promotes neural progenitor differentiation 
(Chambers et al., 2012). Once neuroectodermal progenitors 
are formed, the original stemness markers are replaced with 
other neuro-ectoderm gene markers such as Zinc Finger 
Marker and Forkhead Transcription Factor (Wu et al., 2016). 
Dorsomorphin inhibits the BMP signalling pathway 
(Dasgupta and Seibel, 2018), halting embryogenesis and 
promoting neural differentiation (Feng et al., 2016). Once 
the neuroectodermal progenitors are formed the FGF 
signalling pathway causes neural induction by inhibiting the 
expression of BMP ligands (Dorey and Amaya, 2010). Neural 
differentiation is further encouraged by the release of RA, a 
metabolite of Vitamin A and signalling molecule that 
modulates the development and maintenance of the Central 
Nervous System (CNS) (Oliveira et al., 2018). The Shh 
signalling pathway further induces the differentiation of 
these progenitors into NSCs by promoting self-renewal and 
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proliferation (Liebelt et al., 2016). The differentiation of 
neuroectodermal progenitors to NSCs is confirmed by the 
presence of gene markers such as Nanog and Paired-box 
Protein 6 (Su et al., 2018). Once NSCs are formed, the 
reactivation of the TGF-β pathway induces the proliferation 
of these NSCs, thus sustaining neurogenesis. Rather than 
proliferation, the Wnt signalling pathway further promotes 
the differentiation of NSCs, determining cell specification 
(Navarro Quiroz et al., 2018). 
 
Different studies have shown how MSCs are able to 
differentiate into neural cell types either by using induction 
agents which are added to the culturing media. Neuronal 
inducing agents include RA, brain-derived neurotrophic 
factor (BDNF), and phorbol esters, as well as vasoactive 
intestinal peptide, graphene oxide (GO), silver nanoparticles 
(AgNP), and GO-AgNP nanocomposites (Abdal Dayem et al., 
2018); or the use of conditioned media  from co-cultured 
neural cells such as neurons, oligodendrocytes, and 
Schwann cells (Takeda and Xu, 2015). In their study, Abdal 
Dayem et al. compare parameters for cells which were 
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treated with the RA neural inducing agent to AgNP-treated 
cells. AgNP have several beneficial properties but may also 
result in cytotoxicity (Xu et al., 2013). Abdal Dayem et al. 
report no cytotoxicity in the initial stages of neural induction 
and conclude that the higher reactive oxygen species 
generation enhances the expression of neuronal 
differentiation genes which subsequently results in neurite 
growth. On the other hand, as a result of the AgNP-
treatment, they also report a downregulation of the 
expression of the genes encoding the antioxidant enzymes 
which may damage the neural cells. In this study MSCs 
have been made to transdifferentiate into cells of the 
neuronal cell lineage by adding conditioned medium 
obtained from the culturing of SH-SY5Y. The SH-SY5Y are 
human neuroblastoma-derived cells used in research as in 
vitro models for neural function and differentiation. After 
treating the MSCs with the spent medium the resultant fold 
change for both CD and neural  markers seen between the 
treated and untreated cells was statistically significant when 
tested with Mann-Whitney U. P value <0.05 thus accepting 
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the alternative hypothesis that there is a  difference 
between the two cells types.  
 
1.3.2.1. Neural Progression and Characterisation 
Neuroepithelial cells are neural progenitors that constantly 
self-renew and produce post-mitotic cells (Yamashita, 2013) 
which pass through multiple stages to finally become 
mature neurons (Wang et al., 2014). Once neurons mature 
they lose their stemness properties and are able to receive, 
process and transfer information throughout the CNS (Kole, 
Annis and Deshmukh, 2013). Neural stage markers (Table 
1.2) are expressed by cells that are formed during 
neurogenesis which have been committed to the neuron cell 
linage and these help distinguish between cells which have a 
neural phenotype from other brain cell types (Tanapat, 
2016). 
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 Neural Cell Type 
 Neuroepithelial 
cells 
Intermediate 
Progenitors 
Immature 
Neurons  
Mature Neurons 
Neural 
Marker 
NES  
SOX2 
Notch1  
HES1/3 
E-Cadherin 
Occludin 
SOX10 
TBR2 
MASH1 
ND1 
TUBB3 
Doublecortin 
TBR1 
Stathmin1 
MAP2 
NEU 
Synaptophysin 
160kDa 
Neurofilament 
medium 
200kDa 
Neurofilament 
heavy 
PSD95 
Table 1.2.: Neural Markers indicating the stage of neural differentiation 
Legend: NES – Nestin, ND1 – NeuroD1, TBR2 - T-box brain protein 2, MAP2 - 
Microtubule-associated protein 2, SOX2 - Sex determining region Y-Box 2, 
TUBB3 - Beta III Tubulin, MASH-1 - mammalian achaete-scute homolog-1, NEU 
- neuronal-specific nuclear protein 1, Hes1/3 – Hairy and enhancer of split 1/3, 
SOX10 - Sex determining region Y-Box 10, TBR1 - T-box brain protein 1 and 
PSD95 – Postsynaptic density protein 95. 
 
1.3.3. MicroRNAs 
First discovered in Caenorhabditis elegans (Lee, Feinbaum 
and Ambros, 1993), miRNAs are a family of small, non-
coding single stranded RNAs of approximately 22 
nucleotides in length that bind to the complementary 
sequences in the 3’ untranslated regions of their messenger 
RNA (mRNA) targets (De Antonellis et al., 2014). Once 
bound, these miRNAs become targets for degradation and 
negatively regulate protein expression (Elramah, Landry and 
Favereaux, 2014). This regulation is achieved by repressing 
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translation and/or decreasing transcript stability (Ristori et 
al., 2015), causing the mRNA to degrade and consequently 
affect cell proliferation, differentiation, apoptosis or other 
biological processes (Mahmoudi and Cairns, 2017).  
 
MiRNAs regulate the majority of protein coding genes and 
apart from acting as translation inhibitors, they are also 
directly related to the development and progression of many 
cancers (Manier et al., 2017). Holistically, neurogensis 
involves the self-renewal and fate specification of NSCs, the 
migration and maturation of young neurons and the 
functional integration of new neurons into the neural cavity. 
By base pairing with the target mRNA and subsequent 
regulation of the target gene expression, miRNAs are 
directly involved in all the phases of neurogenesis (Winter, 
2015). During this process, miRNAs are themselves 
regulated by transcription factors such as TLX and epigenic 
factors such as MeCP2 and MBD1 (Shi et al., 2010).  
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1.3.3.1. Nomenclature of microRNAs 
The miRNA naming system follows the miRBase repository 
guidelines (Ambros et al., 2003; Meyers et al., 2008) in the 
form of a three-letter species abbreviation, followed by the 
letters mir/miR and finally a qualifier number. The three 
letter species abbreviation represents the species of the 
miRNA being referred to, for example: ‘hsa' is for Homo 
sapiens, while ‘mmu’ is for Mus musculus. The subsequent 
use of ‘mir’ refers to the primary or precursor form of the 
miRNA, whereas ‘miR’ refers exclusively to the mature form. 
The number assigned to each miRNA is a unique identifier 
and is assigned in sequential order.  Furthermore, the 
identifier number may be appended by a dash-number, 
letter, or the suffix 5p or 3p. The dash-number refers to two 
miRNAs with identical mature sequences transcribed from 
different locations within the genome. The letter indicates 
that the two miRNAs are related to each other, i.e. their 
mature sequences are very similar. The suffix 5p or 3p 
refers to the mature miRNA formed from the 5' arm of the 
hairpin loop, for example: Homo sapiens (Hsa) miR-7-3p 
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refers to the mature miRNA formed from the 3' arm of the 
hairpin loop (Bernardo et al., 2012). 
 
1.3.3.2. Mechanism of action of microRNAs 
Translation inhibition is a four-step process (Oliveto et al., 
2017). In the first stage, the primary transcript folds on 
itself to form a stem-loop structure, which is then cropped, 
forming hairpins known as precursor miRNA (pre-miRNA). 
Cropping is performed by the microprocessor formed by the 
combination of the RNase enzyme Drosha and the cofactor 
DiGeorge syndrome chromosomal region 8. These hairpins 
are shuttled to the cytoplasm by Exportin 5 where the pre-
miRNA is cleaved by Dicer, an RNase III enzyme in the 
cytoplasm. Dicing creates the “Guide Strand” and the 
“Passenger Strand” and these are then loaded on the 
Argonaut protein after which the “Passenger Strand” is 
destroyed. In the final step, the “Guide Strand” together 
with the Argonaut form the RNA Interference Silencing 
Complex and this complex then binds to the target mRNA to 
promote gene silencing and thus represses translation 
(Buhagiar and Ayers, 2015). 
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1.3.3.3. The role of microRNAs in the regulation of 
neurogenesis 
The function of miRNAs in the nervous system is to promote 
axonal development, modulate synaptic activity and support 
regeneration of peripheral nerve tissues (Lai and 
Breakefield, 2012). 
 
The CNS expresses large amounts of miRNAs, which in 
addition to miRNA sequences and their targets not being 
well defined limits the current knowledge on miRNA 
regulation during neurogenesis. However a deeper insight is 
now possible as specific neural cell types may be derived 
from human pluripotent stem cells (Stappert, Roese-Koerner 
and Brüstle, 2015). MiRNAs modulate post-mitotic neural 
cell proliferation during the development of the CNS, 
inducing a balance between proliferation and differentiation 
of neural progenitors (Ristori et al., 2015). In their study 
Ristori et al. show that during development of the hind-brain 
miR-107 controls DICER expression by targeting another 
miRNA (miR-9) which controls neurogenesis. Lowering the 
expression of miR-107 will increase the levels of miR-9 
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which affects DICER and results in an increase of 
both proliferating progenitors and postmitotic neurons. 
Table 1.3 lists the miRNAs involved in neurogenesis 
regulation. 
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miRNA Target Expression Role Source 
miR-9 Hes1 Stathmin  
REST 
+ Downregulates Neural stem cell differentiation 
 
Tan et al., 2012; Delaloy et al., 2010; Packer 
et al., 2008 
miR-29a REST - Promotes Neural differentiation Duan et al., 2014 
miR-124 PTP1B  
SCP1 dlx-2  
Jagged-1 SOX9 
- 
+ 
Promotes Neural differentiation 
Promotes Proliferation of neuronal precursors 
 
Visvanathan et al., 2007; Cheng et al., 2009 
miR-125 SCNBA EPHB2 
KCNQ2 FLNA  
SYN2 NEFM 
+ Promotes Neural differentiation Le et al., 2009 
miR-200 
family 
SOX2 
E2F3 
- Promotes differentiation into neurons Peng et al., 2012 
miR-107 Dicer - Promotes Neurogenesis Ristori et al., 2015 
miR-381 Hes1 + Promotes Neural Stem Cell Proliferation and 
Differentiation 
Shi et al., 2015 
miR-765 Hes1 + Promotes Neural stem cell proliferation and 
differentiation 
Li et al., 2016 
miR-106b~25 
cluster 
TGFβ 
insulin/IGF- FoxO 
+ Promotes Neural Stem/Progenitor Cell Proliferation 
and Neuronal Differentiation 
Brett et al., 2011 
Let-7 family HNF4A - Promotes Neuroblast proliferation and self-renewal Hennchen et al., 2015; Koh et al., 2010 
miR-34a MYCN + Promotes Proliferation Mollinari et al., 2015 
miR-184 AKT2 - Inhibits neuroblastoma cell survival Foley et al., 2010 
miR-302/367 Fibrobasts + Reprogram cells into neurons Zhou et al., 2015 
miR-
181a/125b 
TGFβ 
Nestin 
+ Promotion of the generation of TH-positive neuron Stappert, Roese-Koerner and Brüstle, 2015 
Table 1.3: miRNA involvement in neuronal development 
Legend: Hes1 – Hairy and Enhancer of Split 1, REST - RE-1 silencing transcription factor, PTP1B - polypyrimidine tract-binding protein 1, SCP1 - Small C-
terminal domain phosphatase 1, dlx-2 - distal-less homebox 2, SOX9 - sex determining region Y-box 9, SCNBA - Sodium channel protein type 1 subunit 
alpha, EPHB2 – Ephrin type-B receptor 2,  KCNQ2 – Potassium Voltaged-Gated Channel Subfamily Q Member 2, FLNA – Filmin Alpha, SYN2 – Synapsin II, 
NEFM – Neurofilament medium polypeptide, SOX2 - sex determining region Y-box 2, E2F3 – E2F Transcription Factor 3, TGFβ - transforming growth 
factor-beta, IGF- insulin-like growth factor 1, FOXO - Forkhead transcription factor family O, HNF4A – Hepatocyte nuclear factor 4 alpha, AKT2 - v-akt 
murine thymoma viral oncogene homolog 2, Th – Tyrosine hydroxylase, (+) - upregulation of miRNA expression, (-) - downregulation of miRNA 
expression. 
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1.3.3.4. MicroRNA modulation of stem cell commitment 
MiRNAs have been shown to interact with different signalling 
pathways. They influence the expression of various 
transcripts, creating regulatory feedback loops that affect 
multiple functions within the cell. This subsequently results 
in cell fate modulation of NSCs and their progeny (Garg et 
al., 2013). Over the years, the role played by miRNAs in 
stem cell fate determination and differentiation has gained 
considerable interest and importance and has become more 
recognised. Ongoing research has led to discoveries to new 
miRNA/stem cell related functions, enabling the 
development of new miRNA-based therapies in regenerative 
medicine. It is a well-known fact that cells can be 
reprogrammed using miRNAs. However further elucidation is 
required on whether miRNAs alone can actually induce 
reprogramming or whether they act to improve the 
efficiency of reprogramming core transcription factors such 
as OCT4 and SOX2 (Eguchi and Kuboki, 2016).  
 
Another key aspect to understanding this modulation is by 
identifying the roles of circulating miRNAs and how these 
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may be put to good use as part of miRNA therapeutic 
applications. This form of treatment may only be made 
possible by developing techniques that mimic and deliver 
stable exosomal miRNAs which would then be able to control 
the proliferation and differentiation of stem cells, such as in 
the basics of tissue regeneration (Yao, 2016). 
 
1.3.4. MicroRNAs involved in stem cell to neuroblast to 
mature neuron differentiation 
Neuroblasts or neural precursors are cells which have been 
already committed to developing into neuronal cells. These 
precursors may undergo three distinct dividing stages. The 
first stage is that of symmetrical division. This process 
occurs during the early stages of neural development during 
which the neuroblast divides yielding two identical cells. 
Midway through neural development, the cells undergo 
asymmetrical division. In this stage, the cell divides to 
produce one precursor cell and another cell that is a transit 
amplifying cell (Matsuzaki and Shitamukai, 2015). This 
phase allows the formation of neurons while still having 
precursors available to produce other neurons and/or glia at 
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a later stage. In the final stage, precursors will differentiate 
into either neurons or glia, ending neurogenesis and 
gliogenesis respectively (Hudish and Appel, 2014). 
 
Once stem cells are directed towards the neural lineage, a 
complex network regulates the proliferation, differentiation 
and distribution of neuronal progenitors. Examples of this 
network include the interaction of miR-134 and miR-184, 
which have both been associated with neural progenitor 
maintenance and proliferation (Bian, Xu and Sun, 2013), 
and miR-124 and miR-9, which promote neuronal 
differentiation (Åkerblom and Jakobsson, 2014; Coolen, 
Katz and Bally-Cuif, 2013). MiR-124 and miR-9 target 
several components of the Notch signalling pathway, 
responsible for the  regulation of neuronal development and 
neural progenitor proliferation (Stappert, Roese-Koerner and 
Brüstle, 2015). BMP/TGFβ signalling induces the transition 
of stem cells towards the neural lineage and this pathway is 
inhibited by miR-125a/b and miR-135b, while miR-302/367 
stimulate the signalling and stop neural induction (Boissart 
et al., 2012).  
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1.3.4.1. Rationale for the selection of microRNAs  
This study investigated the role of three miRNAs - miR-107, 
miR-124 and miR-381 – in relation to how these can direct 
the differentiation of MSCs to neural like cells.  
 
MiR-107 is specifically expressed in the brain (Wang et al., 
2014) and acts as a negative regulator of Dicer which 
implies that this miRNA plays a major role in the regulation 
of Dicer-dependent physiological processes such as 
neurogenesis (Ristori et al., 2015). Its overexpression 
causes a decrease in Dicer gene expression, thus stabilising 
Dicer mRNA and increasing the number of neuronal 
progenitors (Ristori et al., 2015).   
 
MiR-124 is a highly expressed tissue-specific miRNA of the 
nervous system  (Ludwig et al., 2016). In order to maintain 
the neural state, miR-124 downregulates the expression of 
non-neural mRNAs by repressing the expression of non-
neural transcripts and thus directing the gene expression 
profile towards the neural state (Xue et al., 2016). A target 
of miR-124 is polypyrimidine tract-binding protein 1 (PTP1B) 
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mRNA, a repressor of neuron-specific pre-mRNA splicing, 
that activates the neuronal gene expression. 
 
MiR-381 targets HES1, a gene highly expressed in the CNS, 
which plays a crucial role in the maintenance of NSCs during 
the development of the embryonic brain.  Down-regulation 
of HES1 causes NSCs to differentiate into mature neurons 
(Shi et al., 2015). Knockdown of the HES1 gene upregulates 
the neural differentiation factor MASH-1, increasing 
neuronal differentiation (Shi et al., 2015).  
 
1.4. Rationale and Aims 
It is widely agreed that miRNAs are responsible for neural 
induction, differentiation and fate specification and thus, 
have potential in the development of next generation 
therapeutic approaches for numerous health conditions. The 
identification of putative miRNAs responsible for neural 
development will further elucidate the mechanisms of action 
involved in both the physiological and pathological processes 
of the CNS. 
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The rationale for the use of miRNAs to transdifferentiate 
MSCs to neural-like cells arose from the possibility of 
targeting protein expression by transiently inhibiting mRNA 
translation by miRNAs, as an alternative to permanent gene 
modification such as in the case of CRISPR. Being a 
transient process, the cells being differentiated should not 
retain any permanent mark of the process. 
 
The aim of this research is to investigate the role of miRNAs 
in MSCs commitment to a neuroblast and/or mature neuron 
cell lineage and to determine whether individual miRNAs can 
induce MSCs to become neuroblasts or undergo further 
neuronal differentiation for potential therapeutic 
applications.  
 
To establish this, MSCs were isolated from Wharton’s Jelly 
and characterised by trilineage differentiation. The MSCs 
were then treated with the conditioned medium of cultured 
SH-SY5Y cells, which induced a neuronal-like differentiation 
of the MSCs. These induced neural-like cells were further 
treated with RA to produce cells which are at a later stage of 
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maturation. All three cell types were then characterised 
using a series of CD and neural markers to obtain an 
indication of the neuronal stage of the different cells. Finally, 
cells were transfected with three miRNA antagonists and the 
change in expression was determined for the corresponding 
miRNA target genes and a panel of neural markers. 
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Chapter 2                   
Materials and Methods 
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2.1. Ethical Approval 
Ethical approval for collection of cords for the culturing of 
MSCs was granted by the University of Malta Research 
Ethics Committee. A copy of this approval and the consent 
forms used can be found in Appendix I. 
 
2.2. Experimental Design 
The number of cords utilised in this project and how each 
was utilised can be viewed in Table 2.1. Since the quantity 
of MSCs cultured was extremely limited, every effort has 
been made to test these cells for at least one 
characterisation attribute as per ISCT recommendation. In 
brief, once the cord was processed and MSCs cultured, 
these cells were characterised by trilineage differentiation. 
Simultaneously, cells were conditioned with spent medium 
from cultured SH-SY5Y cells and subsequently, these cells 
were treated with RA. Hereafter these two cell types were 
referred to as Conditioned Cells (CCs) and RA-treated CCs 
(RA-CCs), respectively. After RNA was extracted from the 
three cell types, Real Time Polymerase Chain Reaction (RT-
qPCR) was performed to determine which CD and neural 
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markers were expressed by these cells. Transfection of 
miRNA antagonist (siRNA) was then performed on all three 
cell types. RNA was once again extracted and tested for the 
expression of the miRNA gene targets and a selection of 
neural markers. 
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Cord Number 1 2 3 4 5 6 7 8 9 10 11 12 13 
Successfully cultured (MSCs)                           
Differentiated with Conditoned Medium (CCs)                    
CCs treated with RA                           
Tri-lineage differentiation of MSCs - Osteo                   
Tri-lineage differentiation of MSCs - Adipose                   
Tri-lineage differentiation of MSCs - Chondro                 
MSCs for CD and neural markers RT-qPCR                            
CCs for CD and neural markers RT-qPCR                  
CC -RA CD and neural markers RT-qPCR                           
MSCs used for transfection of siRNA                 
CCs used for transfection of siRNA                 
CC-RA used for transfection of siRNA                 
MSCs transfection neural markers                           
CCs transfection neural markers                 
CC -RA transfection neural markers                           
MSCs transfection siRNA targets RT-qPCR                 
CCs transfection siRNA targets RT-qPCR                  
CC-RA transfection siRNA Targets RT-qPCR                 
MSCs/Cord discarded                           
CCs discarded                           
Table 2.1: Experimental Layout 
Table representing the number of cord samples processed in this project and how the derived cells were utilised. 
Legend: MSCs – Mesenchymal Stem Cells, CCs – Conditioned Cells, CC- RA – Retinoic Acid treated CCs, RT-qPCR – Real 
Time Polymerase Chain Reaction, siRNA – microRNA antagonist. 
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2.3. Cell Culturing 
2.3.1.Medium for cell culturing 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F-12) (Sigma-Aldrich Cat: D5523) was used as cell 
culture medium. Under aseptic conditions using a Class II 
safety cabinet (SafeFAST Elite, Faster S.r.l.), the medium 
was reconstituted using distilled water prepared by the 
distillation of tap water using the Aquatron automatic water 
still A8000 (Cole-Parmer, UK) and sodium bicarbonate 
(Sigma-Aldrich Cat No: S5761) followed by filtering using a 
0.2µm filter (Thermofisher Scientific, Cat No: 564-0020). 
The stock medium was stored at 4oC. 
 
Prior to use, the medium was supplemented with 20% cryo 
poor plasma (CPP) (obtained from the National Blood 
Transfusion Services Malta). A 1% penicillin/streptomycin 
(P/S) solution, consisting of 10,000 units penicillin and 10 
mg streptomycin per mL in 0.9% sodium chloride (Sigma-
Aldrich Cat No: P0781), was then added to the medium. The 
addition of human plasma provided xeno-free (animal-
derived) nutrients with the added benefit of preventing stem 
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cells from being programmed at an early stage. The CPP 
procedure was adapted from Muraglia et al. (2017). To 
produce the CPP under aseptic conditions, the plasma bag 
was supplemented with calcium chloride (CaCl2) (Anatar Cat 
No: 10241) (2 mg/ml), mixed gently, transferred to a 
Transfer Bag and incubated at 37C for a minimum of 3 
hours. The addition of CaCl2 and heat induced coagulation 
and precipitated residual factors present in the plasma. 
Uncoagulated plasma was then decanted into 50ml falcon 
tubes and stored at -20C. When required the plasma was 
thawed at 37C and centrifuged at 1000 XG for 10 minutes. 
The P/S was added to the medium to prevent bacterial 
contamination of the cell cultures by either gram-positive or 
gram-negative bacteria. Any unused complete medium was 
kept refrigerated at 4oC. 
 
2.3.2. Fibrin clots 
The practice of using sera with unknown animal-derived 
factors such as Foetal Bovine Serum (FBS) is being phased 
out, especially where research models for therapeutic 
applications are being developed (Baron, 2016). Cell lines in 
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culture require high levels of serum. However, animal 
derived sera are not standardised and present high 
variability of the many substances they contain both 
between lots and brands. This variation could greatly 
influence the research results and make these inconsistent 
(Zammit, Farrugia and Baron, 2019).  In this study, FBS 
was substituted with human plasma obtained from healthy 
blood donors whose blood was collected aseptically and 
processed using the closed system quadruple bag blood 
processing system as described above in Section 2.3.1. 
 
Plasma contains clotting factors, which are triggered by 
calcium into initiating the coagulation cascade resulting in 
haemostasis. One of the chemical components of the 
DMEM/F12 formulation is calcium. To prevent the 
coagulation of the media, the plasma was treated with 
CaCl2. This removed most of the coagulation factors from 
the plasma and most of the residual cryoprecipitate was 
removed at a later stage by centrifugation. However, on 
different occasions, when medium was added to the 
cultures, fibrin clots would still form.  
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Since the composition of the plasma used is not 
standardised, the amount of coagulation factors present 
may vary from donor to donor. This makes it rather difficult 
to precipitate all factors, and fibrin clots may develop in the 
presence of excessive calcium, such as in the case during 
chondrogenic differentiation of MSCs, where a gel like 
matrix was formed allowing the differentiated chondrocytes 
to take on a 3D-like structure. 
 
During culturing of the MSCs, when the Wharton’s Jelly was 
incubated with the medium, sometimes this would coagulate 
due to residual traces of plasma present in the cord itself. 
Even though care was taken to clean the cord properly by 
the washing stages, if the cord is not bled properly at the 
collection stage, some Wharton’s Jelly would end up 
becoming blood stained, ultimately causing the formation of 
a fibrin clot when the medium is added. When formed, this 
clot was easily removed on the subsequent medium changes 
and by the time MSCs started to appear in culture, fibrin 
clots were no longer forming.  
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In both cases, the gel-like substance produced by the 
coagulated medium was easily removed, since once the 
fibrin clot is removed the remaining gel converts back to a 
liquid. The disadvantage of this method is that any cells 
trapped in the fibrin clot would be lost. To prevent such 
losses, cells undergoing chondrogenic differentiation had 
minimum medium changes, especially towards the end of 
the 21 day differentiation period. 
 
2.3.3. Culturing of Human Mesenchymal Stem Cells 
Primary cell cultures are those cultures which are grown 
directly from donor tissue. Such cultures are different from 
cell lines because they are not immortalised or transformed 
by oncogenes. This means they have a finite lifespan of a 
few months. Cells for culturing were obtained from tissue by 
tissue maceration.  
 
2.3.3.1. Collection of cord sample 
Donors were recruited from the Obstetrics and Gynaecology 
Ward, Mater Dei Hospital, Triq Dun Karm, L-Imsida, Malta. 
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The pregnant donors were informed of the ethically 
approved study and informed consent was obtained.  Not 
too long after birth, a piece of the umbilical cord of around 5 
to 10cm was cut off close to the placenta, entirely bled and, 
to preserve stem cell viability, stored by complete 
submersion in phosphate buffer saline (PBS) (Sigma-Aldrich, 
Cat: P3813) at a temperature of 2–8oC. The sample was 
processed within 24 hours because the cells would not be 
healthy after 24-hours at 4oC in PBS without glucose. As a 
prophylaxis to prevent contamination, 1% P/S was added to 
the storage PBS solution.   
 
2.3.3.2. Isolation and culturing of human mesenchymal 
stem cells 
This isolation method follows the Points of Good Practice for 
the Sampling of Cords and Culturing of Mesenchymal Stem 
Cells by Zammit and Baron (2017). The transport PBS 
solution was discarded, and the cord was washed vigorously 
with 70% ethanol for 1 minute. This step helped prevent 
contamination by any foreign matter present on the surface 
of the cord, however a longer exposure to ethanol would 
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lead to loss of cell viability.  The ethanol was then removed, 
and the sample washed three times for 1 minute each with 
cold PBS. The PBS removed any remaining traces of alcohol 
and debris from the surface of the cord. Once the cord had 
been cleaned, the epithelial and vascular tissues were 
removed, and the Wharton’s Jelly extracted. The jelly was 
then cut into small pieces and transferred to a 12-well plate 
and a T25 flask. The tissue was then allowed to rest for 10 
minutes to allow better adherence. Finally, enough complete 
medium to cover the base of the well/flask was added and 
these were then incubated at 37oC with 5% CO2 in a 
humidified environment.  
 
Half the medium was replaced every 3 days. This allowed 
replenishing of nutrients and removal of debris while 
retaining some of the circulating growth factors released by 
the tissue itself. Once cells started to grow and colonies 
formed, the tissue pieces together with the spent medium 
were removed. Once the desired confluence (minimum of 
50% confluence) was achieved the cells were detached with 
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2ml 2mM Ethylenediaminetetraacetic acid disodium salt 
dihydrate (EDTA) (Sigma-Aldrich, Cat: E5134). 
2.3.4. Culturing of conditioned Mesenchymal Stem Cells 
Conditioned medium consists of a variety of biomolecules, 
including miRNAs released by the cells into the culture 
medium during growth. These secreted biomolecules may 
play a role in processes such as cell growth, differentiation, 
invasion and angiogenesis by regulating cell-to-cell and cell-
to-extracellular matrix interactions. 
 
2.3.4.1. Preparation of SH-SY5Y cells spent medium 
For this project, the Neuroblastoma cell line SH-SY5Y was 
donated by Dr Duncan Ayers from the Centre for Molecular 
Medicine and Biobanking, University of Malta. The frozen 
SH-SY5Y cells were thawed, transferred to a sterile 15ml 
falcon tube containing 4ml complete DMEM (using human 
plasma) and centrifuged at 250 XG for 10 minutes. The 
supernatant was then discarded, and the cell pellet was 
suspended in 3ml complete DMEM (using human plasma). 
The suspension obtained was transferred to a sterile flask 
and cultured as per Section 2.3.3.2.  After 2 days, the spent 
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medium was discarded so that dead cells, traces of animal-
derived products from prior cryo-storage culturing and any 
remnant dimethyl sulfoxide (DMSO) in which the cells had 
been frozen were all removed. Fresh complete medium 
(3ml) was added and the flasks were re-incubated. After 3 
days the medium was collected, centrifuged at 500 XG for 
15 minutes at 4oC, transferred to a sterile falcon tube and 
refrigerated if not required.  To maintain a stock of fresh 
spent medium readily available, the SH-SY5Y cultures were 
split with the aid of 2ml 2mM EDTA (Sigma-Aldrich, Cat: 
E5134) in PBS and these were seeded in a T25 flask at a 
density of 1 x106cells/mL and re-incubated to maintain a 
stock of fresh conditioned medium. Any surplus SH-SY5Y 
cells were frozen in 5% DMSO (Sigma-Aldrich Cat: 276855-
2L) and 95% CCP at -80oC. 
 
2.3.4.2. Conditioning of Mesenchymal Stem Cells 
To direct MSCs to become neural like cells, the MSCs were 
incubated with a ratio mixture of 1:1 of complete medium 
and conditioned medium obtained from the SH-SY5Y cells in 
culture. For optimal results, the conditioned medium should 
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be not more than 3 – 4 days old. Since the conditioned 
medium is an in-house prepared medium, no additional 
preservatives were added, so a prolonged storage will 
deteriorate the substance which are inducing the 
differentiation of the MSCs. Cells were then cultured as per 
section 2.3.3.2. Within 24 hours, over 70% of MSCs had 
started to differentiate. The medium was changed every 3 
days or as necessary and, once confluent, CCs were 
detached with 2ml 2mM EDTA (Sigma-Aldrich, Cat: E5134) 
in PBS and frozen in a solution of 5% DMSO and 95% CCP 
at -80oC. 
 
2.3.4.3. Culturing of neural-like cells 
The protocol for producing mature neural-like cells was 
adapted from Shipley et al. 2016. CCs were seeded in a 12-
well plate at a density of 1x105 cells. Culture medium per 
well was prepared by using 960μl DMEM/F-12, 26μl CPP, 
10μL P/S, 1μl N2 supplement (Thermofisher Scientific 
Gibco® Cat: 17502048 – composition: human transferrin 
(10000mg/l), insulin recombinant full chain (500mg/l), 
progesterone (0.63mg/l), putrescine (16611mg/l) and 
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selenite (0.52mg/l)), and 1μl RA.  Cells were then incubated 
at 37oC with 5% CO2 in a humidified environment.  The 
medium was changed every 3 to 4 days. Within three weeks 
of RA treatment cells developed neuritic projections. 
Hereafter these cells were referred to as CC-RA.  
 
2.4. MSC functional identification  
To verify the multipotency of the cultured MSCs, these were 
treated for tri-lineage differentiation using the Human 
Mesenchymal Stem Cell Functional Identification Kit (R&D 
Systems, Cat No.: SC006). 
 
Once the MSCs in culture reached an adequate degree of 
confluence (approximately 40%), culturing medium was 
replaced by oestogenic, adipogenic or chondrorogenic 
differentiation medium. The oestogeneic and adipogenic 
differentiation media were prepared using StemXVivo 
Oesteogenic/Adipogenic Base Media (R&D Systems, Cat No.: 
CCM007), 1% P/S and osteogenic or adipogenic supplement 
at a 1:20 dilution. Chondrogenic medium consisted of 
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DMEM/F12, 1% P/S, 1% ITS supplement and 1% 
chondrogenic supplement. 
 
Differentiation medium was changed every 4 -5 days. Cells 
were then incubated at 37oC with 5% CO2 in a humidified 
environment. After 21 days, osteocytes were stained using 
the von Kossa staining method to determine the formation 
of calcification matrix within the cells; adipocytes were 
stained with Oil-Red-O for detection the lipid vacuoles; 
chondrocytes were stained with Alcian Blue for identifying 
the presence of glycosaminoglycans, which compose the 
extracellular matrix of cartilage. Prior to staining, all wells 
were gently washed with a volume of 500μl PBS after which 
cells were fixed in 500μl Tokuda-Baron Fixative (TB Fix) for 
15 minutes (Tokuda et al., 2018). Following fixation, the 
wells were washed twice using 500μl PBS. 
  
2.4.1. Von Kossa staining 
Cells were stained with 500μl 1% silver nitrate (Sigma-
Aldrich, Cat No.: 209139) solution (1g in 100ml distilled 
water) and incubated under ultraviolet light (60-watt lamp) 
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for 20 minutes. Following incubation, wells were washed 
three times with 500μl distilled water. Cells were treated for 
5 minutes with 500μl 5% sodium thiosulfate (Sigma-Aldrich, 
Cat No.: 1603121000) (5g in 100ml distilled water). This 
was added to remove any residual un-reacted silver and 
washed again three times with distilled water. Cells were 
stained with 1% Nuclear Fast Red Solution (0.1g nuclear 
fast red (Sigma-Aldrich, Cat No.:  6409-77-4), 5g 
aluminium sulfate (Sigma-Aldrich, Cat No.:7784-31-8) in 
100ml distilled water) for 5 minutes and rinsed again using 
distilled water. A volume of 500μl distilled water was added 
to the wells and microscopically viewed for calcium deposits 
that would have stained black or brown-black (depending on 
the strength of the UV light). 
 
2.4.2. Oil-red-O staining 
A stock concentration of 3% oil-red-o staining was prepared 
by diluting 0.30g Oil Red-O powder (Sigma-Aldrich, Cat No.: 
OD625) in 100ml 2-propanol at 99%. Prior to staining, a 
working solution was freshly prepared by diluting the 3% Oil 
Red-O in distilled water in a ratio of 6:4 and filtered using a 
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0.2µm filter. Cells were stained with 500μl of the diluted Oil 
Red-O. After 15 minutes of staining, the Oil Red-O was 
removed, and wells washed gently in 500μl distilled water. 
Finally, wells were topped with a fresh volume of 500μl 
distilled water and checked microscopically for the presence 
of red lipid vacuoles.    
 
2.4.3. Alcian Blue staining 
Cells were stained for 30 minutes using 500μl Alcian Blue 
solution (100mg Alcian Blue (Sigma-Aldrich, Cat No.: 
A5268) in 60 ml ethanol and 40 ml acetic acid) previously 
diluted in distilled water in a ratio of 1:3. The wells were 
then washed gently in 500μl distilled water. Finally, wells 
were topped with 500μl distilled water and checked 
microscopically for the presence of glycosaminoglycans. 
 
2.5. RNA extraction and cDNA synthesis 
RNA extracted from MSCs, CCs, and RA-CCs followed by 
complementary DNA (cDNA) synthesis was used to 
determine the respective gene expression by RT-PCR.  
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2.5.1. mRNA extraction 
MRNA was extracted and purified from MSCs, CCs and RA-
CCs using the SV Total RNA Isolation System (Promega Cat 
No.: Z3100). RNA extraction is a well-established procedure 
and to efficiently purify RNA, this extraction kit employs the 
selective binding properties of a silica-based membrane with 
the speed of microspin technology. Once purified, the 
single-stranded RNA is converted into cDNA by using the 
enzyme reverse transcriptase. 
 
2.5.1.1. Cell lysate preparation 
The cells were dislodged using 2mM EDTA in PBS, 
neutralised with complete DMEM and centrifuged at 250 XG 
for 5 minutes. The supernatant was discarded, and the cell 
pellet was re-suspended in 1ml PBS. The cells were 
centrifuged once again at 250 XG for 5 minutes and the 
supernatant was discarded. A volume of 175µl of RNA Lysis 
Buffer were added to the washed cells, paying attention to 
disperse the pellet, and then vortexed to ensure proper 
mixing. The mixture was then passed 4-5 times through a 
20-gauge needle to shear the genomic DNA and transferred 
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to a 1.5ml microcentrifuge tube. To the tube, 350µl of RNA 
Dilution Buffer were added and thoroughly mixed by 
inverting 3-4 times before placing in a 70°C heat block for 3 
minutes, followed by centrifugation at 14000 XG for 10 
minutes at a temperature of 20°C. 
 
2.5.1.2. mRNA extraction procedure 
The clear lysate obtained after centrifugation was 
transferred to a fresh microcentrifuge tube, 200µl 95% 
ethanol were added and mixed 3–4 times by pipetting. The 
mixture was transferred to a spin column and centrifuged at 
14000XG at 22C for 1 minute. The liquid in the collection 
tube was discarded and 600µl of RNA wash were added and 
then centrifuged 14000XG at 22C for a further 1 minute. 
After discarding the liquid in the collection tube, 250µl of 
RNA Wash Buffer were added to the column and centrifuged 
at high speed for 2 minutes. The spin basket was 
transferred to a fresh 1.5ml microcentrifuge tube and 
elution was performed by adding 100µl nuclease-free water 
and centrifuging at 13000xG at 22C for 1 minute. The 
purified RNA was quantified by spectrophotometry and 
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stored at -70°C. Kit instructions may be viewed in Appendix 
II. 
 
2.5.1.3. Determination of mRNA concentration 
Purity and homogeneity of the sample are important factors 
when performing molecular analysis. Nucleic acids are 
purified with the help of commercially available kits that 
allow for the separation of most cellular components. 
However, proteins or other organic component residues may 
still be present in the eluate. To ensure minimum 
contamination of the sample, it is essential to verify its 
purity by photometric measurements. The ratios of the 
absorbance values at the wavelengths 230nm, 260nm and 
280nm provide a clear picture of the purity of a nucleic acid 
sample. A pure sample is quantified as having an 
absorbance of ≥2.0 at A260/A230 and an absorbance of 1.8 
- 2.1 at a wavelength of A260/A280.  
 
RNA concentration was determined using the Eppendorf 
BioPhotometer (Eppendorf®, Germany) by measuring the 
64 
 
absorbance of a 1:5 (total volume 100μl) diluted extract at 
260 nm (A260). 
 
2.5.1.4. mRNA cDNA synthesis 
DNA can be synthesised from an RNA template by a 
procedure known as reverse transcription (RT), which 
produces cDNA. This procedure uses an RNA template and a 
short primer complementary to the 3’ end of the RNA to 
initiate the first cDNA strand that is in turn amplified by 
PCR. 
 
cDNA synthesis was performed using the GoScript™ Reverse 
Transcriptase system (Promega Corporation, Cat No.: 
A5000). The kit consists of a reverse transcriptase and an 
optimised set of reagents for efficient synthesis of first-
strand cDNA in preparation for PCR amplification. The kit is 
designed to convert up to 5µg of total RNA or up to 500ng 
of poly(A) RNA into first-strand cDNA. 
 
 
 
65 
 
2.5.1.4.1. mRNA cDNA synthesis procedure 
The RNA/primer mixture was prepared as per Table 2.2. 
Every time cDNA was prepared a total of 5µg experimental 
RNA was used per reaction. Each tube was securely closed 
and incubated in a preheated 70°C heating block for 5 
minutes, after which they were immediately placed on ice 
for a minimum of 5 minutes. To collect the condensate and 
maintain the original volume, the mixture was then 
centrifuged for 10 seconds and kept on ice until the RT mix 
was prepared as per Table 2.3. A volume of 15µl of the RT 
reaction mix was transferred to each reaction tube on ice 
and 5µl of RNA and primer mix added to obtain a final 
reaction volume of 20µl per tube. Synthesis was performed 
as per Table 2.4. 
 
Component Volume 
Experimental RNA (5µg/reaction) 4µl 
Primer [Random Primer (0.5µg/reaction) or gene-specific 
primer (10pmol/reaction) 
1µl 
Nuclease-Free Water 0µl 
Final volume 5µl 
Table 2.2: RNA and Primer mixture 
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Component Volume 
Nuclease-Free Water (to a final volume of 15µl) 5.8µl 
GoScript™ 5X Reaction Buffer 4.0µl 
MgCl2 (final concentration 1.5mM) 1.2µl 
PCR Nucleotide Mix (final concentration 0.5mM each 
dNTP)  
1.0µl 
Recombinant RNasin® Ribonuclease Inhibitor 2.0µl 
GoScript™ Reverse Transcriptase 1.0µl 
Final volume 15.0µl 
Table 2.3: Reverse transcription mix 
 
Phase Temperature Duration 
Denaturation 95°C 5 minutes 
Annealing 55°C 60 minutes 
Extension 70°C 15 minutes 
Table 2.4: cDNA synthesis reaction temperatures and duration 
 
2.6. Polymerase Chain Reaction 
2.6.1. Real Time Quantitative Polymerase Chain Reaction  
RT-qPCR is used to detect, characterise and quantify RNA. 
The RT-qPCR follows standard PCR protocols in the sense 
that first the RNA must be reverse transcribed into cDNA 
and then amplified by repeating cycles of denaturation, 
annealing and elongation. However, since fluorescent 
labelling is used during sample preparation, it is possible to 
monitor the data live as the reaction progresses. 
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2.6.2. House-keeping Gene 
To balance out sample-to-sample variation in RT-qPCR 
efficiency and sample quantification errors, gene 
quantification analysis entails that qPCR data be normalised 
against a reference gene (endogenous control) (Bustin, 
2002).  To select the most suitable house-keeping gene for 
an experiment, a series of such genes needs to be analysed 
using the same experimental set-up which would then be 
used to analyse the samples. The gene which would have 
shown the least expression variation between the different 
experimental conditions would then be selected. In this 
study, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was chosen as the house-keeping reference gene, based on 
a study conducted by Willems et al., (2006). In their study, 
Willems et al. tested the stability of ten reference genes 
during neural differentiation of embryonic stem cells. GAPDH 
ranked as the 3rd housekeeping gene according to the 
normalisation tools geNorm and Normfinder. 
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2.6.3. Primers 
A crucial step when setting up a RT-qPCR is that of 
designing and using the correct primers, since this can 
significantly impact the quality and reliability of the results.  
Primers are, on average, composed of 20 base pairs and 
have a melting point between 55C and 65C. To prevent 
the amplification of contaminating genomic DNA, the primer 
must span an exon junction. Ideally the 3’ end of the primer 
should contain a C or G residue, as both T and A tend to 
bind in a non-specific way and to ensure maximum product 
stability the GC content should be approximately 50-60%.  
 
2.6.3.1. Primer Design 
The primary transcript variant of the human gene of interest 
was retrieved from the GenBank sequence repository 
genome browser. The first and last 100 bases of each exon 
were noted. A shortlist of sequence pairs of 20bp, one 
before and one after an intron, up to 250bp apart in the 
transcribed mRNA were selected. These sequences where 
selected based on a number of parameters: the 3’ end 
should contain C or G residues (CG clamp), melting 
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temperature of each primer should be 50-60oC and within 
5oC of each other, the GC content should be 40-60%, the 
sequence should contain no nucleotide repeats, and should 
not form secondary structures or primer dimers. To confirm 
their specificity in the human genome, the selected 
sequences where run through nucleotide BLAST (National 
Center for Biotechnology Information) and the result should 
have given a single gene output (possibly showing multiple 
variants).     
 
Table 2.5 lists the forward and reverse sequences of the 
primers used throughout this project. These where 
synthesised by and purchased from Integrated DNA 
Technologies. 
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Primer Forward Reverse 
SOX2 CAAGATGCACAACTCGGAGA GGGCAGCGTGTACTTATCCT 
OCT4 AGTGAGAGGCAACCTGGAGA GGAGACCCAGCAGCCTCAAA 
TUBB3 GGAGATCGTGCACATCCAG TCGAGGCACGTACTTGTGAG 
GAPDH GAAGGTGAAGGTCGGAGTCA GAAGATGGTGATGGGATTTC 
NES TCCTGGAGGCTGAGAACTCC CTGGCCAAGGTAGGGGTACG 
ND1 TAAATTGAGACGCATGAAGG GGTGGTGGGTTGGGATAAGC 
MASH1 GAACTGATGCGCTGCAAACG CATGCTCGTCCAGCAGCTGC 
NEU TGTACACACCAGCACAGACC CGAACATTTGCCGCAAGTCG 
MAP2 ATACAGGGAGGATGAAGAGG GGAGAAGGAGGCAGATTAGC 
DICER CTTTCTTTGGACTGCCATGG GTTGACCAAGAACACCGTCC 
HES1 CCGGATAAACCAAAGACAGC GGTGCTTCACTGTCATTTCC 
PTP1B CTTGTGTCACTAACGGACCG CTTCAGCATCAGGAGGTTGG 
CD34 TGAAGCCTAGCCTGTCAC CGCACAGCTGGAGGTCTTAT 
CD45 GTGTTTCATCAGTACAGACG GTTGTGGTTGAAATGACAGC 
CD73 ATGGTGTGGAAGGACTGATC CCTCACTTTCTGAGCGATG 
CD90 TGCTCTTTGGCACTGTGG AGAGGGAGAGCAGGAGCAG 
CD105 GGGGTCAACACCACAGAG CAGGACCCTCAGGATGTG 
Table 2.5: List of Primers 
The forward and reverse (5’  3’) primers designed for all gene 
markers, miRNAs and miRNA target genes. 
Legend: SOX2 - SRY (sex determining region Y)-box 2, OCT4 - Octamer-
binding transcription factor 4, TUBB3 - -III-Tubulin, GAPDH - 
glyceraldehyde-3-phosphate dehydrogenase, NES – Nestin, ND1 – 
NeuroD1, MAP2 - Microtubule-associated protein 2, MASH-1 - 
mammalian achaete scute homolog-1, NEU - neuronal-specific nuclear 
protein 1 and HES1 – Hairy and enhancer of split 1, CD – Cluster of 
Differentiation 
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2.6.3.2. Primer preparation 
Primers in a lyophilised state were obtained from Integrated 
DNA Technologies and were reconstituted by adding the 
amount of sterile nuclease-free water indicated in the data 
analysis sheet, thus obtaining a concentration of 
100pmoles/μl. The tubes were flicked for 15 times and 
vortexed for 1 minute to obtain a homogeneous solution. 
Stock primers were stored at -20oC. Low concentration 
working solutions were prepared by diluting with sterile 
nuclease-free water to obtain a 10μM concentration for PCR. 
Aliquots were stored at a temperature of -20C. 
 
2.6.4. RT-qPCR procedure 
The reaction set-up was prepared as per Table 2.6 by 
thawing and mixing together 2xQuantiTect SYBR Green PCR 
Master Mix, primers and RNase-free water. These were 
mixed well and 9μL were dispensed into the PCR tubes to 
which 1μL of the cDNA template was added. The tubes were 
placed in the Rotor-Gene Q (Qiagen, Netherlands) which 
was programmed as per Table 2.7. 
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Component Volume per reaction 
2xQuantiTect SYBR Green PCR Master Mix 5.0μL 
Forward Primer 0.5μL 
Reverse Primer 0.5μL 
cDNA 1.0μL 
RNase-free water 3.0μL 
Total reaction volume 10.0μL 
Table 2.6: RT-qPCR reaction volumes 
Legend: RT-qPCR - Real Time Quantitative Polymerase Chain Reaction 
 
Step Time Temperature Ramp rate 
PCR initial heat activation 15 min 95C 20C/s 
Denaturation 15 secs 94C 20C/s 
Annealing 30 secs 50C 20C/s 
Extension 30 secs 72C 2C/s 
Table 2.7: RT-qPCR set-up 
Legend: RT-qPCR - Real Time Quantitative Polymerase Chain Reaction 
 
2.6.4.1. Interpretation of RT-qPCR data 
During qPCR, fluorescence accumulates over a period of 40 
cycles. The resultant amplification curve is composed of four 
different phases: the linear ground, early exponential, log-
linear and plateau. The quantification cycle (Cq) determining 
the threshold should be set at the beginning of the log-
linear phase (Caraguel et al., 2011).   
 
Absence or presence of the marker of interest is determined 
in relation to the Cq value obtained for the Non-Template 
Control (NTC). The NTC was performed using the same 
qPCR technique previously described with the difference that 
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no cDNA was added to the mixture (replaced by nuclease-
free water). The primers used for the NTC were for GAPDH 
thus the Cq value obtained for the NTC should be considered 
as a background reaction. Based on this, all markers whose 
Cq values resulted higher than the NTC or within a 
difference of less than 1 of a Cq were considered as to be 
negative/absent and not expressed by the cells.   
 
Cq values were normalised against GAPDH providing the 
delta-Cq (Cq) value. This was calculated using the 
following formula: 
Cq = Cq Gene of Interest – Cq House Keeping Gene  
 
The difference in gene expression, the delta-delta Cq 
(Cq), was established using the previously calculated Cq. 
Calculation was performed as follows: 
Cq = - (Cq of Treated Cells - Cq of Untreated Cells) 
 
To calculate the difference in the gene expression between 
MSCs and CCs, MSCs were taken to be the untreated cells, 
while CCs were considered to be the treated cells. With 
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regards to the change that occurred between the CCs and 
CC-RA cells, CCs were considered the untreated cells while 
the CC-RAs were considered the treated ones. In the case of 
the transfection results, the siRNA transfected cells were the 
treated cells, while the untreated cells were those 
transfected using the negative control (scramble siRNA). 
 
2.7. Transfection 
Transfection is the process of artificially introducing nucleic 
acids, DNA or RNA, into cells by utilising means other than 
viral infection. The insertion of DNA into a cell enables the 
expression or production of proteins using the machinery of 
the cells themselves, whereas insertion of complementary 
RNA into a cell is used to down-regulate the production of a 
specific protein by interfering with translation. 
 
For this project the three cell types were each transfected 
with miRNA antagonists. 
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2.7.1. Transfection reagent 
The transfection reagent used was the FluoMag Transfection 
Reagent by OZ Biosciences (Cat No.: FN10100). The 
FluoMag transfection reagent used for this experiment 
contains fluorescent-labelled magnetic beads thus allowing 
the visualisation of these nanoparticles in vitro. Once the 
vector aggregates to the nanoparticles, the magnetic 
particles are then concentrated onto the cells by an external 
magnetic field. The cellular uptake of the nanoparticles is 
accomplished by endocytosis and pinocytosis and can be 
visually seen by fluorescent microscopy. 
 
2.7.2. Antagomirs and negative controls 
Antagomirs are oligonucleotides that inhibit the action of the 
endogenous miRNAs. Once an antagomir binds to miRNA it 
forms a double stranded structure which is recognised and 
digested by DICER. Negative controls play a very important 
role when performing research based on miRNA since they 
are used to create a baseline for mRNA knockdown 
efficiency. Table 2.8 summaries the antagonists used for 
transfection. The negative control used was 
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MISSION® Synthetic microRNA Inhibitor (Sigma-Aldrich, Cat 
No.: NCSTUD001).  
 
Antagomirs 
Name Sequence Code Supplier 
siR-107 GAAGCCCGACAAGCGC 75334453 Integrated 
DNA 
Technologies 
siR-124 ACAGAGAGCGCCCGAA 75334451 
siR-381 GGCACACCGCGGCCA 75334452 
Table 2.8: Antagomirs used for transfection 
Legend: siR – MicroRNA antagonists 
 
2.7.3.Transfection Procedure 
Cells were seeded in a 12-well plate at a density of 1x105. A 
volume of 1ml complete medium was added to each well 
and the plate was incubated overnight at 37oC with 5% CO2 
in a humidified environment thus allowing cells to reattach 
to the bottom of the wells. The following day, for each well 
due to be transfected, an Eppendorf tube was labelled with 
the antagomir and a mixture of plain DMEM F12, antagomir 
and transfection reagent were added as per Table 2.9. The 
tubes were mixed well and incubated at room temperature 
for 15 minutes. 
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Component Volume per well 
Plain DMEM F12 50μl 
Antagomir/Negative control 10μl 
Transfection Reagent 2μl 
Total volume 62μl 
Table 2.9: Volumes required for transfection 
Legend: DMEM F12 - Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12. 
 
Once the incubation time elapsed, the plate was labelled 
according to which antagomir would be transfected where 
and the medium removed from the wells. A volume of 938μl 
complete medium was added to the Eppendorf tube, mixed 
well by pipetting up and down and transferred to the 
corresponding labelled well. Once the desired transfections 
were pipetted, the plate was placed on the magnet and 
incubated at 37oC with 5% CO2 in a humidified environment 
for 48 hours. After the 48-hour incubation period, the wells 
were washed twice with 500μl of PBS. Wells were then 
topped up with 500μl of PBS and viewed under the 
fluorescent microscope to confirm transfection efficiency 
was satisfactory the RNA was extracted, converted to cDNA 
and tested with RT-qPCR for neural markers and target gene 
markers for their respective miRNA. 
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2.8. Green Fluorescent Protein 
2.8.1. Bacterial transformation and plating 
The competent DH5E. coli bacteria had been previously 
prepared and these where made available by the 
Department of Clinical Pharmacology, University of Malta. 
These were stored in aliquots of 100μL. An aliquot of these 
competent cells was put on ice to thaw. Once thawed, 50μL 
of these cells were added to 50ng of Green Fluorescent 
Protein (GFP) plasmid DNA (Lonza, Cat No.: VDC-1040) in a 
total volume of 5μL. The mix was kept on ice for 5 minutes. 
The tube was placed on a heating block (Eppendorf, 
Germany) at 42oC for 90 seconds and afterwards 
immediately placed on ice for 5 minutes. A volume of 300μL 
Luria Broth (LB) (Sigma-Aldrich Cat No: L3522-250G) 
containing no antibiotics was added to the tube and 
incubated in a water bath (Memmert, Belgium) at 37oC for 
45 minutes. A volume of 350μL of bacterial culture was used 
to inoculate an LB plate containing ampicillin (Sigma-Aldrich 
Cat No: A5354). This was spread using a sterile disposable 
loop. The plate was left to stand at RT for 10 minutes and 
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then incubated (Helmer Scientific, USA), upside-down 
overnight at 37oC. 
 
2.8.2. Plasmid extraction 
Plasmid extraction was performed using the AccuPrep® 
Plasmid Mini Extraction Kit (Bioneer, Cat No: K-3030-1). 
The kit instructions may be found in Appendix II.  A falcon 
tube containing 5ml LB medium supplemented with 
ampicillin (Sigma-Aldrich Cat No: 10835242001) was 
inoculated with one colony transformed with GFP as 
described in Section 2.8.1. The concentration of ampicillin 
used was 1μg/ml of LB. The culture was placed in a shaking 
incubator (New Brunswick Scientific, USA) at 250rpm and 
incubated overnight at 37oC. The following day, the bacterial 
was pelleted by centrifugation (Eppendorf, Germany) at 
3000rpm for 15 minutes. The pellet was resuspended in 
250μL Resuspension Buffer and transferred to an Eppendorf 
tube. A volume of 250μL Lysis Buffer was added and the 
tube was inverted gently 6 times, after which 350μL 
Neutralisation Buffer were added. The tube was again 
inverted gently for 6 times and centrifuged at 14000rpm for 
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1 minute. The supernatant was transferred to a spin-column 
assembly and centrifuged for another 1 minute at 
14,000rpm. The flowthrough was discarded and 700μL Wash 
Buffer were added. The tube was centrifuged again for 1 
minute at 14,000rpm. The flowthrough was discarded once 
more and the tube was centrifuged for 1 minute at 
14,000rpm. The spin-column was transferred to a clean 
1.5ml tube, 100μL Elution Buffer were added and the set-up 
was incubated at room temperature for 2 minutes. After this 
incubation, the tube was centrifuged for 1 minute at 
14,000rpm. The plasmid concentration was measured by a 
spectrophotometer (Eppendorf, Germany) using a dilution of 
2 in 100 (2μL plasmid in 98μL distilled water). The plasmid 
size and integrity were confirmed by gel electrophoresis. 
 
2.8.3. Gel electrophoresis  
The gel was prepared by dissolving 0.5g of agarose (Sigma-
Aldrich Cat No: A9539) in 50mL 1x Tris-acetate-EDTA (TAE) 
buffer (Sigma-Aldrich Cat No: T8280) (10x TAE Buffer 40 
mM Tris, 20mM acetate, 2mM EDTA; pH 8.1). The mixture 
was heated in a microwave until all the agarose had 
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dissolved, after which 1μL of ethidium bromide (Sigma-
Aldrich Cat No: E1510) was added (1μL for every 50mL of 
1x TAE buffer). The ethidium bromide enabled the 
visualisation of nucleic acid fragments in the gel under UV 
light. The agarose mixture was poured into the mould and a 
well comb was fixed in place. Once the gel had solidified, 
the comb was removed and the mould together with the gel 
was placed in the electrophoresis tank. The tank was filled 
with 1x TAE buffer until the gel was completely submerged. 
A 1000bp molecular ladder (BioRad, Cat: 170-8204) was 
loaded into the first lane of the gel and 10μL of the plasmid 
was loaded in a separate well. The electrophoresis tank was 
closed, and the power supply was set to a voltage of 50V 
with a current of 200 mA for 40 minutes. Once 
electrophoresis was complete, the gel was removed from 
the electrophoresis tank and viewed on a transilluminator 
(Ultra-Violet Products Ltd., UK) to visualise the bands of 
plasmid products. The size of the DNA bands obtained was 
calculated by comparing their migration distances with that 
of the known molecular weight marker. 
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2.8.4. Transfecting Green Fluorescent Protein 
GFP was transfected as per Section 2.7. Reaction volumes 
may be viewed at Table 2.10. 
 
Component Volume per well 
Plain DMEM F12 50μl 
GFP (7µg) 10μl 
Transfection Reagent 2μl 
Total volume 62μl 
Table 2.10: Volumes required for GFP transfection 
Legend: DMEM F12 - Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12, GFP –Green Fluorescent Protein 
 
2.9. Statistical Analysis 
Statistics were analysed using the IBM SPSS Statistics 
version 24. Data may be viewed in Annex IV. 
 
2.9.1. Neurite length analysis 
Neurite growth post RA treatment was assessed using 
ImageJ as indicated by Pemberton et al (2018). The data 
was checked for being normally distributed using the 
Sharpio-Wilk test. Normal distribution of the data was 
defined as P>0.05. Once this was established, the difference 
in neurite length between RA treated and untreated cells 
was determined by T-Test analysis. The null hypothesis 
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implicated that there was no significant difference between 
the neurite lengths seen in treated and untreated cells and 
is accepted if P>0.05. The alternative hypothesis states that 
there is a significant difference between the neurite length 
of treated and untreated cells and is accepted if P<0.05.  
 
2.9.2. RT-qPCR analysis 
RT-qPCR data was analysed using the Mann-Whitney U test. 
Due to the small sample size outliers could not be 
eliminated, thus the data was considered not to be normally 
distributed. The null hypothesis was that there was no 
difference in the gene express measured during RT-qPCR 
analysis between treated and untreated cells. The 
alternative hypothesis stated that there is a difference in the 
gene expression of treated and untreated cells. The null 
hypothesis is accepted if the result falls above the desired 
significance threshold, P<0.05.   
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Chapter 3 
Results 
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3.1. Cell Culture 
3.1.1. Isolation of Mesenchymal Stem Cells 
Primary cell culture depends on various factors including, 
but not limited to, the quality of the source from which 
these cells are derived and their ability to expand. For this 
study, 13 cord-lengths were sampled (as detailed in Table 
2.1) and MSCs were successfully cultured from 12 of these 
samples. Cells grew out from the cultured Wharton’s Jelly 
approximate three to four weeks after processing (Figure 
3.1A) and gradually took on a spindle-shaped phenotype. 
On appearance of these spindle-shaped cells and cluster of 
cells, the Wharton’s Jelly pieces were removed to allow 
expansion of the cell population (Figure 3.1B). The 
maximum confluency obtained was between 50 – 60% 
within 30to 40days of culture (Figure 3.1C). In some 
instances, the 50-60% confluence was achieved after 60 
days. However, when cell clusters were not formed, the cells 
showed signs of senescence, becoming  large and flat 
followed by cytotoxin release which initiated apoptotic 
signalling in the cells(Haines, Juhasz and Tosaki, 2013).  
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Figure3.1: Isolation of Mesenchymal Stem Cells from Cord Samples 
Mesencyhmal Stem Cells (MSCs) were cultured from Cords 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13. The above figure is a 
representation of how MSCs were observed in culture. Once extracted from the cord, Wharton’s Jelly was placed in a 12-
well treated cell culture plate and cultured using xeno-free medium. The Wharton’s Jelly started to release spindle 
shaped cells (A) by the third week of incubation. Once cells started to form clusters (B), the tissue was removed from the 
plate.  A confluence of 50% - 60% was obtained within a minimum of 40-days of culturing. Once confluent, the cells 
derived where used in experiments to determine trilineage differentiation, differentiation to neural-like cells (via exposure 
to spent medium), characterisation by CD and neural markers and transfection with miRNA antagonist. Scale bar 
represents 20µm.   
Legend: MSCs – Mesenchymal Stem Cells, CD – Cluster of differentiation, miRNA - microRNA 
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3.1.2. Mesenchymal Stem Cell Trilineage differentiation 
One of the major characteristic that defines an MSC is its 
ability to differentiate into osteocytes, adipocytes and 
chondrocytes. The trilineage differentiation capability of the 
cultured MSCs was confirmed by standard induction 
protocols, and illustrative examples of differentiation are 
shown in Figures 3.2 – 3.4. 
 
The MSCs used for osteogenic differentiation were obtained 
from Cords 1, 3 and 5; adipocytes were differentiated from 
Cords 1, 4 and 5; and chondrocytes were derived from 
Cords 7, 8 and 9.To undergo this differentiation, MSCs were 
cultured in the induction medium for 21 days. Osteogenic 
MSC differentiation was confirmed by von Kossa staining - a 
calcium stain. Positivity for this differentiation was 
confirmed by the presence of a brownish-black to a deep 
black staining of the matrix mineralisation (Figures 3.2A – 
C).
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Figure 3.2: Osteogenic differentiation 
Mesenchymal Stem Cells (MSCs) cultured from Wharton’s Jelly extracted from Cord 1 (A), Cord 3 (B) and Cord 5 (C) were made to differentiate into 
osteocytes by means of an induction medium. Cells were cultured for 21-days in osteogenic induction medium, fixed in TB-Fix and then stained using the 
von Kossa staining method to detect the calcium deposits. MSC to osteogenic differentiation resulted in a light brown to blackish stain of the cells 
producing calcium. Figure D is a negative control and represents how undifferentiated MSCs look after von-Kossa staining is carried out, confirming that 
the brown-blackish stained cells are indeed due to these cells becoming calcium producing osteocytes. Scale bar represents 20µm.   
Legend: MSCs – Mesenchymal Stem Cells, TB-Fix – Tokuda-Baron fixative  
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Culturing of MSCs under adipogenic conditions induced the 
formation and accumulation of lipid-rich vacuoles within the 
cell cytoplasm which were visualised by staining red after 
exposure to the adipogenic stain Oil Red O (Figures 3.3A – 
C).
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Figure 3.3: Adipogenic differentiation 
Mesenchymal Stem Cells (MSCs) cultured from Wharton’s Jelly extracted from Cord 1 (A), Cord 4 (B) and Cord 5 (C) were made to differentiate into 
adipocytes by means of an induction medium. Cells were cultured for 21-days in adipogenic induction medium. Cells were then fixed in TB-Fix (A, C and D) 
and 4%PFA (B) prior to staining. MSC to adipogenic differentiation was confirmed by Oil-Red-O staining. This stain is specific for lipid vacuoles which are 
per se stained red. Figure D is a negative control and represents how undifferentiated MSCs look when stained with the Oil-Red-O, confirming that the red 
stained vacuoles are indeed a result of MSCs differentiating in adipocytes. Scale bar represents 20µm.   
Legend: MSCs – Mesenchymal Stem Cells, TB-Fix – Tokuda-Baron fixative  
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Chondrogenic differentiation was determined by the 
presence of glycosaminoglycan which was detected by 
staining of the cartilage extracellular matrix with Alcian Blue 
(Figures 3.4A – C).  
 
To confirm the validity of the staining procedures, MSCs 
which were not treated for the trilineage differentiation were 
also stained using the same protocols. In all three instances, 
no characteristic traits associated with the positive staining 
seen in the differentiated cells were observed in these 
negative controls (Figures 3.2D, 3.3D and 3.4D).
 Figure 3.4: Chondrogenic differentiation 
Mesenchymal Stem Cells (MSCs) cultured from Wharto
chondrocytes by means of an induction medium. Cells 
fixed in TB-Fix prior to staining with Alcian Blue. MSC t
the extracellular matrix. Figure D is a negative control 
the blue stained 3D cell formation is indeed a result of M
Legend: MSCs – Mesenchymal Stem Cells, TB-Fix – Toku
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were 3D cultured in fibrin clots and chondrogenic induction
o chondrogenic differentiation was confirmed by staining of 
and represents how undifferentiated MSCs look when staine
SCs differentiating into chondrocytes. Scale bar represents 2
da-Baron fixative 
 
9 (C) were made to differentiate into 
 medium for 21-days. Cells were then 
the glycosoaminoglycans secreted into 
d with the Alcian Blue, confirming that 
0µm.   
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Although all MSCs were exposed to the differentiation 
agents for the same period of time, it should be noted that 
MSCs were induced at different ages. The uniqueness of the 
source from which the cells were cultured has a great 
impact on the growth and proliferation of each cell 
population. A rapid proliferation of MSCs caused cell clusters 
to overlap and form fingerprint-like sheets; when a slow 
proliferation was obtained, the clusters were not compacted 
and individual cells were distinguishable. For example, in 
osteogenic differentiation, cells from Cord 3 grew in sheets 
making uniform staining of each cell difficult(Figure 3.2.B) 
as opposed to the cells stained from Cord1 (Figure 3.2A). 
Cells from Cord 5 started to show typical senescent 
characteristics by the time differentiation induction was 
concluded (Figure 3.2C). Estimating the number of MSCs 
that differentiated was problematic since in the case of 
osteotocytes, even if morphological changes were not 
apparent, these cells still produced calcium. This indicates 
that although they did not reach the point where a 
morphological change was induced MSCs had still begun to 
differentiate. Adipogenic differentiation was characterised by 
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the formation of lipid droplets, which may be easily removed 
during the washing stages of the staining procedure. This 
makes the actual number of droplets which were initially 
present very difficult to estimate. The chondrogenic-induced 
MSCs grew into a 3D-like structure making it impossible to 
determine how many cells were effectively present in the 
structure itself. It should also be noted that the difference in 
morphology of cells from Cord 4 (Figure 3.3B) was because 
cells were fixed in 4% paraformaldehyde. In view of the 
effect this fixative had on the cells, all subsequent 
preparations were fixed using TB-Fix.  
 
 
3.2. Neuronal differentiation of cultured 
Mesenchymal Stem Cells 
3.2.1. Conditioned Cells  
The spent medium from culturing of SH-SY5Y cells was used 
as a condition media to induce MSCs to differentiate into 
neuron-like cells. The spent medium was only collected from 
flasks whose cells were confluent to maximise the collection 
of biomolecules. Preparation of the spent medium and 
storage may be found in section 2.3.4.1. To prevent MSCs 
95 
 
from differentiating due to cell contact, the spent medium 
was centrifuged to remove dead cells and other debris 
before use. The MSCs isolated from Cords 5, 6, 7, 8, 9, and 
13 were induced to differentiate by adding the conditioned 
medium at a ratio of 1:1. The CCs used for this study were 
from cultures 5, 6 and 13. CCs from cultures 7, 8, and 9 had 
to be discarded due to contamination. On addition of the 
spent medium, the treated MSCs differentiated into neural-
like cells within 24-hours (Figure 3.5A). By the third day, 
except for MSCs showing senescence, all remaining cells had 
differentiated (Figure 3.5B) and a confluence of 80 – 90% 
was achieved within the next thirty days (Figure 3.5C). 
MSCs which were not treated with the spent medium did not 
acquire the characteristic star shaped morphology of neural-
like cells. 
96 
 
 
Figure 3.5: Conditioning of Mesenchymal Stem Cells to Neural-like cells 
Mesencyhmal Stem Cells (MSCs) cultured from Cords 5, 6 and 13 were treated with the spent medium obtained from culturing of SH-SY5Y - the in vitro 
model used for neural function and differentiation experiments (at a ratio of 1:1), which induced cells to differentiate into neural-like cells. The figure 
above represents the transition of MSCs to neural-like cells as seen during this experiment.  MSCs (A) started to differentiate within 24-hrs (B) of the 
addition of the spent medium and were fully differentiated within 72-hrs. Cells were left to proliferate (C) until confluence was reached (D) in 
approximately 3-weeks. Once confluence was achieved, cells were passaged and used for additional experiments (CD and neural marker characterisation, 
Retinoic Acid treatment and transfection of miRNA antagonist). Scale bar represents 20µm.   
Legend: MSCs – Mesenchymal Stem Cells, CD – Cluster of differentiation, miRNA - microRNA 
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3.2.2. Conditioned Cells treated with Retinoic Acid 
CCs were treated with RA to encourage the neuronal 
differentiation of these cells towards a more mature stage. 
For this study, the CCs treated with RA were cultures from 
Cords 5, 6 and 13. Morphological differences were visible 
between the RA-treated and untreated cells.  Untreated cells 
have a large, flat, epithelial-like morphology with numerous 
short projections extending outward (Figure 3.6A and 3.6C), 
while RA-treated CCs develop several neural-like projections 
that connect to surrounding cells forming a neuron-like 
network (Figure 3.6B and 3.6C). These morphological 
changes were observed in approximately 80 – 90% of the 
treated cells within a maximum of three weeks of starting 
the RA treatment. Prolonging RA treatment for longer than 
three weeks caused the development of fibroblast-like cells. 
Retinoid signalling may promote the growth of endoderm, 
adipocytes, fibroblast-like cells or neural tissue (Soprano, 
Teets and Soprano, 2007). Neural fate differentiation 
depends on the ability of RA to reduce the FGF/Extracellular 
Receptor Kinase signalling which is responsible for self-
renewal (Stavridis, Collins and Storey, 2010).  
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Figure 3.6: Morphological appearance of Conditioned cells with and without Retinoic Acid treatment. 
Conditioned Cells (CCs) derived from Mesenchymal Stem Cells cultured from Cord 5 (A), Cord 6 (B) and Cord 13 (C) were seeded in a 12-well treated cell 
culture plate at a density of 1x104 cells/ml and cultured in medium supplemented with cryo poor plasma CCP and treated with 0.2% Retinoic Acid (RA) for 
15-days. RA treatment caused the Conditioned Cells to elongate and develop dendrites (from Cord 5, Cord 6 and Cord 13 CCs as seen in D, E and F 
respectively) thus assuming the phenotypic characteristic of neuron-like cells.  Once confluence was achieved the total RNA of cells was extracted to be 
used in experiments for CD and neural marker characterisation and transfection of miRNA antagonist. Scale bar represents 20µm.   
Legend: CC – Conditioned Cells, RA- Retinoic Acid, CD – cluster of differentiation, miRNA – microRNA 
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3.2.2.1. Comparing neurite growth between Conditioned 
Cells and Retinoic Acid Treated Conditioned Cells 
The neurite projections of CCs and CC-RAs were measured 
using ImageJ. A total of 25 cells have been measured and 
results may be viewed in Table 3.1. An average neurite 
length of 3.8µm was observed in CCs while CC-RA presented 
neurite lengths of 15.1µm.  Statistical analysis (seen in 
Annex IV) determined this difference to be significant.   
  Cell Neurite length 
CCs CC-RAs 
1 4.39 18.00 
2 4.67 16.75 
3 5.24 16.60 
4 5.53 12.20 
5 4.19 10.89 
6 4.40 16.65 
7 4.34 18.38 
8 0.96 25.27 
9 6.04 13.29 
10 5.81 13.10 
11 3.82 17.30 
12 4.30 14.74 
13 1.41 15.39 
14 1.99 12.60 
15 3.24 11.85 
16 4.84 19.16 
17 2.55 11.57 
18 2.97 17.34 
19 4.46 11.37 
20 6.30 8.76 
21 1.41 17.57 
22 1.45 10.42 
23 3.36 14.10 
24 2.91 14.58 
25 5.14 19.08 
Table 3.1: Neurite Length 
The neurite length in CCs and CC-RAs was measured using Image J. CCs 
presented an average length of 3.8 µm while CC-RA cells had an average neurite 
length of 15.1µm. Statistical analysis showed this difference to be significant 
(P<0.05). 
Legend: CCs – Conditioned Cells, CC-RAs – Retinoic Acid treated CCs 
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3.3. Characterisation by cluster of differentiation cell 
surface markers 
MSCs, CCs and CC-RA cells were evaluated via RT-qPCR for 
the recommended ISCT CD markers for the characterisation 
of Wharton’s Jelly-derived MSCs. These included CD73, 
CD90, CD105, CD34 and CD45. The samples used to 
perform this characterisation were cells cultured and 
differentiated from Cords 5, 6 and 13. The average Cq of 
each CD marker is shown in Table 3.2 and the raw data is 
available in Appendix III.  CD90 and CD105 were detected 
during the early cycles of the RT-qPCR for all the three cell 
types. In MSCs, CD73 was detected during the final cycles 
of the RT-qPCR and both CD 34 and CD45 were beyond the 
40th cycle and so not detected by the system, while in CCs 
and CC-RAs, expression of CD73, CD34 and CD45 registered 
values very close to the 40th cycle.  
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Cell Type Sample CD73 CD90 CD105 CD34 CD45 
MSC 
Cord 5 31.65 24.43 26.11 39.85 40.00 
Cord 6 33.80 27.62 28.63 40.00 40.00 
Cord 13 32.82 26.97 31.36 40.00 40.00 
CC 
Cord 5 38.95 22.07 24.00 31.82 40.00 
Cord 6 32.98 20.27 23.67 32.87 34.62 
Cord 13 40.00 24.60 25.64 33.76 40.00 
CC-RA 
Cord 5 35.69 27.01 26.19 38.59 40.00 
Cord 6 40.00 29.43 29.69 40.00 40.00 
Cord 13 40.00 27.43 26.20 35.83 40.00 
Table3.2: Characterisation by CD Markers 
The RNA extracted from the cultured MSCs, CC and CC-RA cells was 
analysed by RT-qPCR for the expression of a panel of CD markers. The 
table shows the average cycling quantification (Cq) values detected 
during the analysis. The Cq is detected when the sample reaction 
surpasses that of pre-assigned threshold. The maximum Cq value 
reading is 40.00. When a sample Cq reaches this value, the expression 
which is being sought is said to be absent (value is inversely proportion 
to the expression). The average Cq for the expression of CD73 is seen to 
decrease in both CC and CC-RA cells. CD34 and CD45 expression are 
relatively close to the 40.00 limit for all the three cell types. On the 
other hand, CD 90 and CD105 were detected during much early cycles 
of the RT-qPCR run.   
CD – Cluster of differentiation, MSC – Mesenchymal Stem Cells, CC – 
Conditioned Cells, CC-RA – Retinoic Acid treated CC, Cq – cycle 
quantification, RT-qPCR – Real Time quantification polymerase chain 
reaction 
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Figures 3.7 and 3.8 show the average fold change of these 
CD markers expressed by CC and CC-RA cells when these 
are compared to MSCs and CCs respectively. Graphs are 
plotted with the fold change on the y-axis and the CD of 
interest on the x-axis. The baseline (1.00) for comparing 
MSCs and CCs were the MSCs. When comparing CC and CC-
RAs the baseline (starting point) was the CD expression in 
CCs. This means that in the case of Figure 3.7, the bars are 
showing whether the fold changed in CCs increased or 
decreased in respect to CD expression of the MSCs. In 
Figure 3.7A, CD73 in CCs was not detected and therefore 
the fold change decreased from 1.00 to 0.00. CD90 was also 
decreased by a fold change of 0.20, while as per Figure 
3.7B, CD105 had a fold change increase of 1964.57. It was 
not possible to calculate the fold change of CD34 and CD45 
because these where not expressed. 
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Similarly, in Figure 3.8, graphs are representing the Fold 
change in expression in CC-RA with respect to CCs.  In 
Figure 3.9, both CD90 and CD105 have a fold change 
decrease of 4.2 and 0.79 respectively.  It was not possible 
to calculate the fold change of CD34 and CD45 in the three 
cell types because these where not expressed. The same 
hold for CD73 in CC and CC-RA cells. 
 
Figure 3.8: Fold change in Neural Marker RNA expression from 
Conditioned Cells to Retinoic Acid-treated Conditioned Cells.  
The figure illustrates the average fold change difference between the CD 
markers detected in CCs and CC-RA cells during RT-qPCR analysis. The 
starting point of this calculated fold change was the CCs, which was 
considered to be the baseline (1.00). Thus, a fold-change difference of 
less than 1.00 represents a decrease in expression, concurrently a fold 
change greater than 1.00 shows an increase in marker expression. 
When comparing CD markers expressed by the CCs and CC-RA cells, the 
fold difference for CD90 was 0.42 while CD105 had a fold difference of 
0.79. CD73, CD34 and CD45 were not expressed by CCs and CC-RA. N 
represents the number of technical replicates. Error bars represent the 
RQmin and RQmax. The * denotes a significance in the fold difference 
between the cell types (P<0.05). 
Legend: CC - Conditioned Cells, CC-RA – Retinoic Acid treated CC, CD-
Cluster of differentiation, RT-qPCR – Real Time quantification 
polymerase chain reaction 
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3.4. Cell Characterisation by Neural Markers 
Neural lineage markers are expressed by cells that are 
formed during neurogenesis and help distinguish between 
cells which have a neural phenotype and other brain cell 
types (Tanapat, 2016). In the absence of specific 
differentiating agents MSCs can express neural markers, 
which in turn confirms their predisposition to differentiate 
into cells of non-mesengenic lineages such as neurons 
(Fazeli et al., 2015). 
 
MSCs, CCs and CC-RA cells were evaluated via RT-qPCR for 
RNA expression of neuronal markers determining a specific 
neural stage: neuroepithelial (NES and SOX2), intermediate 
progenitors (MASH1), immature (TUBB3 and ND1) and 
mature (MAP2 and NEU). Again, the samples tested were 
cells cultured from Cords 5, 6 and 13. Testing for the 
neuronal stage of the cell type has confirmed that MSCs can 
transdifferentiate into neural-like cells upon addition of 
neuroblastoma-spent medium, thus becoming CCs. This cell 
type was further differentiated towards maturity upon 
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treatment with RA, ultimately resulting in the development 
of CC-RA cells. 
 
OCT4 is not a neural marker but was included in this panel 
to monitor the loss of stemness during the transition from 
MSCs to neural-like cells. OCT4 is usually still expressed at 
lower levels by the developing neural cells since it promotes 
neuroectoderm formation. Eventually this marker is 
drastically reduced to a point where it is no longer 
expressed by fully mature neural cells (Lee et al., 2010). 
 
Table 3.3 shows the average neural marker Cq values 
obtained by RT-qPCR analysis and the raw data is shown in 
Appendix III. With the exception of MAP2 and NEU, all the 
neural markers (and OCT4) tested in the MSCs registered 
signals during the early cycles of the RT-qPCR analysis. CC 
and CC-RA cells follow a similar pattern, meaning that 
neural markers and OCT4 where again detected during the 
early cycles. MAP2 and NEU were also detected in CC and 
CC-RA cells except for marker NEU in the cells isolated from 
cord5. 
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Cell Type Sample NES SOX2 OCT4 TUBB3 MASH1 ND1 MAP2 NEUN 
MSC 
Cord 5 30.00 25.84 24.53 27.16 21.58 25.87 39.36 39.76 
Cord 6 30.40 26.62 24.81 29.91 24.68 26.66 38.43 40.00 
Cord 13 34.06 32.57 31.24 33.16 30.09 32.81 40.00 40.00 
CC 
Cord 5 21.30 26.58 29.05 18.78 21.41 25.51 21.17 30.28 
Cord 6 16.60 24.96 27.34 15.68 17.68 20.73 17.42 28.20 
Cord 13 20.41 24.43 23.69 19.99 22.70 24.72 20.56 28.85 
CC-RA 
Cord 5 26.23 28.45 27.96 24.38 24.05 27.15 25.11 40.00 
Cord 6 25.80 31.52 27.42 25.29 25.10 28.33 25.05 33.45 
Cord 13 26.40 19.98 18.23 26.02 18.57 18.89 25.86 35.86 
Table 3.3: Neuronal Markers RNA expression  
The table shows the average neuronal marker expression cycle quantification (Cq) data obtained from the RT-qPCR 
analysis of the RNA extracted from MSCs, CCs and CC-RA cells. The Cq is detected when the sample reaction surpasses 
that of pre-assigned threshold. The maximum Cq value reading is 40.00. When a sample Cq reaches this value, the 
expression which is being sought is said to be absent (value is inversely proportion to the expression). In MSCs both 
MAP2 and NEU are on the threshold limit (40.00) indicating that no reaction was registered during the RT-qPCR analysis. 
The same is observed in NEU for CC-RA cells isolated from Cord 5. The remaining markers where all detected during the 
early cycles of the analysis.  
Legend: MSCs – Mesenchymal Stem Cells, CCs – Conditioned Cells, CC-RAs – Retinoic Acid treated CCs,  Cq – cycle 
quantification, RT-qPCR – Real Time quantification polymerase chain reaction, NES – Nestin, SOX2 - Sex determining 
region Y-Box 2, OCT4 - Octamer-binding transcription factor 4, MASH1 - Mammalian achaete-scute homolog-1, TUBB3 - 
Beta III Tubulin, ND1 – NeuroD1, MAP2 - Microtubule-associatedprotein, NEU - Neuronal-specific nuclear protein 1 
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Figures 3.9 and 3.10 show the fold changes of these 
markers. Graphs were plotted using the same criteria 
described in Section 3.3, i.e. the expression of MSCs was 
taken as the starting point (1.00) when comparing fold 
change between MSCs and CCs. On the other hand, CCs 
were the baseline for the difference between CCs and CC-RA 
cells. Any fold differences of less or higher than 1.00 were 
shown respectively as a decrease and increase. 
 
Figure 3.9A-B, shows an increase in the fold change of NES 
(22.74), TUBB3 (24.35). MAP2 (9757.90) and NEU (24.59) 
and a fold change decrease in SOX2 (0.15), OCT4 (0.08) 
MASH1 (0.16) and ND1 (0.17).  
 
 . 
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When comparing CC and CC-RA in Figure 3.10, NES (0.33), 
TUBB3 (0.24) and MAP2 (0.82) all had a fold change which 
was less than the 1.00 baseline. The same figure reports the 
values for SOX2 (69.81), OCT4 (173.85), MASH1 (14.51), 
ND1 (11.39) and NEU (2.57) as being over the 1.00 mark.  
   
Figure 3.10: Fold change in Neural Marker 
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3.5. Transfection of microRNA antagonists 
MiRNAs are known to regulate the differentiation of both 
MSCs and neural cells. However, little is known regarding 
whether individual miRNAs can induce this change. In this 
study, antagonists to miR-107, miR-124 and miR-381 have 
been tested to verify if these miRNAs may indeed cause 
MSCs to differentiate into neuroblasts. Furthermore, the 
same antagonists have been tested to elucidate 
whetherthese miRNAs may encourage these cells to 
differentiation further on towards becoming mature 
neurons. 
 
3.5.1. Transfection Efficiency 
Transfection efficiency is limited by several factors which 
include the health and viability of the cells, the number of 
passages, the degree of confluence and the transfection 
method used. In this study tranfection of CCs was done 
after 7 days from the 2nd passage, and CC-RA cells were 
transfected on the 21st day of the RA-treatment.  
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Primary cultures are difficult to maintain as these have both 
a limited growth potential and life-span. The MSCs used for 
transfection were cultured from Cords 9 and 11, and CCs 
and RA-CC cells were from cultures 5, 6 and 13. MSCs were 
transfected on the 22nd day from when the first cells were 
isolated.  On the 20th day, MSCs were seeded in 12-
wellplatesat a density of 1x104cells/ml. The recovery rate of 
MSCs was expected to be much lower than that of CCs and 
CC-RA cells since upon dissociation cells may initiate 
apoptosis signalling (Deng et al., 2017). MSC transfection 
was performed within two days of seeding to minimise such 
losses.  To prevent the same thing happening to the CC-RA 
cells, these were seeded as CCs, treated with RA directly in 
the 12-well plate and transfected after 21 days  Similarly 
CCs were transfected after 21 days from when these were 
transformed from the MSCs using the conditioned medium. 
Uptake of the transfection reagent (fluorescent labelled 
beads) by the cells was confirmed by fluorescent microscopy 
(Figures 3.11– 3.18). 
 
114 
 
After treating cells with the transfection reagent for 48-
hours, they were washed in PBS to remove any unbound 
microparticles and viewed microscopically using x200 
magnification. Brightfield microscopy (Figure 3.11– 3.18 
images A – D) shows that all cells maintained both 
membrane architecture and structure integrity. When 
observing the same fields at the same magnification using a 
red fluorescence filter (Figure 3.11– 3.18images F – I), it is 
possible to view the bound nanoparticles which appear as 
fluorescent specks. Merging of both brightfield and 
fluorescent images (Figure 3.11– 3.18images K – N), gives 
an approximation of the number of cells which absorbed and 
incorporated the transfection reagent. To ensure that the 
fluorescence was caused by the transfection 
reagent,untransfected cells were also viewed under the 
same conditions (Figure 3.11– 3.18images E, J and O). No 
fluorescence was seen when viewed using the red filter, 
which is evidence that the fluorescent specks seen in the 
transfected cells were indeed the consequence of the 
magnetic fluorescent microparticles. The overall transfection 
efficiency characterised by the uptake of the microparticles 
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showed that most cells did indeed incorporate the magnetic 
beads. However, this efficiency only indicates how many 
microparticles have been incorporated into the cells. It is 
not possible to know the exact amount of miRNA antagonist 
that actual aggregated to the beads and how much of this 
was taken up by the cell itself. The efficiency of these 
microparticles was confirmed by transfection of GFP and the 
results are illustrated in Figure 3.19. CCs and CC-RA cells 
used for the GFP transfection were both from Cord 6. This 
result confirms that transfection of GFP was successful, thus 
since the miRNA antagonists are smaller in length, it is 
reasonable to conclude that these too were able to 
aggregate to the microparticles and be subsequently taken 
up by the cells. 
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Figure 3.11: Transfection of Cord 9 Mesenchymal Stem Cells 
miRNA antagonists were transfected into Cord 5 MSCs using magnetic florescent nanoparticles upholding the xeno-free set-up adopted throughout 
the whole experiment. Cells were transfected for 48-hrs and washed in PBS to remove any nanoparticles which had not been incorporated in the 
cells. Brightfield images (A – E) show that the membrane architecture and structure of the cells were intact after the uptake of the nanoparticles. 
Once on the cells, the nanoparticles were incorporated in the cell by endocytosis and the attached miRNA antagonist was uptaken via pinocytosis. 
Incorporation of the nanoparticles is represented by the fluorescent images (F-J) and the merged images (K-O) show the position of the 
nanoparticles in relation to the cell. The negative control represents the cells transfected with the MISSION® Synthetic microRNA Inhibitor. Scale bar 
represents 20µm.   
Legend: MSCs – Mesenchymal Stem Cells 
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Figure 3.12: Transfection of Cord 11 Mesenchymal Stem Cells 
miRNA antagonists were transfected into Cord 11 MSCs using magnetic florescent nanoparticles upholding the xeno-free set-up adopted throughout 
the whole experiment. Cells were transfected for 48-hrs and washed in PBS to remove any nanoparticles which had not been incorporated in the 
cells. Brightfield images (A – E) show that the membrane architecture and structure of the cells were intact after the uptake of the nanoparticles. 
Once on the cells, the nanoparticles were incorporated in the cell by endocytosis and the attached miRNA antagonist was uptaken via pinocytosis. 
Incorporation of the nanoparticles is represented by the fluorescent images (F-J) and the merged images (K-O) show the position of the 
nanoparticles in relation to the cell. The negative control represents the cells transfected with the MISSION® Synthetic microRNA Inhibitor. Scale bar 
represents 20µm.   
Legend: MSCs – Mesenchymal Stem Cells 
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Figure 3.13: Transfection of Cord 5 Conditioned Cells 
miRNA antagonists were transfected into Cord 5 CCs using magnetic florescent nanoparticles upholding the xeno-free set-up adopted throughout the 
whole experiment. Cells were transfected for 48-hrs and washed in PBS to remove any nanoparticles which had not been incorporated in the cells. 
Brightfield images (A – E) show that the membrane architecture and structure of the cells were intact after the uptake of the nanoparticles. Once on 
the cells, the nanoparticles were incorporated in the cell by endocytosis and the attached miRNA antagonist was uptaken via pinocytosis. 
Incorporation of the nanoparticles is represented by the fluorescent images (F-J) and the merged images (K-O) show the position of the 
nanoparticles in relation to the cell. The negative control represents the cells transfected with the MISSION® Synthetic microRNA Inhibitor. Scale bar 
represents 20µm.   
Legend: CCs – Conditioned Cells 
119 
 
  
Figure3.14: Transfection of Cord 6 Conditioned Cells 
miRNA antagonists were transfected into Cord 6 CCs using magnetic florescent nanoparticles upholding the xeno-free set-up adopted throughout the 
whole experiment. Cells were transfected for 48-hrs and washed in PBS to remove any nanoparticles which had not been incorporated in the cells. 
Brightfield images (A – E) show that the membrane architecture and structure of the cells were intact after the uptake of the nanoparticles. Once on 
the cells, the nanoparticles were incorporated in the cell by endocytosis and the attached miRNA antagonist was uptaken via pinocytosis. 
Incorporation of the nanoparticles is represented by the fluorescent images (F-J) and the merged images (K-O) show the position of the 
nanoparticles in relation to the cell. The negative control represents the cells transfected with the MISSION® Synthetic microRNA Inhibitor. Scale bar 
represents 20µm.   
Legend: CCs – Conditioned Cells 
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Figure 3.15: Transfection of Cord 13 Conditioned Cells 
miRNA antagonists were transfected into Cord 13 CCs using magnetic florescent nanoparticles upholding the xeno-free set-up adopted throughout 
the whole experiment. Cells were transfected for 48-hrs and washed in PBS to remove any nanoparticles which had not been incorporated in the 
cells. Brightfield images (A – E) show that the membrane architecture and structure of the cells were intact after the uptake of the nanoparticles. 
Once on the cells, the nanoparticles were incorporated in the cell by endocytosis and the attached miRNA antagonist was uptaken via pinocytosis. 
Incorporation of the nanoparticles is represented by the fluorescent images (F-J) and the merged images (K-O) show the position of the 
nanoparticles in relation to the cell. The negative control represents the cells transfected with the MISSION® Synthetic microRNA Inhibitor. Scale bar 
represents 20µm.   
Legend: CCs – Conditioned Cells 
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Figure 3.16: Transfection of Cord 5 Retinoic Acid treated Conditioned Cells 
miRNA antagonists were transfected into Cord 6 CC-RA cells using magnetic florescent nanoparticles upholding the xeno-free set-up adopted 
throughout the whole experiment. Cells were transfected for 48-hrs and washed in PBS to remove any nanoparticles which had not been 
incorporated in the cells. Brightfield images (A – E) show that the membrane architecture and structure of the cells were intact after the uptake of 
the nanoparticles. Once on the cells, the nanoparticles were incorporated in the cell by endocytosis and the attached miRNA antagonist was uptaken 
via pinocytosis. Incorporation of the nanoparticles is represented by the fluorescent images (F-J) and the merged images (K-O) show the position of 
the nanoparticles in relation to the cell. The negative control represents the cells transfected with the MISSION® Synthetic microRNA Inhibitor. Scale 
bar represents 20µm.   
Legend: CC-RA – Retinoic Acid treated Conditioned Cells  
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Figure 3.17: Transfection of Cord 6 Retinoic Acid treated Conditioned Cells 
miRNA antagonists were transfected into Cord 6 CC-RA cells using magnetic florescent nanoparticles upholding the xeno-free set-up adopted 
throughout the whole experiment. Cells were transfected for 48-hrs and washed in PBS to remove any nanoparticles which had not been 
incorporated in the cells. Brightfield images (A – E) show that the membrane architecture and structure of the cells were intact after the uptake of 
the nanoparticles. Once on the cells, the nanoparticles were incorporated in the cell by endocytosis and the attached miRNA antagonist was uptaken 
via pinocytosis. Incorporation of the nanoparticles is represented by the fluorescent images (F-J) and the merged images (K-O) show the position of 
the nanoparticles in relation to the cell. The negative control represents the cells transfected with the MISSION® Synthetic microRNA Inhibitor. Scale 
bar represents 20µm.   
Legend: CC-RA – Retinoic Acid treated Conditioned Cells  
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Figure 3.18: Transfection of Cord 13 Retinoic Acid treated Conditioned Cells 
miRNA antagonists were transfected into Cord 13 CC-RA cells using magnetic florescent nanoparticles upholding the xeno-free set-up adopted 
throughout the whole experiment. Cells were transfected for 48-hrs and washed in PBS to remove any nanoparticles which had not been 
incorporated in the cells. Brightfield images (A – E) show that the membrane architecture and structure of the cells were intact after the uptake of 
the nanoparticles. Once on the cells, the nanoparticles were incorporated in the cell by endocytosis and the attached miRNA antagonist was uptaken 
via pinocytosis. Incorporation of the nanoparticles is represented by the fluorescent images (F-J) and the merged images (K-O) show the position of 
the nanoparticles in relation to the cell. The negative control represents the cells transfected with the MISSION® Synthetic microRNA Inhibitor. Scale 
bar represents 20µm.   
CC-RA – Retinoic Acid treated Conditioned Cells  
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Figure3.19: Transfection of Green Fluorescent Protein 
Green Fluoresent Protein (GFP) was transfected into CCs and CC-RA cells to further confirm the efficiency of the transfection employing the 
fluorescent nanoparticles. Again, bright field images (A and E) confirm the membrane architecture and structure of the cells were intact after 
transfection. The green fluorescence images (B and F) indicate that GFP was transfected into the cells, while the red fluorescent images (C and G) 
show the incorporation of the nanoparticles in the cell. The merged images (G and H) identify the GFP transfected cells in relation to the incorporated 
nanoparticles and the other cells. Scale bar represents 20µm.   
Legend: GFP – Green Fluorescent Protein,  CCs - Conditioned cells,  CC-RA – Retinoic Acid treated CC 
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3.5.2. The effect of microRNA antagonist transfection on 
target genes 
Shown in Table 3.4 are the Cq values registered during the 
RT-qPCR analysis for the three targets genes expressed by 
MSCs, CCs and CC-RA cells post transfection of siR-107 
(target DICER), siR-124 (target PTP1B) and siR-381 (target 
HES1). Included in the table are the Cq values obtained 
when measuring the target gene expression in the cells 
transfected with the negative control, i.e. the cells 
transfected with the MISSION® Synthetic microRNA 
Inhibitor. The target gene expression in MSCs post siRNA 
(and control) transfection register Cq values during the final 
cycles of the RT-qPCR. Cord 9 HES1 and Cord 11 DICER 
having a Cq value of 40.00, meaning that no RNA for these 
two genes was detected. A similar pattern may be seen with 
CCs. However, in this case RNA for PTP1B Cq values were 
detected during the early cycles. For this target, Cq values 
ranged from 25.57 – 26.38 in the siRNA transfected cells 
and from 27.96 – 28.97 in the cells transfected with the 
MISSION® Synthetic microRNA Inhibitor. With regards to 
the expression of these target genes found in CC-RA cells, 
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Cq values for DICER ranged from 27.25 – 30.01, PTP1B was 
detected between 25.90 – 31.91 and HES1 values where 
between 25.60 – 29.63. Raw data may be viewed in 
Appendix III. 
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Cell Type Sample DICER PTP1B HES1 
DICER  
NEG  CTL 
PTP1B  
NEG CTL 
HES1  
NEG CTL 
MSC 
Cord 9 32.61 32.94 40.00 34.90 34.45 33.49 
Cord 11 40.00 31.46 31.30 34.43 30.37 32.49 
CC 
Cord 5 30.13 26.38 36.58 34.24 28.97 38.58 
Cord 6 32.31 26.39 33.82 31.89 28.26 32.03 
Cord 13 32.14 25.57 30.15 32.43 27.96 29.37 
CC-RA 
Cord 5 28.45 31.91 25.60 29.02 23.43 28.03 
Cord 6 30.01 26.76 29.63 28.60 22.82 27.54 
Cord 13 27.32 25.90 26.56 27.25 23.33 27.33 
Table 3.4: Gene Target RNA expression. 
The table shows the average cycle quantification (Cq) which represent the time taken for the qPCR set-up to detect the 
signal emitted during amplification. Cultured cells where transfected with miRNA antagonist for 48-hrs after which total 
RNA was extracted and analysed using RT-qPCR to detect the expression of their respective targets. The targets were as 
follows: DICER for transfection of siR-107, PTP1B for siR-124 and HES1 for siR-381. Except for HES1 and DICER in MSCs 
respectively from Cord 9 and Cord 11, all other targets registered a Cq value. Cq values are inverse to the amount of 
target nucleic acid, meaning that lower Cq values (typically below 29 cycles) indicate high amounts of target sequence 
while higher Cq values (above 38 cycles) mean a lower amount of target nucleic acid. With the exception of the two 
results whose Cq was 40.00, all other targets registered a Cq results which ranged between 22.82 and 38.58. The 
negative control is the MISSION® Synthetic microRNA Inhibitor. 
Legend: MSCs – Mesenchymal Stem Cells, CCs – Conditioned Cells, CC-RAs – Retinoic Acid treated CCs, NEG CTL – 
Negative miRNA antagonist control, NTC – Non template control, HES1 – Hairy and enhancer of split 1, PTP1B - Protein-
tyrosine phosphatase 1B,  Cq – cycle quantification, RT-qPCR – Real Time quantification polymerase chain reaction 
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DICER plays an important regulatory role in several 
biological functions. The DICER1 gene produces a protein 
which regulates the RNA expression of other genes and is 
responsible for the formation of miRNAs. Due to its various 
regulatory effect on gene RNA expression, DICER is also 
associated with cell growth, proliferation and differentiation 
(U.S. Department of Health & Human Services, 2019). 
DICER is regulated by miR-107, where a decreased RNA 
expression of this miRNA increases DICER, promoting 
neurogenesis (Ristori et al., 2015).  
 
Like other members of the Hairy and Enhancer of Split 
proteins, HES1 is responsible for several physiological 
processes including cellular differentiation, cell cycle 
arrest, apoptosis and self-renewal (Liu, Dai and Du, 2015). 
The presence of miR-381 increases the RNA expression of 
HES1 (Shi et al., 2015). 
 
MiR-124 regulates the progression of neural differentiation. 
The RNA expression of the mRNA binding proteinPTP1B, a 
global regulator of pre-mRNA splicing, is down-regulated by 
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miR-124(Neo et al., 2014).  One of the roles of PTP1B is to 
prevent the early onset of neural progenitors (Linares et 
al., 2015).This means that in the presence of themR-124 
antagonist, the PTP1B gene RNA expression should 
increase and prevent neural differentiation.  
 
Figure 3.20 A - C show the average fold change in gene 
target expression obtained after transfecting the three cell 
types with the siRNAs for MSCs (A), CCs (B) and CC-RA 
(C). The baseline (1.00) is based on the Cq values 
registered during the RT-qPCR analysis of the cells 
transfected with the MISSION® Synthetic microRNA 
Inhibitor, that is the Negative control is the starting point of 
the fold change.  Results show that post transfection the 
fold change in MSCs was 8.25 for DICER, 0.03 for PTP1B 
and 1.14 in HES1. In CCs the fold change seen in DICER 
was 12.22, in PTP1B 5.13 and HES1 1.81. Finally, the 
calculated fold change in CC-RA cells was 5.93 for DICER, 
0.08 for PTP1B and 1.55 for HES1. 
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3.5.3. Neural marker RNA expression post-transfection 
with microRNA antagonists 
The changes in the RNA expression of neural markers NES, 
TUBB3, ND1, MAP2 and NEU were assessed post-
transfection of the miRNA antagonists. These markers were 
selected from the previous panel since: NES is the primary 
marker for neural epithelial cells and  should reflect the 
transdifferentiation of the MSCs and further maturation of 
the neural cells; TUBB3 is the marker which is most likely to 
show the change during the transition from MSCs to neural-
like cells; ND1 was the only marker used in the previous 
panel which represents the intermediate neural progenitor 
stage; Both MAP2 and NEU are late neural markers and 
would confirm whether the CCs and CC-RA cells had 
proceeded to a more mature stage. 
 
RT-qPCR data for the expression of these markers has been 
summarised in Table 3.5 (raw Data in Appendix III).  
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A: NES 
Cell Type Sample si107 si124 si381 NEG CTL 
MSC 
Cord 9 36.60 34.54 40.00 34.26 
Cord 11 40.00 33.27 40.00 33.86 
CC 
Cord 5 30.95 28.81 29.14 30.24 
Cord 6 32.49 30.34 29.68 31.02 
Cord 13 32.23 30.60 29.81 30.75 
CC-RA 
Cord 5 29.05 27.82 24.01 26.23 
Cord 6 39.55 28.83 26.81 25.88 
Cord 13 25.75 26.82 26.95 26.40 
 
B: TUBB3 
Cell Type Sample si107 si124 si381 NEG CTL 
MSC 
Cord 9 32.11 32.82 31.16 34.34 
Cord 11 35.36 31.64 29.08 32.96 
CC 
Cord 5 28.73 27.14 27.04 28.14 
Cord 6 28.51 28.34 28.20 28.76 
Cord 13 32.61 31.64 29.08 32.86 
CC-RA 
Cord 5 26.94 27.07 22.60 24.38 
Cord 6 31.86 32.98 25.94 25.29 
Cord 13 26.38 34.86 24.89 26.02 
 
C: ND1 
Cell Type Sample si107 si124 si381 NEG CTL 
MSC 
Cord 9 26.75 29.15 27.89 29.18 
Cord 11 19.30 19.46 19.34 18.89 
CC 
Cord 5 28.40 25.62 30.48 26.83 
Cord 6 28.58 30.51 30.54 30.08 
Cord 13 40.00 35.43 40.00 36.36 
CC-RA 
Cord 5 28.07 35.33 25.73 27.15 
Cord 6 29.41 23.94 27.45 28.33 
Cord 13 18.94 18.46 19.17 18.89 
 
 
 
 
 
 
 
D: MAP2 
Cell Type Sample si107 si124 si381 NEG CTL 
MSC 
Cord 9 39.83 40.00 39.26 39.96 
Cord 11 40.00 40.00 40.00 40.00 
CC 
Cord 5 29.82 26.98 28.03 29.52 
Cord 6 29.93 29.05 29.04 29.80 
Cord 13 36.42 32.49 34.18 31.66 
CC-RA 
Cord 5 28.32 26.68 23.64 25.11 
Cord 6 38.04 33.04 25.73 25.05 
Cord 13 26.02 30.96 25.31 25.86 
 
E: NEU 
Cell Type Sample si107 si124 si381 NEG CTL 
MSC 
Cord 9 40.00 40.00 40.00 39.80 
Cord 11 40.00 40.00 40.00 40.00 
CC 
Cord 5 40.00 40.00 40.00 40.00 
Cord 6 40.00 40.00 40.00 30.10 
Cord 13 30.50 32.48 30.49 30.94 
CC-RA 
Cord 5 40.00 40.00 40.00 40.00 
Cord 6 40.00 36.32 40.00 33.60 
Cord 13 34.25 35.46 35.54 35.09 
Table 3.5: Neural markers RNA Expression post miRNA antagonist 
transfection. 
The table shows the average neural marker expression cycle quantification (Cq) 
data obtained from the RT-qPCR analysis of MSCs, CCs and CC-RA cells after these 
where tranasfected with siRNAs. The Cq is detected when the sample reaction 
surpasses that of pre-assigned threshold. The maximum Cq value reading is 40.00. 
When a sample Cq reaches this value, the expression which is being sought absent 
(value is inversely proportion to the expression). A panel of neural markers was 
tested post transfection of miRNA antagonist siR-107, siR-124 and siR-381. The 
average cycling quantification (Cq) of these markers ranged from 25.75 – 34.86 for 
NES (A), 22.60 – 34.86 for TUBB3 (B), 18.46 - 40.00 for ND1 (C), 23.64 - 40.00 
for MAP2(D) and 30.10 - 40.00 for NEU (E). The negative control is the 
MISSION® Synthetic microRNA Inhibitor. 
Legend: MSCs – Mesenchymal Stem Cells, CCs – Conditioned Cells, CC-RAs – 
Retinoic Acid treated CCs, NEG CTL – Negative miRNA antagonist control si – 
miRNA antagonist, NES – Nestin, TUBB3 –Beta III Tubulin, ND1 – Neuro D1, 
MAP2 – Microtubule-associated protein, NEU – Neuronal-specific nuclear protein
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As seen in Table 3.5A, NES expression in MSCs was detected 
during the late cycles of the RT-qPCR analsysis with Cq 
values ranging from 33.27 – 40.00. To note that even RNA 
extracted from the cells transfected with the negative control 
were detected relatively late (Cq values of 3426 and 33.86). 
Except for the cells transfect with the siR-381, CCs follow a 
similar pattern to that of MSCs with Cq values of over 30.00. 
Transfection of siR-381 resulted with the expression of NES 
being signaled just below the 30th cycle. Transfections for CC-
RA cells showed NES expressed at an early stage of the RT-
qPCR. Except for CC-RA cells extracted from Cord 6 
transfected with siR-107 (which had a Cq value of 39.55) all 
other transfected cells had Cq values ranging between 24.01 
and 29.05. 
 
TUBB3 (as seen in Table 3.5B) was also expressed by the 
three cell types. Cq values for MSCs ranged were on the 
higher end of the RT-qPCR cycles with Cq values 29.08 – 
35.36. Both CCs and CC-RA cells had TUBB 3 detected at an 
earlier stage with Cq values ranging between 27.04 – 32.86 
for CCs and between 24.38 – 34.86 for CC-RAs.  
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Table 3.5C show the Cq values for the three cell types when 
tested for the expression of ND1 post transfection of siRNA. 
Both MSCs and CC-RA registered the expression of ND1 
during the first phases of the RT-qPCR analysis with Cq 
values ranging from 18.89 – 29.18 in MSCs and from 18.46 – 
35.33 in CC-RA. CCs showed ND1 expression at a later 
cycling period (Cq values ranging from 25.62 – 36.36), with 
Cord 5 transfection of siR-107 and siR-381 not expressing 
ND1 (Cq value of 40.00).  
 
Expression of MAP2 (Table 3.5D) signalling was not 
registered within MSCs (Cq values where 40.00 or within less 
than 1Cq of this threshold). In contract both CC and CC-RA 
cells were able to express MAP2 after transfection of the 
siRNAs. CCs were able to express MAP2 at with a Cq value 
between 26.98 – 36.42. Post transfection CC-RA MAP2 was 
detected at Cq values ranging from 23.64 – 33.04. CC-RA 
Cord 6 transfected with siR-107 expressed MAP2 at a very 
late stage during RT-qPCR analysis (Cq value 38.04). 
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Table 3.5E shows that NEU expression was not detected 
neither in MSCs post transfection nor in the cells transfected 
with the MISSION® Synthetic microRNA Inhibitor. This was 
also seen in CC and CC-RA cells isolated from Cord 5. Testing 
CCs obtained from Cord 6 shows that while NEU expression 
was registered in the negative control transfection (Cq 
30.10), no expression was seen post siRNA transfection (Cq 
value 40.00). This was not the case with CCs from Cord 13 
whose NES expression was relatively detected during the 
same cycling period (Cq value between 30.49 – 32.48). A 
similar result to that of Cord 13 CCs was observed with CC-
RA cells from the same cord. All Cq values from the siR-
transfection and negative control where within approximately 
1Cq from each other (values ranged from 34.25 -35.4). 
Expression of NES in CC-RA cells from Cord 6 was seen in 
both the negative control (Cq 33.60) and post siR-124 
transfection (Cq 36.32) but not post transfection of siR-107 
and siR-381 (Cq 40.00). 
 
Figure 3.21 - 3.25 shows the average fold difference in 
neural marker expression post siRNA transfection. Once 
136 
 
again, the fold change was calculated against the negative 
control Cq values.  
 
Figure 3.21 groups the fold change seen in NES for the 
three cell types. Here, MSC (A) resulted as having a fold 
change of 0.03, 0.12 and 0.02 respectively for transfection 
of siR-107, siR-124 and siR-381; CCs (B) had a fold 
change of 0.66 with siR-107, 0.40 with siR-124 and 1.32 
with siR-381; The fold change seen in CC-RAs (C) was 
0.87 for siR-107, 0.27 for siR-124 and 1.01 for siR-381. 
 
  
 
 
 
 
137 
 
 
Figure 3.21: NES RNA expr
transfection 
The figure represents the aver
NES expressed post transfecti
CCs (B) and CC-RAs (C) cells 
point of this calculated fold c
Control (MISSION® Synthetic
considered to be the baseline (
represents no expression, so
greater is the loss of the expr
of siR-107 produced a fold dif
and 0.87 in CC-RA cells; siR-12
in MSCs, 0.40 in CCs and 0.
transfection of siR-381 resulte
1.01 in CC-RA cells. N represe
Error bars represent the RQ
significance in the fold differen
Legend: MSCs – Mesenchyma
Cells, CC-RAs – Retinoic Acid 
quantification polymerase chai
microRNA 
 
ession post miRNA antagonists 
age fold change difference between the 
on of miRNA antagonists by MSCs (A), 
during RT-qPCR analysis. The starting 
hange was the Negative Transfection 
 microRNA Inhibitor), which was 
1.00). A fold-change difference of 0.00 
 the smaller the Fold-difference the 
ession of NES in the cells. Transfection 
ference of in MSC of 0.03, 0.66 in CCs 
4 transfection fold difference was 0.12 
27 in CC-RAs and fold difference for 
d as 0.87 in MSCs, 0.27 in CCs and 
nts the number of technical replicates. 
min and RQmax.  The * denotes a 
ce between the cell types (P<0.05). 
l Stem Cells, CCs – Conditioned 
treated CCs, RT-qPCR – Real Time 
n reaction, NES – Nestin, miRNA – 
138 
 
The fold change for the expression of TUBB3 is shown in 
Figure 3.22. The MSCs show a fold change of 0.59 for siR-
107, 0.34 for siR-124 and 14.09 for siR-381. The fold 
change in CCs was 2.61 with siR-107, 0.54 with siR-124 
and 4.43 with siR-381. The change seen in CC-RA (C) was 
0.77, 0.00 and 1.53 respectively for siR-107, siR-124 and 
siR-381. 
 
 h
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Figure 3.23 shows the fold change in the expression of ND1. 
MSCs (A) had a fold change of 0.61 after transfection of siR-
107, 0.52 after siR-124 and 0.57 after siR381. Following 
transfection the fold change seen in CCs (B) was 0.34 for 
siR-107, 0.43 for siR-124 and 0.44 for siR-381. The fold 
change for CC-RA (C) cells was 1.48 with siR-107, 1.39 with 
siR-124 and 1.05 with siR-381.  
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Figure 3.24 represents the fold change in MAP2. MAP2 was 
not expressed by MSCs. The fold change seen in CCs (A) 
was 1.75, 0.60 and 1.08 respectively for transfection of siR-
107, siR-124 and siR-381. CC-RA (B) cells resulted as 
having a fold change of 0.55 with siR-107, 0.01 with siR-
124 and 1.30 with siR-381.  
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Fold change for NEU expression post transfection is 
summarised in Figure 3.25. MSCs did not express NEU so 
the fold change could not be calculated. In CCs (A) there is 
a fold change of 0.87 post transfection of siR-107, of 0.01 
post siR-124 and of 0.38 post siR-381. CC-RA (B) cells 
showed a fold change of 1.74 with siR-107, 0.26 with siR-
124 and 0.42 with siR-381. 
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Chapter 4 
Discussion 
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4.1. Project development 
In this project a selection of miRNAs which are known to be 
involved in neuronal development were considered as a 
means to induce transdifferentiation of MSCs towards 
becoming neural like cells and if possible to mature these 
further along the neuronal cell lineage. To obtain neural-like 
cells, MSCs were conditioned with spent medium of the SH-
SY5Y. No miRNA work was done on the SH-SY5Y; these cells 
were only cultured to obtain their spent medium. Soon after 
MSCs where treated with the spent medium, the MSCs 
differentiated into neural-like cells which were referred to as 
CCs. The CCs were further treated with RA to cause these to 
develop further. These matured cells where called CC-RA. At 
this stage of the project, 3 cells types at different stages of 
differentiation had been generated. The MSCs were the 
initial stage, the CCs were the second stage, where cells 
were in the primary phases of neruogenesis, and the CC-
RAs were the third stage, which were neural-like cells at a 
more advance neuronal stage. Both CD and neuronal 
markers helped characterise the shift in protein expression 
from MSCs to CCs to CC-RAs. Once these cells were 
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transfected with the siRNAs, the target gene expression for 
each miRNA was analysed to see whether the transfection 
had had any effect on neurogenesis. Following this, the 3 
cells types were retested for a selection of neural markers 
which are characteristic of the different neuronal stages. 
This was done to see whether the siRNAs had any effect on 
the neural expression, which would have indicated the 
transition of the MSCs to a neural cell lineage.     
 
MSCs are known to differentiate into neural cells and over 
the past thirty years, MSCs have been extensively 
researched for neuronal applications due to their unique 
properties, i.e. their multipotentiality and ease of isolation 
(Fellows et al., 2016), together with the possibility to 
expand and manipulate these cells in vitro (Takeda and Xu, 
2015). Regeneration of nervous tissue has always been 
problematic due to one major factor: mature neural cells do 
not proliferate or differentiate.  MSCs are not limited by this 
but are however limited by the number of population 
doublings, depending on the age of the patient and culture 
conditions (Turinetto, Vitale and Giachino, 2016). Direct 
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reprogramming of the cells results in their 
transdifferentiation into ectodermal cells. During tissue 
repair MSCs regulate the microenvironment via there 
immunomodulatory effect. The release of cytokines and 
other molecules, such as growth factors which include 
EGF ,  keratinocyte growth factor, vascular endothelial 
growth factor-αlpha, TGF, macrophage inflammatory protein 
and insulin-like growth factor-1 (IGF-1) (Lin and Du, 2018), 
helps to restore the damaged cells, and also stimulate the 
immune response for removal of necrotic tissue (Ayala-
Cuellar et al., 2019). At this stage, circulating MSCs may 
start to differentiate, replacing the cells (Squillaro, Peluso 
and Galderisi, 2016). This differentiation ability was shown 
in a study where BM derived MSCs were able to differentiate 
into functional pancreatic β cell phenotypes (Chen, Jiang 
and Yang, 2004). This was later confirmed by Chao et al. 
(2008) who showed that MSCs transdifferentiate into islet-
like clusters which express both insulin and glucagon. 
 
The brain is the leading organ regulating the body. 
However, regeneration of neural tissue is not possible, 
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which makes any type of brain damage permanent, thus 
potentially causing a decrease in quality of life. The 
regeneration ability of the brain is strongly restricted to a 
substantial functional restoration and unlike other organs 
such as skin and liver, it is not able to regrow any structural 
loss (Yao, Mu and Gage, 2012). The transdifferentiation of 
MSCs to cells of the neuronal lineage has further expanded 
the potential therapeutic applications of these stem cells. 
Several clinical trials have employed MSCs in the neuro-
regenerative field, including treatment of traumatic brain 
injury, Parkinson’s Disease, Multiple Sclerosis, Ischaemic 
Stroke and Amyotrophic Lateral Sclerosis (Roszek and 
Czarnecka, 2014). Such trials have confirmed MSCs are 
indeed capable of restoring nervous system functionality.  A 
property of MSCs seen during stem cell therapy is their 
ability to migrate to the site of injury and restore function 
(De Becker and Riet, 2016). Once the MSCs migrate to the 
neurological lesions, they initiate repair by releasing a group 
of neurotrophins and subsequently differentiate into the 
neural cell lineage (Jahromi et al., 2017). Apart from cell-
cell signalling and physically replacing the damaged cells by 
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differentiating, there are other ways in which MSCs may 
restore cell function and tissue repair. MSC paracrine 
activity involves the secretion of different proteins such as 
neurotrophic factors and cytokines. It also comprises 
microvesicles and exsomes which contain genetic material, 
and are transferred to other cells. Growth factors such as 
VEGF, nerve growth factor and IGF-1 are also major 
components of the MSC secretome (Martins et al., 2017). 
 
4.2. Mesenchymal Stem Cells isolated from 
Wharton’s Jelly maintain multipotency 
The trilineage differentiation was performed on the cells 
extracted from three biological replicates. However, due to 
the limited number of cells isolated from the cords, a full 
trilineage differentiation was not performed on each cohort. 
This confirmed that the technique used for MSC isolation 
was appropriate and that these cells maintained their 
stemness characteristics. The trilineage differentiation 
results were confirmed by staining the differentiated MSCs 
with specific histological stains i.e. von Kossa for the 
calcification matrix found in osteocytes, Oil-Red-O for 
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staining of the lipid vacuoles which are produced by the 
metabolism of adipocytes and Alcian Blue for 
glycosaminoglycans present in chondrocytes. To confirm 
that the positive staining was due to the MSC differentiation 
induction procedure, undifferentiated MSCs were also 
stained and these did not show any positive reactivity. 
Nowadays, other markers such as osteopontin and 
osteocalcin in the case of osteogenic differentiation are also 
being considered (Shen et al., 2019).  
  
Throughout this study, experimental procedures were 
limited by the amount of MSCs isolated, thus it was not 
possible to undertake every test on all cord samples. To 
confirm the MSC extraction and culturing techniques had 
been successful, the trilineage differentiation of MSCs was 
spread over a cohort of 7 cord samples. These cells were 
induced to differentiate into osteocytes, adipocytes and 
chondrocytes. To adhere with the ISCT recommendations as 
much as possible, MSCs cultured from each cord were 
confirmed to be MSCs by having these cells differentiate into 
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at least one of the tri-lineage differentiation cell type and/or 
characterised by the CD markers guideline. 
 
4.3. Mesenchymal Stem Cells can differentiate into 
neural-like cells 
The in vitro transdifferentaition of MSCs into neural-like cells 
can be achieved by culturing MSCs in the presence of 
cerebrospinal fluid (Otify et al., 2014) and neural inducer 
agents (Rafieemeh, Kheirandish and Soleimani, 2016) 
including  angiogenic factor bFGF (Mohammad et al., 2015) 
and Cardiotrophin-1, a cytokine from the Interlukin-6 family 
that induces the growth or cardiac myocytes and neural 
tissue development (Peng et al., 2017). Other studies have 
shown that MSCs cocultured in the presence of other cells 
(e.g. myoblasts) where able to differentiate into cardiac 
muscle (Witt et al., 2017) and addition of cerebrospinal fluid 
induced MSCs to transdifferentiate into neural cells (Ge et 
al., 2015). After transdifferentiation, these cells developed 
into multipolar and bipolar neuronal progenitor cells mixed 
with oligodendrocyte progenitor cells and neural elongated-
like stem cells. In addition immunohistochemistry for glial 
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fibrillary acidic protein and cytological stains for Nissel 
bodies, neurites and glycogen confirmed this morphological 
change.  The SH-SY5Y cell line is widely used as an in vitro 
model for neural experiments. To obtain accurate results 
these cells should be differentiated to a mature stage. 
Shipley et al. (2016) showed that it is possible to bring 
about the maturation of SH-SY5Y by the addition of RA. 
They demonstrated that when treated with RA, the SH-SY5Y 
developed extensive and elongated neuritic projections and 
were positive for neural markers MAP2 and neurofilament H. 
In addition to the methods which induce MSC differentiation 
mentioned previously, commercial kits that induce such 
differentiation might also be considered a form industrial 
spent medium. In this study, the transdifferentiation of 
MSCs to the neuronal cell lineage was induced in vitro by 
the addition of spent medium obtained from the culturing of 
the neuroblastomic cell line SH-SY5Y and these induced cells 
were further differentiated by RA treatment. On treating 
MSCs with the spent medium, the cells changed structure 
and assumed a star-shaped morphology followed by the 
generation of neuritic projections with RA treatment. 
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However to fully determine whether or not MSCs have 
indeed transdifferentiated into neurons these cells need to 
be further characterised as shown in previous studies. 
Furthermore to fully confirm the transdifferentiation these 
neural-like cells should be able to transmit electricity.  
 
The RNA expression for a panel of CD markers was tested 
before and after neural differentiation. The cultured MSCs 
were positive for CD73, CD90 and CD105, and negative for 
CD34 and CD45 which is in accordance with the ISCT 
guidelines for the identification of MSCs. However, some 
studies have shown that although MSCs were both plastic-
adherent and positive for trilineage differentiation, testing of 
the recommended CD markers resulted in a positive 
expression of CD34 and CD45 (Okolicsanyi et al., 2015). 
Apart from the markers tested in this project, other CD 
markers have been associated with the identification of 
MSCs, such as CD44, CD29 and CD10 (a table listing these 
CD markers may be viewed at Table 1.1). The CD markers 
used for characterisation are not exclusive for MSC profiling 
but are also expressed by non-stem cells. For example, 
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CD44 is a CD marker used to characterise MSCs derived 
from adipose tissue (Ullah, Subbarao and Rho, 2015) and is 
also widely expressed on cancer cells (Wang et al., 2018).  
When identifying and categorising MSCs, the source of the 
tissue and method of isolation and expansion should be 
considered in conjunction with other characteristics such as 
stemness properties (ability to self-renew), lineage 
differentiation and expression of transcription factors (such 
as OCT4, NANOG, and SOX2) (Okolicsanyi et al., 2015). 
 
In this study, the RNA expression level of CD markers of the 
three cell types tested (MSCs, CCs and CC-RAs) varied 
between samples isolated from different cords (so-called 
biological replicates). Each RT-qPCR analysis was performed 
in triplicates. The results obtained helped exclude any 
experimental errors for that particular set-up, meaning that 
any variation seen between the biological replicates was 
indeed due to a biological variation. This difference in 
expression level between biological samples was highlighted 
because RNA expression analysis was performed, and the 
observed variations may not have been detected if CD 
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marker characterisation had been performed by a qualitative 
technique such as immunocytochemical staining. A similar 
outcome would be seen if CD markers were analysed using 
a cell sorting technique which identifies a cell based on the 
presence of a surface marker. Similarly, to 
immunocytochemistry, cell sorting is more a qualitative 
approach and only classifies the presence of the markers 
tested as being present or not. The quantitative data which 
is obtained from such analysis is based on the number of 
cells which express the marker of interest and not at what 
intensity this is expressed.   
 
4.4. Mesenchymal Stem cells express neural markers 
Neuroepithelial cells are neural progenitors and are 
constantly self-renewing and producing post-mitotic cells 
that become immature neurons (Zhang and Jiao, 2015). 
NES and SOX2 are both early neural progenitor markers and 
where found to be present (but were expressed at different 
levels) in all three cells types (MSCs, CCs and CC-RAs). In 
undifferentiated MSCs, NES is still expressed and a degree 
of this expression is maintained even when these undergo 
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differentiation e.g. to osteocytes (Wong, Ghassemi and 
Yellowley, 2014). The fold change increase in NES 
expression seen in the CCs compared to MSCs indicates that 
MSCs are being differentiated into neural-like cells. When 
comparing CC-RAs and CCs, the decrease in NES fold 
change shows CC-RA cells are at a more mature neuronal 
stage. Since SOX2 acts both as a stemness marker and as 
an early neural marker (Heo et al., 2016), using this marker 
helps characterise the stemness of the MSCs and also 
monitors the differentiation of MSCs to CCs to CC-RAs. 
Comparing CCs and MSCs, an decreased fold change in 
SOX2 expression was obtained in CCs indicating loss of 
stemness, while the fold increase seen between the CC-RA 
and CC cell types may suggest an increase in the shift 
towards neural-like cells, since SOX2 is important for the 
regulation of NSCs proliferation (Shimozaki, 2014). 
Intermediate progenitors undergo mitosis to produce 
neurons (Wang et al., 2014) and MASH1 is a transcription 
factor essential for neural differentiation (Peng et al., 2015). 
As with SOX2, MASH1 presented a fold decrease in CCs 
when compared to MSCs and a fold increase when CC-RA 
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were compared to CCs. Driving the immature neural stage 
are the transcription factors ND1 and TUBB3. ND1 
transforms non-neuronal ectodermal cells into fully 
differentiated neurons (Navarro Quiroz et al., 2018), while 
TUBB3 is expressed by neurons at the early stages of 
morphological differentiation (Kovacs, Szabo and Pirity, 
2016). The fold change decrease in ND1 but increase in 
TUBB3 expression between CCs and MSCs is a clear 
indicator that once conditioned with the spent medium, 
MSCs are being induced to become neuron-like cells. 
Subsequent treatment with RA prompted the CCs into 
further differentiation, as suggested by the fold decrease in 
TUBB3 and increase in ND1. This neural stage transition was 
indeed confirmed by MAP2 and NEU. These two markers 
were not detected in MSCs but were expressed by CCs, thus 
the increase fold-change expression. The lack of expression 
of these two neural markers is expected in MSCs, since 
these markers denote an advanced neuronal stage of 
development. It is unclear why both CC and CC-RA cells of 
Cord 5 did not express NEU. To exclude a technical error, 
the sample was retested alongside SH-SY5Y cells (which are 
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known to express NEU) and expression of NEU in SH-SY5Y 
was confirmed but was still absent in Cord 5 cells.  In CC-RA 
cells a fold change increase was seen in NEU and a fold 
decrease resulted in MAP2 showing that CC-RAs are more 
mature than CCs. 
 
As with the case of the CD marker analyses, neural 
expression analysis using RT-qPCR has demonstrated that 
the biological replicates have different levels of neural RNA 
expression. In terms of differentiation, the time span from 
when the cord is prepared and MSCs are isolated up until 
the moment they are conditioned with the spent medium is 
critical. Despite being processed and maintained in the 
exact same conditions and keeping passages to a minimum, 
cells from different cord samples may have retained a 
different proliferation and differentiation potential. 
Furthermore, MSCs are known to express neuronal 
associated proteins and under stress cell structure may 
resemble that obtained during neural development. Croft 
and Przyborski (2006) suggest that this morphological 
change is mainly caused by cellular shrinkage as a result of 
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F-Actin disruption and changes in gene transcription brought 
about by inhibition of PKC signalling. Thus, changes in cell 
morphology and molecular expression do not provide a 
reliable indicator of neural differentiation and other 
properties such as synapse formation, neuronal polarity and 
electrophysiology should be considered for confirming 
neuronal development.  
 
4.5. MicroRNAs may induce transdifferentiation of 
Mesenchymal Stem Cells  
In this study 3 miRNAs (miR-107, miR-124 and miR-381) 
were investigated to determine whether these alone were 
capable of (i) inducing the transdifferentiation of MSCs into 
neural cells and (ii) differentiating CCs and CC-RA cells 
further along the neural cell lineage. To confirm if these 
miRNAs can indeed induce MSCs to differentiate, each 
miRNA was tested for its corresponding target gene. DICER, 
which is crucial for the biogenesis of small regulatory RNAs 
and acts as a regulator of other cellular processes (Song 
and Rossi, 2017), was the gene used to monitor the 
transfection of miR-107. PTP1B which promotes neural 
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programming of stem cells (Matulka et al., 2013) was 
selected as the target for miR-124 and HES1 which 
regulates NSC proliferation and differentiation is targeted by 
miR-381(Shi et al., 2015). The fold change in expression of 
the target genes of these 3 miRNAs (DICER, PTP1B and 
HES1) was analysed by RT-qPCR to determine the effect of 
transfection of siRNA 107, 124 and 381. DICER and PTP1B 
are negatively regulated in the presence of miR-107 and 
miR-124 respectively, meaning that a decrease in these 
miRNAs will cause an increase of the target gene 
expression. By up-regulating these genes, neurogenesis and 
neural differentiation is inhibited.  HES1 is upregulated in 
the presence of miR-381, inhibiting NSC proliferation and 
differentiation. On transfecting the antagonist of these 
miRNAs, it was expected that a net increase in both DICER 
and PTP1B and a net decrease in HES1 would be observed. 
 
There are numerous methods to transfect cells which can be 
based on either using a physical or chemical approach that 
may or not include viral vectors. In this study a physical 
non-viral approach was considered because (i) the 
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experimental design was xeno-free so no viruses/plasmids 
were used and (ii) chemical transfection would expose the 
cell to additional stress since these agents reduce the 
negative charge of the nucleic acids.  
 
Some of the results obtained in relation to the change in 
expression of the target genes were not as expected. This 
might have been caused by the transfection method used. 
When these gene targets were analysed post-transfection of 
their respective miRNA antagonist, no expression change 
was observed in most samples. The reason for such results 
is either that transfection was not as efficient as expected or 
the antagonist also targeting other genes, which are not 
involved in neuronal differentiation. This is known as the off-
target effect, which arises when an introduced RNA has a 
base sequence that can interact with multiple genes 
reducing their expression. Alternatively, there may have 
been over-expression of the target gene itself, induced by 
the mechanism of cell survival upon encountering the 
respective antagonist. Regarding the results which showed 
either an increase or decrease in target genes expression in 
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the opposite direction of what was expected, it is reasonable 
to assume that either there was no uptake of the siRNA by 
the cell or that the miRNA is involved in processes which act 
both for and against neural differentiation.  From the overall 
results observed, only the HES1 gene in MSCs and the 
DICER gene in CCs and CC-RA cells were in accordance with 
the function of the siRNA.  
 
4.6. Neural markers may also be affected by 
microRNAs 
A panel of neural markers was analysed for the presence of 
a net change in expression post-transfection with miRNA 
antagonists. These comprised NES - representing the 
neuroepithelial stage; TUBB3 and ND1 - for the detection of 
immature neurons and, MAP2 and NEU - for the detection of 
mature neurons.  
 
DICER is a regulator of neurogenesis and although studies 
have shown that it does not directly affect NES expression 
(Pons-Espinal et al., 2017), it is possible that a reduction in 
DICER expression would eventually influence the levels of 
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NES and TUBB3 because of a drop in the number of NSCs 
being produced. Since DICER is fundamental for the optimal 
progression of neurogenesis, and is also a requirement for 
the proliferation, viability, migration and differentiation of 
neural cells, its decrease would directly cause a reduction in 
ND1 (Davis, Mor and Ashery-Padan, 2011). Expression of 
the neural markers MAP2 and NEU is in turn reduced in the 
presence of elevated DICER levels (McLoughlin et al., 
2012)as this favours NSC production.   
 
Transfection of siR-107 did upregulate DICER in CC and CC-
RA cells but not in MSCs. However, a general net decrease 
in NES expression was observed in all the three cell types, 
suggesting a decrease in the number of NSCs. in MSCs, 
expression of ND1 and TUBB3 were decreased post-
transfection with the antagonist. An increase in expression 
of TUBB3 was observed in CCs, however expression of ND1 
decreased in these cells. For CC-RA cells, ND1 expression 
increased and TUBB3 decreased. The lack of net change in 
expression observed in some of the different biological 
replicates of CC and CC-RA cells may be due to inefficient 
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transfection of these cells. In some of the biological 
replicates a net decrease in NES expression was effectively 
observed, indicating that neurogenesis was reduced in these 
samples. The decrease in NES neuronal markers expressed 
by these cell types overall shows that miR-107 may have 
the potential of transdifferentiating MSCs into neuronal cells 
and push neurons towards a more mature stage. Using a 
zebra fish model, Risatori et al. (2015) demonstrated that 
neural progenitors are enriched with miR-107 leading to a 
decrease in neurogenesis and brain development. In their 
study, the question of whether expression of miR-107 
regulated DICER during neurogenesis was addressed. 
Mimics were directly injected in the embryos and brain 
development was monitored. The increase in miR-107 
caused the loss of the midbrain-hindbrain boundary and 
inhibition of miR-107 caused an increase in expression of 
neural progenitors and neural differentiation.  
 
miR-124 is implicated in neurogenesis, although both its 
function and mechanism in this system are still not clear 
and need to be further analysed (Jiao et al., 2017). The 
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impact of PBTP1 on expression of neural markers is still 
poorly defined, nevertheless investigations show that the 
presence of miR-124 enhances the expression of neuronal 
markers NES (Jiao et al., 2017), TUBB3 (Wei et al., 2018), 
MAP2 (Zou et al., 2014) and NEU (Saraiva et al., 2018), 
whilst down-regulating ND1 (Sun et al., 2015). 
 
In contrast to the decreased levels of PTP1B expression 
seen post-transfection of the miR-124 antagonist a change 
in neural marker expression was still seen. Once again, the 
lack of a net expression change in some of the samples may 
be the result of a lower transfection efficiency. Out of the 
three siRNAs tested, siR-124 was the one which caused the 
greatest change in expression in the neural markers in CC-
RA cells. To a lesser degree, siR-124 also caused changes in 
the neural expression of CCs, indicating that cells in the 
early stages of neural maturation are also affected by miR-
124. In a study conducted by Jiao et al. (2017), NSCs were 
cultured from rat embryos and transfected with miR-124 
mimics. An MTT assay showed a significant increase in the 
number of NSCs which was confirmed by an increase in NES 
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expression. The study supports the findings of this project 
since transfection of siR-124 resulted in a decrease of NES 
expression. 
 
HES1 is a downstream regulator of the Notch signalling 
pathway, which in turn is responsible for stem cell neural 
fate determination (Perron et al., 2018). Over-expression of 
HES1 directly increases expression of NES and TUBB3 due 
to this gene being a promoter of NSC proliferation and 
differentiation (Shi et al., 2015). Similarly, expression of 
both neural markers would decrease with a lowering of 
HES1 expression. ND1 is a downstream marker of HES1 
meaning that a suppression of HES1 expression would 
maintain neural cells in an undifferentiated state (Liu, Dai 
and Du, 2015) and the inverse correlation between HES1 
and MAP2 induces mature neural differentiation upon a 
decrease in HES1 expression (Fiaschetti et al., 2014). Shi et 
al. (2015) used rat embryos to isolate NSCs and 
subsequently transfect them with miR-381 mimics. RT-qPCR 
analysis confirmed the upregulation of NES and TUBB3 and 
Western Blot confirmed HES1 as a target for miR-381.  
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In the current study, expression of HES 1 was increased 
post-transfection with siR-381 in the CCs and CC-RA cell 
types in contrast to downregulation observed in MSCs. 
However, there was no change in expression of most of the 
neural markers in CCs and CC-RA cells following transfection 
with the miR-381 antagonist. Furthermore, an increase in 
TUBB3 expression in CCs was observed, indicating that 
there was no or little uptake of miR-381 by these cells. With 
regards to MSCs, the expression of NES decreased, TUBB3 
increased and no change was seen for ND1. These results 
suggest that either miR-381 does not transdifferentiate 
MSCs or cause neurons to move further down the neuronal 
pathway or transfection was inefficient.  
 
Transfection is a multi-factorial process that depends on the 
cellular binding and internalisation of the complex as well as 
subsequent release and uptake. The health of the cell, 
metabolic activity and proliferation rate are also critical 
factors which contribute to a successful transfection. The 
cell type also affects the transfection outcome. For instance, 
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primary cells such as MSCs and immature progenitors lack 
cell surface receptors that trigger receptor-complex 
interactions and internalisation, have a lower proliferation 
rate and often lack the ability to bind to transfection 
complexes. The age of the culture and degree of confluence 
are other factors which determine the efficiency of a 
transfection protocol. Since cells that are proliferating are 
more likely to take up foreign nucleic acids, it is important 
that prior to transfection, cells are not fully confluent or in a 
stationary growth phase. In addition, low confluence of cells 
may result in inadequate yields of RNA for expression 
analysis. Transfection efficiency is reduced in cells which 
have been repeatedly passaged, particularly cells which are 
entering senescence and hence, in this study the number of 
passages was kept to a minimum. In this study, both age 
and proliferation were a major limitation when transfecting 
MSCs. Reaching a point where cells were confluent enough 
to obtain a minimum usable RNA concentration took time 
and, in some cases, MSCs may have entered cellular 
senescence, thus making transfection more difficult. 
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MiRNAs regulate multiple gene targets and in turn, specific 
miRNAs can also become targets of other miRNAs. As a 
result of such multi-level regulation, an overall net change is 
not always achievable. The transfected miRNA antagonist 
may be influencing a range of target genes other than the 
one under investigation.  
 
4.7. Knowledge Contribution 
4.7.1. Contributing to the Professional Biomedical Practice 
Standard good laboratory practice provides the guidelines of 
which basic precautions should be followed to ensure that 
experiments are conducted in the most appropriate way to 
obtain reliable results. Although certain practices, such as 
the use of protective clothing and the thorough cleaning of 
work areas are well-established, other methods require 
further optimisation to achieve the desired outcome.  
 
In this project, MSCs were isolated from Wharton’s Jelly. 
The number of cells extracted was somewhat limited. This 
indicates that an alternative approach for isolating these 
cells, such as using a full enzyme digest technique, where 
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the Wharton’s Jelly would be treated with Collagenase II for 
several hours and processed further to extract the single 
cells, needs to be considered. Even though the extracted 
cells were few, the degree of contamination observed during 
culturing was around 10%, which is as one would expect. All 
laboratories experience contamination at one stage or 
another, and this is normally due to bacteria, fungi or yeast 
infections. The contaminations seen in this study were more 
likely to have been a consequence of some contaminated 
dissection utensils rather than a repercussion of 
contaminated cord lengths, based on the fact that 
contamination of cell culture was experienced by all the 
researchers working in the laboratory at the same time. The 
method devised to preserve the cord lengths by using PBS 
and P/S was one of the steps taken to prevent such 
contamination, as the P/S present would have already 
started acting on any contaminants present on the epithelia 
of the cord lengths. Although using DMEM-F12 might have 
helped preserve the cells, the glucose in the medium would 
also have sustained bacterial growth. Washing the cord 
lengths with 70% ethanol was another step taken to remove 
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any persistent contaminates; however this had the 
drawback that an exposure longer than 1 minute resulted in 
no cell growth. The subsequent washing with PBS was 
intended to remove any alcohol traces and additional debris 
present on the cord epithelia. 
 
Another factor which contributed to successful MSC culturing 
was the correct bleeding of the cord lengths during 
sampling. Improper bleeding led to Wharton’s Jelly 
becoming heavily blood stained. In such cases the red blood 
cells would be a persistent presence during culturing, 
causing debris to settle at the bottom of the plate and thus 
not allowing the plastic-adherent cells to grow. Washing the 
Wharton’s Jelly with an erythrocyte lysing buffer may solve 
the issue, however insight is required on whether the MSCs 
would be affected by this additional washing step or not. 
Another alternative to consider is the addition of heparin to 
the transport medium. This would prevent the blood from 
clotting in the veins and arteries of the cord lengths. 
However, such an outcome would depend on the actual 
length of the cord, whether delayed clamping of the cord at 
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birth was practiced and the possibility that the transport 
medium would not have completely permeated the inside of 
the cord length.  
 
MSCs are known to undergo early differentiaton when 
cultured using animal-derived products. A step taken for the 
prevention of early differentiation was providinga xeno-free 
setup by substituting FBS for human derived plasma. 
Although it might be more practical opting for commercial 
serum-free medium, such products are still not properly 
defined, with numerous components not being disclosed due 
to product protection. While it is true that plasma 
constituents may vary from person to person, the fact that 
this is derived from healthy blood donors intended for 
transfusion, to support the treatment of several conditions 
implies that the quality of the plasma falls within rigorous 
standard requirements, which per semeans that its 
constituents are well-defined. However, there is aneed for 
additional optimisation to completely deplete the plasma 
from its clotting factors, so as to prevent undesired 
coagulation from occurring.  This would cause subsequent 
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loss of MSCs that would have become embedded in the 
resultant fibrin cloth. 
 
It is widely accepted that MSCs necessitate characterisation 
in order to be called as such. Trilineage differentiation and 
CD markers are what the ISCT suggests as the gold 
standard for characterising MSCs. However, both methods 
are not exclusive of this cell type. Perivascular cells which 
are being regarded as MSC precursors may also undergo 
trilineage differentiation and have many CD markers in 
common with MSCs. On the other hand, the overlap in CD 
markers present across the various cell types makes their 
use very limited. Ideally a broader spectrum of CD markers 
should be considered in conjunction with other markers 
(such as stemness markers) that are intended to 
demonstrate the multipotency potential of these cells. 
 
Another modification which was adopted in this project is 
the use of TB-Fix during the fixative stage of the trilineage 
characterisation. Most papers suggest the use of 4% PFA; 
however when used in this project, this concentration of PFA 
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showed unfavourable results, as cells lost structure and 
definition. TB-Fix proved to be much more tolerated where 
stem cells were involved.   
 
When considering performing qPCR experiments, testing a 
series of house-keeping genes for a specific cell type would 
further provide consistent and robust data. Ideally for every 
marker tested an NTC should be performed in conjunction 
with every run. This is meant to eliminate any background 
reactions which might be interfering with that specific 
marker. When observing NTC values note should be taken of 
the overall Cq values. These should remain consistent 
throughout and have a maximum variation of 1Cq between 
replicates. In this project, the variance seen in NTC values 
may indicate a degree of contamination which may have 
influenced the results of such experiments. If contamination 
is suspected, it is suggested to start by changing the 
components of the set-up one at a time. The first step 
would be ensuring that the working space has been cleaned 
with RNAse Zap and that all consumables are sterile. This 
would eliminate any residual RNA present. Following this, 
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the next step would be changing the nuclease free water, 
since water contamination is very common. If contamination 
is still suspected to be present there is no alternative left 
other than to change all the reagents. 
 
Becoming proficient in a technique or mastering a skill is 
just the start. It is learning to view things from a different 
perspective that ensures a continuous improvement in 
standard practices.  
 
4.7.2. Future investigations of miRNA transdifferentiation  
Further research on the regulation of activity of the selected 
miRNAs would help elucidate their impact on MSCs 
transdifferentiation. Transfection of miRNA mimics – agents 
that imitate the action of miRNAs - would confirm the up or 
down-regulation of target gene expression by over-
expression of the selected miRNAs. The size and structure of 
miRNA mimics and siRNA antagonists are identical so 
transfection efficiency should be similar i.e. any technical 
limitation for siRNAs will be encountered for mimics as well 
(Wang, 2011). Functionally however, mimics and siRNA 
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antagonists are not just equal and opposite. While they are 
expected to target the same genes, they are generally 
designed to bind specifically to one target gene so the off-
target effects will be different between miRNAs mimics and 
siRNA antagonists for any given target. This means that an 
effect may be observed with only the miRNA mimics or the 
siRNA antagonists, particularly for miRNAs that target 
opposing genes within a pathway. Neuronal development 
can be visualised as a number of troughs representing the 
cellular stages from stem cells to fully differentiated neurons 
and peaks representing the differentiation steps. These 
cellular stages are namely neurogenesis, followed by the 
formation of distinct cell populations, differentiation and 
outgrowth of axons and dendrites. During this development 
not all cells progress through these stages at the same time 
thus resulting in a mixed population of neuronal cells.  In 
order for cells to progress to the next stage of neuronal 
differentiation, a number of genes have to be expressed at 
the correct levels, at the same time, so as to overcome a 
specific threshold (thus envisioned as a peak) and enter the 
next cellular phase (envisioned as a trough). Since the 
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regulatory processes of neuronal development are very 
complex each stage can be envisioned as a very long 
trough, with cells within a population having progressed to 
different degrees along a particular stage. During this 
transition the chromatin of a cell is not stable and as a 
result of this instability, the overall gene expression within a 
specific cell might be closer to the biological threshold of the 
previous stage than the next stage. This makes 
differentiating all the cells within a population towards one 
specific stage of neuronal development extremely difficult. 
Furthermore, tipping the balance towards de-differentiation 
might be easier for a certain cell population than towards 
differentiation further down the neuronal lineage.  
 
A microarray for global transcription and global miRNA 
expression then confirm the effect of up regulation or 
downregulation of miRNAs on the target genes. 
Furthermore, it would also indicate which miRNAs are 
present, thus helping in selecting and short-listing miRNAs 
for additional functional assay experiments.  
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Using additional stemness markers to SOX2 and OCT4 
would better support the characterisation of MSCs, 
eliminating the need of using CD markers that have 
limitations due to their lack of specificity. Other stemness 
markers to be considered include NANOG and Glial fibrillary 
acidic protein. Concurrently, additional neural markers 
would help categorise further the neural stage of the 
differentiated cells and the effect the miRNAs may have on 
their development.  
 
In this study, spent medium has played an important part in 
the differentiation of MSCs into cells of the neuronal lineage. 
There are undoubtedly components that are being released 
by the SH-SY5Y in culture that induce MSCs to differentiate. 
Identifying the components present in the conditioned 
medium may help to characterise more completely what 
factors are initiating and directing the differentiation of the 
MSCs. Once a number of these substances are identified, 
further testing would be required to verify if these can boost 
miRNA modulation. 
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4.8. Conclusion 
Utilisation of MSCs is simple and safe with their plasticity in 
regenerative medicine making this therapeutic approach 
both suitable and efficient. Such an approach would reduce 
the need for donor tissue in transplantation, ultimately 
reducing drastically the complications associated with this 
procedure. In addition, treatment of a disease at an early 
stage with MSCs would reduce the need for life-long 
treatment (Martin-Rendon and Gyöngyösi, 2017). 
 
The aim of this project was to identify putative miRNAs that 
cause MSCs to differentiate into neural precursors and/or 
cells of mature neuronal cell lineage. Being able to direct the 
differentiation of MSCs to become NSCs or further down the 
neuronal cell lineage, presents potential therapeutic 
applications. Transfection with the selected inhibitors 
showed that MSCs do react to the presence of miR-107 and 
miR-124 antagonists (NES was downregulated thus a 
reduction in neurogenesis). However, due to the marginal 
changes observed these miRNAs are not sufficient to induce 
such a change on their own. CCs were more susceptible to 
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miRNAs 107 and 124 as observed by the upregulation of the 
targets DICER and PTP1B showing potential to further 
differentiate intermediate neural progenitors and immature 
neuron cell types.  
 
MiRNAs are crucial elements involved in the mechanisms of 
cell cycle, proliferation, differentiation, apoptosis, and 
metabolism. They are responsible for neural induction, 
neuronal differentiation and fate specification and thus have 
begun to develop into a next generation therapeutic 
approach for many conditions. Stem cells have a well-
established role in therapeutic approaches and, by 
combining putative miRNAs responsible for the neural 
development with stem cells, it could be possible to further 
elucidate the mechanisms of action involved in both the 
physiological and pathological processes of the CNS. 
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CD Markers 
MSC 
Cord 5 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH Cq CD73 q CD90 Cq CD105 Cq CD34 Cq CD45 
Run1 34.60 31.59 24.34 26.91 40.00 40.00 20.76 10.83 3.58 23.33 19.24 19.24 
Run2 35.18 31.75 24.31 25.58 40.00 40.00 20.91 10.84 3.40 22.18 19.09 19.09 
Run3 33.65 31.61 24.64 25.85 39.55 40.00 20.97 10.64 3.67 22.18 18.58 19.03 
 
MSC 
Cord 6 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run1 40.00 33.36 27.39 28.78 40.00 40.00 24.23 9.13 3.16 25.62 15.77 15.77 
Run2 40.00 33.61 27.79 28.48 40.00 40.00 24.18 9.43 3.61 24.87 15.82 15.82 
Run3 39.13 34.42 27.67 28.64 40.00 40.00 23.90 10.52 3.77 24.87 16.10 16.10 
 
MSC 
Cord 13 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run1 34.33 32.43 26.60 31.10 40.00 40.00 25.72 6.71 0.88 30.22 14.28 14.28 
Run2 34.67 33.46 27.37 31.48 40.00 40.00 26.27 7.19 1.10 30.38 13.73 13.73 
Run3 34.58 32.57 26.93 31.50 40.00 40.00 26.18 6.39 0.75 30.75 13.82 13.82 
 
 
CC 
Cord 5 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run1 34.76 39.30 22.05 23.96 31.18 40.00 16.28 23.02 5.77 18.19 14.90 23.72 
Run2 34.51 39.08 21.98 23.97 32.23 40.00 16.36 22.72 5.62 18.35 15.87 23.64 
Run3 35.73 38.48 22.18 24.07 32.06 40.00 16.23 22.25 5.95 18.12 15.83 23.77 
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CC 
Cord 6 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run1 32.36 33.02 20.16 23.55 33.45 34.30 15.26 17.76 4.90 18.65 18.19 19.04 
Run2 33.23 32.74 20.22 23.54 33.79 34.20 15.20 17.54 5.02 18.52 18.59 19.00 
Run3 32.81 33.18 20.42 23.91 33.38 35.36 15.27 17.91 5.15 18.76 18.11 20.09 
 
CC 
Cord 13 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run1 33.11 40.00 24.30 25.82 33.79 40.00 18.69 21.31 5.61 20.21 15.10 21.31 
Run2 33.62 40.00 24.82 22.49 34.13 40.00 18.77 21.23 6.05 19.44 15.36 21.23 
Run3 32.81 40.00 24.67 25.61 33.36 40.00 18.96 21.04 5.71 19.90 14.40 21.04 
 
CC-RA 
Cord 5 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH dCq CD73 dCq CD90 dCq CD105 dCq CD34 dCq CD45 
Run1 31.98 35.33 26.98 26.36 38.94 40.00 19.70 15.63 7.28 19.08 19.24 20.30 
Run2 31.61 35.22 27.08 25.94 38.07 40.00 19.73 15.49 7.35 18.59 18.34 20.27 
Run3 31.08 36.52 26.96 26.27 38.76 40.00 19.71 16.81 7.25 19.02 19.05 20.29 
 
CC-RA 
Cord 6 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run1 40.00 40.00 29.05 30.18 40.00 40.00 22.86 17.14 6.19 23.99 17.14 17.14 
Run2 40.00 40.00 29.73 29.25 40.00 40.00 22.84 17.16 6.89 22.36 17.16 17.16 
Run3 39.86 40.00 29.51 29.63 40.00 40.00 23.12 16.88 6.39 23.24 16.88 16.88 
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CC-RA 
Cord 13 NTC CqCD73 CqCD90 CqCD105 CqCD34 CqCD45 CqGAPDH Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run1 34.42 40.00 27.95 26.09 35.69 40.00 20.42 19.58 7.53 18.56 15.27 19.58 
Run2 34.42 40.00 27.18 26.34 35.47 40.00 20.72 19.28 6.46 19.88 14.75 19.28 
Run3 34.53 40.00 27.15 26.18 36.32 40.00 20.67 19.33 6.48 19.70 15.65 19.33 
 
 
 From MSCs to CC From CC to CC-RA 
Cord 5 Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run 1 -12.19 -2.19 5.14 4.34 -4.48 7.39 -1.51 -0.89 -4.34 3.42 
Run 2 -11.88 -2.22 3.83 3.22 -4.55 7.23 -1.73 -0.24 -2.47 3.37 
Run 3 -11.61 -2.28 4.06 2.75 -4.74 5.44 -1.3 -0.9 -3.22 3.48 
 
 From MSCs to CC From CC to CC-RA 
Cord 6 Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run 1 -8.63 -1.74 6.97 -2.42 -3.27 0.62 -1.29 -5.34 1.05 1.9 
Run 2 -8.11 -1.41 6.35 -2.77 -3.18 0.38 -1.87 -3.84 1.43 1.84 
Run 3 -7.39 -1.38 6.11 -2.01 -3.99 1.03 -1.24 -4.48 1.23 3.21 
 
 From MSCs to CC From CC to CC-RA 
Cord 13 Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 Cq CD73 Cq CD90 Cq CD105 Cq CD34 Cq CD45 
Run 1 -14.6 -4.73 10.01 -0.82 -7.03 1.73 -1.92 1.65 -0.17 1.73 
Run 2 -14.04 -4.95 10.94 -1.63 -7.5 1.95 -0.41 -0.44 0.61 1.95 
Run 3 -14.65 -4.96 10.85 -0.58 -7.22 1.71 -0.77 0.2 -1.25 1.71 
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Neural Markers Pre-Transfection 
MSC 
Cord 5 NTC CqNES CqSOX2 CqOCT4 CqTUBB3 CqMASH1 CqND1 CqMAP2 CqNEU CqGAPDH 
Run1 32.93 30.07 26.02 24.66 27.3 21.77 25.94 39.12 39.29 20.5 
Run2 33.91 30.21 25.74 24.40 26.97 21.56 25.83 39.87 40.00 20.42 
Run3 33.43 29.71 25.77 24.52 27.20 21.42 25.84 39.08 40.00 20.41 
 
MSC 
Cord 5 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run1 9.57 5.52 4.16 6.80 1.27 5.44 18.62 18.79 
Run2 9.79 5.32 3.98 6.55 1.14 5.41 19.45 19.58 
Run3 9.30 5.36 4.11 6.79 1.01 5.43 18.67 19.59 
 
 
MSC 
Cord6 NTC CqNES CqSOX2 CqOCT4 CqTUBB3 CqMASH1 CqND1 CqMAP2 CqNEU CqGAPDH 
Run1 32.62 30.60 26.76 24.92 29.53 24.48 26.36 38.03 40.00 23.12 
Run2 31.91 29.41 26.62 24.87 29.86 24.89 26.77 38.15 40.00 23.13 
Run3 32.21 30.12 26.49 24.63 30.33 24.67 26.86 39.12 40.00 23.40 
 
MSC 
Cord6 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run1 7.48 3.64 1.80 6.41 1.36 3.24 14.91 16.88 
Run2 6.28 3.49 1.74 6.73 1.76 3.64 15.02 16.87 
Run3 6.72 3.09 1.23 6.93 1.27 3.46 15.72 16.60 
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MSC 
Cord 13 NTC CqNES CqSOX2 CqOCT4 CqTUBB3 CqMASH1 CqND1 CqMAP2 CqNEU CqGAPDH 
Run1 38.46 33.51 32.71 31.41 33.08 29.34 31.84 40.00 40.00 24.68 
Run2 38.45 34.12 32.84 30.65 33.19 29.82 33.08 40.00 40.00 24.84 
Run3 38.00 34.56 32.15 31.65 33.21 31.10 33.50 40.00 40.00 25.62 
 
MSC 
Cord 13 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run1 8.83 8.03 6.73 8.40 4.66 7.16 15.32 15.32 
Run2 9.28 8.00 5.81 8.35 4.98 8.24 15.16 15.16 
Run3 8.94 6.53 6.03 7.59 5.48 7.88 14.38 14.38 
 
 
CC 
Cord 5 NTC CqNES CqSOX2 CqOCT4 CqTUBB3 CqMASH1 CqND1 CqMAP2 CqNEU CqGAPDH 
Run1 29.74 21.33 26.37 28.32 18.81 21.63 25.44 21.27 30.15 16.42 
Run2 29.67 21.34 26.37 29.48 18.78 21.22 25.58 21.06 30.55 16.37 
Run3 30.02 21.23 27.00 29.35 18.76 21.38 25.50 21.17 30.15 16.42 
 
CC 
Cord 5 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run1 4.91 9.95 11.90 2.39 5.21 9.02 4.85 13.73 
Run2 4.97 10.00 13.11 2.41 4.85 9.21 4.69 14.18 
Run3 4.81 10.58 12.93 2.34 4.96 9.08 4.75 13.73 
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CC 
Cord 6 NTC CqNES CqSOX2 CqOCT4 CqTUBB3 CqMASH1 CqND1 CqMAP2 CqNEU CqGAPDH 
Run1 32.26 16.58 25.20 27.45 15.32 17.79 20.76 17.73 28.42 14.19 
Run2 33.36 16.49 24.98 27.41 15.82 17.23 20.69 17.35 27.93 14.07 
Run3 32.53 16.72 24.71 27.15 15.89 18.03 20.73 17.18 28.24 14.03 
 
CC 
Cord 6 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run1 2.39 11.01 13.26 1.13 3.60 6.57 3.54 14.23 
Run2 2.42 10.91 13.34 1.75 3.16 6.62 3.28 13.86 
Run3 2.69 10.68 13.12 1.86 4.00 6.70 3.15 14.21 
 
 
CC 
Cord 13 NTC CqNES CqSOX2 CqOCT4 CqTUBB3 CqMASH1 CqND1 CqMAP2 CqNEU CqGAPDH 
Run1 40.00 20.49 24.25 23.60 20.15 22.78 24.21 19.90 28.22 15.66 
Run2 40.00 20.42 24.73 23.72 20.02 22.58 25.05 21.33 29.29 15.80 
Run3 40.00 20.32 24.32 23.76 19.81 22.75 24.90 20.46 29.04 15.92 
 
CC 
Cord 13 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run1 4.83 8.59 7.94 4.49 7.12 8.55 4.24 12.56 
Run2 4.62 8.93 7.92 4.22 6.78 9.25 5.53 13.49 
Run3 4.40 8.40 7.84 3.89 6.83 8.98 4.54 13.12 
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CC-RA 
Cord 5 NTC CqSOX2 CqOCT4 CqMASH1 CqGAPDH Cq SOX2 Cq OCT4 Cq MASH1 
Run1 32.98 28.19 28.04 24.32 19.70 8.49 8.34 4.62 
Run2 32.61 28.64 28.11 23.41 19.73 8.91 8.38 3.68 
Run3 33.08 28.51 27.73 24.42 19.71 8.80 8.02 4.71 
 
CC-RA 
Cord 5 NTC CqNES CqTUBB3 CqMAP2 CqNEU CqGAPDH Cq NES Cq TUBB3 Cq MAP2 Cq NEU 
Run1 40.00 26.16 24.63 24.97 40.00 19.92 6.24 4.71 5.05 20.08 
Run2 40.00 25.63 24.32 25.22 40.00 19.96 5.67 4.36 5.26 20.04 
Run3 40.00 26.91 24.20 25.15 40.00 19.80 7.11 4.40 5.35 20.20 
 
CC-RA 
Cord 5 NTC CqND1 CqGAPDH Cq ND1 
Run1 40.00 26.96 17.52 9.44 
Run2 40.00 27.56 17.53 10.03 
Run3 40.00 26.93 17.47 9.46 
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CC-RA Cord 6 NTC CqSOX2 CqOCT4 CqMASH1 CqGAPDH Cq SOX2 Cq OCT4 Cq MASH1 
Run1 40.00 32.39 27.41 24.85 22.86 9.53 4.55 1.99 
Run2 40.00 30.80 27.64 25.41 22.84 7.96 4.80 2.57 
Run3 39.86 31.38 27.21 25.04 23.12 8.26 4.09 1.92 
 
CC-RA Cord 6 NTC CqNES CqTUBB3 CqMAP2 CqNEU CqGAPDH Cq NES Cq TUBB3 Cq MAP2 Cq NEU 
Run1 34.44 26.47 25.25 25.91 33.19 22.44 4.03 2.81 3.47 10.75 
Run2 34.82 25.54 25.65 24.94 33.45 22.37 3.17 3.28 2.57 11.08 
Run3 34.74 25.39 24.96 24.29 33.72 21.81 3.58 3.15 2.48 11.91 
 
CC-RA 
Cord 6 NTC CqND1 CqGAPDH Cq ND1 
Run1 40.00 27.76 21.15 6.61 
Run2 40.00 28.70 21.02 7.68 
Run3 40.00 28.52 21.15 7.37 
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CC-RA 
Cord 13 NTC CqSOX2 CqOCT4 CqMASH1 CqGAPDH Cq SOX2 Cq OCT4 Cq MASH1 
Run1 34.42 20.91 22.19 21.90 20.42 0.49 1.77 1.48 
Run2 34.42 21.30 22.31 21.46 20.72 0.58 1.59 0.74 
Run3 34.53 21.03 22.18 21.35 20.67 0.36 1.51 0.68 
 
CC-RA 
Cord 13 NTC CqNES CqTUBB3 CqMAP2 CqNEU CqGAPDH Cq NES Cq TUBB3 Cq MAP2 Cq NEU 
Run1 40.00 26.47 25.96 25.85 34.38 17.41 9.06 8.55 8.44 16.97 
Run2 40.00 26.48 25.94 25.82 34.88 17.50 8.98 8.44 8.32 17.38 
Run3 40.00 26.25 26.16 25.90 36.01 17.74 8.51 8.42 8.16 18.27 
 
CC-RA 
Cord 13 NTC CqND1 CqGAPDH Cq ND1 
Run1 40.00 18.93 15.59 3.34 
Run2 40.00 19.01 15.68 3.33 
Run3 40.00 18.73 15.64 3.09 
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From MSCs to CC 
Cord 5 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run 1 4.66 -4.43 -7.74 4.41 -3.94 -3.58 13.77 5.06 
Run 2 4.82 -4.68 -9.13 4.14 -3.71 -3.80 14.76 5.40 
Run 3 4.49 -5.22 -8.82 4.45 -3.95 -3.65 13.92 5.86 
 
 
From MSCs to CC 
Cord 6 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run 1 5.09 -7.37 -11.46 5.28 -2.24 -3.33 11.37 2.65 
Run 2 3.86 -7.42 -11.6 4.98 -1.4 -2.98 11.74 3.01 
Run 3 4.03 -7.59 -11.89 5.07 -2.73 -3.24 12.57 2.39 
 
 
From MSCs to CC 
Cord 13 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run 1 4.00 -0.56 -1.21 3.91 -2.46 -1.39 11.08 2.76 
Run 2 4.66 -0.93 -2.11 4.13 -1.80 -1.01 9.63 1.67 
Run 3 4.54 -1.87 -1.81 3.70 -1.35 -1.10 9.84 1.26 
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From CC to CC-RA 
Cord 5 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run 1 -1.33 1.46 3.56 -2.32 0.59 -0.42 -0.20 -6.35 
Run 2 -0.70 1.09 4.73 -1.95 1.17 -0.82 -0.57 -5.86 
Run 3 -2.30 1.78 4.91 -2.06 0.25 -0.38 -0.60 -6.47 
 
 
From CC to CC-RA 
Cord 6 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run 1 -1.64 1.48 8.71 -1.68 1.61 -0.04 0.07 3.48 
Run 2 -0.75 2.95 8.54 -1.53 0.59 -1.06 0.71 2.78 
Run 3 -0.89 2.42 9.03 -1.29 2.08 -0.67 0.67 2.30 
 
 
From CC to CC-RA 
Cord 13 Cq NES Cq SOX2 Cq OCT4 Cq TUBB3 Cq MASH1 Cq ND1 Cq MAP2 Cq NEU 
Run 1 -4.23 8.10 6.17 -4.06 5.64 5.21 -4.20 -4.41 
Run 2 -4.36 8.35 6.33 -4.22 6.04 5.92 -2.79 -3.89 
Run 3 -4.11 8.04 6.33 -4.53 6.15 5.89 -3.62 -5.15 
 
 
234 
 
Gene Targets 
MSC 
Cord 9 NTC CqDICER CqPTP1B CqHES1 CqDICER NEG CTL CqPTP1B NEG CTL CqHES1 NEG CTL Cqsi107 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 32.93 33.12 40.00 34.67 34.44 33.82 23.51 26.17 26.30 27.45 
Run2 40.00 32.39 32.78 40.00 35.10 34.23 33.18 23.64 26.23 26.06 27.58 
Run3 40.00 32.52 32.92 40.00 34.92 34.69 33.47 23.29 25.72 26.21 27.57 
 
MSC 
Cord 9 dCqsi107 DICER Cqsi124 PTP1B Cqsi381 HES1 CqDICER NEG CTL Cq PTP1B NEG CTL Cqsi381 NEG CqDICER CqPTP1B Cq HES1 
Run1 9.42 6.95 13.70 7.22 6.99 7.52 -2.20 0.04 -6.18 
Run2 8.75 6.55 13.94 7.52 6.65 7.12 -1.23 0.10 -6.82 
Run3 9.23 7.20 13.79 7.35 7.12 7.26 -1.88 -0.08 -6.53 
 
 
MSC 
Cord 11 NTC CqDICER CqPTP1B CqHES1 CqDICER NEG CTL CqPTP1B NEG CTL CqHES1 NEG CTL Cqsi107 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 40.00 31.86 32.07 34.41 30.33 32.89 31.50 27.57 22.49 26.83 
Run2 40.00 40.00 31.55 30.71 35.07 29.56 32.29 30.53 27.88 22.42 26.45 
Run3 40.00 40.00 30.98 31.11 33.80 31.21 32.29 30.27 27.69 22.29 26.25 
 
MSC 
Cord 11 Cqsi107 DICER Cqsi124 PTP1B Cqsi381 HES1 CqDICER NEG CTL CqPTP1B NEG CTL Cqsi381 NEG CqDICER CqPTP1B CqHES1 
Run1 8.50 4.29 9.58 7.58 2.76 6.06 -0.92 -1.53 -3.52 
Run2 9.47 3.67 8.29 8.62 1.68 5.84 -0.85 -1.99 -2.45 
Run3 9.73 3.29 8.82 7.55 3.52 6.04 -2.18 0.23 -2.78 
 
 
 
 
235 
 
 
 
 
CC 
Cord 5 NTC CqDICER CqPTP1B CqHES1 CqDICER NEG CTL CqPTP1B NEG CTL CqHES1 NEG CTL Cqsi107 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 39.58 29.79 26.02 36.66 34.03 28.27 38.31 25.92 24.01 24.04 25.90 
Run2 40.00 30.28 26.36 36.50 34.21 29.07 38.88 25.95 24.32 24.16 25.83 
Run3 40.00 30.33 26.77 36.58 34.48 29.56 38.54 26.11 24.09 24.27 24.90 
 
CC 
Cord 5 Cqsi107 DICER Cqsi124 PTP1B Cqsi381 HES1 CqDICER NEG CTL Cq PTP1B NEG CTL Cqsi381 NEG CqDICER CqPTP1B Cq HES1 
Run1 3.87 2.01 12.62 8.13 4.26 12.41 4.26 2.25 -0.21 
Run2 4.33 2.04 12.34 8.38 4.75 13.05 4.05 2.71 0.71 
Run3 4.22 2.68 12.31 9.58 5.47 13.64 5.36 2.79 1.33 
 
 
CC 
Cord 6 NTC CqDICER CqPTP1B CqHES1 CqDICER NEG CTL CqPTP1B NEG CTL CqHES1 NEG CTL Cqsi107 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 35.23 33.02 26.48 33.97 31.61 28.17 32.33 27.46 24.21 27.07 24.08 
Run2 34.31 32.04 26.67 34.35 32.37 28.19 32.59 27.84 24.29 27.07 24.55 
Run3 34.51 31.86 26.03 33.14 31.69 28.42 31.16 28.05 24.31 26.82 24.47 
 
CC 
Cord 6 Cqsi107 DICER Cqsi124 PTP1B Cqsi381 HES1 CqDICER NEG CTL Cq PTP1B NEG CTL Cqsi381 NEG CqDICER CqPTP1B Cq HES1 
Run1 5.56 2.27 6.90 7.53 3.96 8.25 1.97 1.69 1.35 
Run2 4.20 2.38 7.28 7.82 3.90 8.04 3.62 1.52 0.76 
Run3 3.81 1.72 6.32 7.22 4.11 6.69 3.41 2.39 0.37 
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CC 
Cord 11 NTC CqDICER CqPTP1B CqHES1 CqDICER NEG CTL CqPTP1B NEG CTL CqHES1 NEG CTL Cqsi107 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG 
GAPDH 
Run1 36.32 31.70 25.69 30.42 32.90 27.70 29.07 26.82 24.41 27.96 25.97 
Run2 36.74 32.08 25.29 29.92 32.10 28.36 29.89 26.04 24.79 27.49 25.84 
Run3 35.93 32.65 25.73 30.12 32.30 27.81 29.14 26.26 24.85 27.03 25.90 
 
CC 
Cord 11 Cqsi107 DICER Cqsi124 PTP1B Cqsi381 HES1 CqDICER NEG CTL Cq PTP1B NEG CTL Cqsi381 NEG CqDICER CqPTP1B Cq HES1 
Run1 4.88 1.28 2.46 6.93 3.29 3.10 2.05 2.01 0.64 
Run2 6.04 0.50 2.43 6.26 3.57 4.05 0.22 3.07 1.62 
Run3 6.39 0.88 3.09 6.40 2.96 3.24 0.01 2.08 0.15 
 
RA-CC 
Cord 5 NTC CqDICER CqPTP1B CqHES1 CqDICER NEG CTL CqPTP1B NEG CTL CqHES1 NEG CTL Cqsi107 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG 
GAPDH 
Run1 40.00 28.68 31.80 25.64 28.55 23.42 28.02 20.40 27.71 17.57 19.82 
Run2 40.00 28.27 32.12 25.44 29.55 23.45 27.86 20.52 27.17 17.67 20.07 
Run3 40.00 28.39 31.80 25.71 28.95 23.42 28.22 20.46 27.99 17.52 19.88 
 
CC-RA 
Cord 5 Cqsi107 DICER Cqsi124 PTP1B Cqsi381 HES1 CqDICER NEG CTL Cq PTP1B NEG CTL Cqsi381 NEG CqDICER CqPTP1B Cq HES1 
Run1 8.28 4.09 8.07 8.73 -4.29 8.20 0.45 -8.38 0.13 
Run2 7.75 4.95 7.77 9.48 -3.72 7.79 1.73 -8.67 0.02 
Run3 7.93 3.81 8.19 9.07 -4.57 8.34 1.14 -8.38 0.15 
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RA-CC 
Cord 6 NTC CqDICER CqPTP1B CqHES1 CqDICER NEG CTL CqPTP1B NEG CTL CqHES1 NEG CTL Cqsi107 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG 
GAPDH 
Run1 40.00 29.92 26.62 29.02 28.78 22.84 27.51 24.33 18.05 21.26 18.89 
Run2 40.00 30.07 26.54 30.16 28.68 22.79 27.39 24.09 18.14 21.45 18.78 
Run3 39.68 30.04 27.11 29.70 28.33 22.84 27.72 23.99 17.97 21.12 19.32 
 
CC-RA 
Cord 6 Cqsi107 DICER Cqsi124 PTP1B Cqsi381 HES1 CqDICER NEG CTL Cq PTP1B NEG CTL Cqsi381 NEG CqDICER CqPTP1B Cq HES1 
Run1 5.59 8.57 7.76 9.89 4.79 8.62 4.30 -3.78 0.86 
Run2 5.98 8.40 8.71 9.90 4.65 8.61 3.92 -3.75 -0.10 
Run3 6.05 9.14 8.58 9.01 4.87 8.40 2.96 -4.27 -0.18 
 
 
RA-CC 
Cord 11 NTC CqDICER CqPTP1B CqHES1 CqDICER NEG CTL CqPTP1B NEG CTL CqHES1 NEG CTL Cqsi107 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG 
GAPDH 
Run1 40.00 27.07 25.97 26.39 26.71 23.27 27.69 15.77 15.49 16.02 15.59 
Run2 40.00 27.77 25.84 26.24 27.02 23.34 27.12 15.87 15.79 16.05 15.68 
Run3 40.00 27.12 25.89 27.06 28.01 23.39 27.18 15.93 15.61 16.00 15.64 
 
CC-RA 
Cord 11 Cqsi107 DICER Cqsi124 PTP1B Cqsi381 HES1 CqDICER NEG CTL Cq PTP1B NEG CTL Cqsi381 NEG CqDICER CqPTP1B Cq HES1 
Run1 11.30 10.48 10.37 11.12 7.78 12.10 -0.18 -2.70 1.73 
Run2 11.90 10.05 10.19 11.34 7.55 11.44 -0.56 -2.50 1.25 
Run3 11.19 10.28 11.06 12.37 7.78 11.54 1.18 -2.50 0.48 
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Neural Markers Post Transfection 
MSC 
Cord 9 NTC Cqsi107 NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 37.72 36.32 34.88 40.00 34.12 23.64 24.41 26.54 26.92 
Run2 36.90 36.99 34.10 40.00 34.57 23.66 24.22 26.04 27.00 
Run3 37.16 36.50 34.63 40.00 34.09 24.02 24.55 26.31 27.18 
 
MSC 
Cord 9 Cqsi107NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi107 NES Cqsi124 NES Cqsi381 NES 
Run1 12.68 10.47 13.46 7.20 -5.48 -3.27 -6.26 
Run2 13.33 9.88 13.96 7.57 -5.76 -2.31 -6.39 
Run3 12.48 10.08 13.69 6.91 -5.57 -3.17 -6.78 
 
MSC 
Cord 9 NTC Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 37.72 32.07 32.91 30.98 34.69 23.64 24.41 26.54 26.92 
Run2 36.90 31.92 32.71 31.37 34.08 23.66 24.22 26.04 27.00 
Run3 37.16 32.33 32.85 31.12 34.25 24.02 24.55 26.31 27.18 
 
MSC 
Cord 9 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 
Run1 8.43 8.50 4.44 7.77 -0.66 -0.73 3.33 
Run2 8.26 8.49 5.33 7.08 -1.18 -1.41 1.75 
Run3 8.31 8.30 4.81 7.07 -1.24 -1.23 2.26 
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MSC 
Cord 9 NTC Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 26.66 29.25 27.86 28.75 23.51 26.17 26.30 27.45 
Run2 40.00 26.84 29.33 27.56 29.42 23.64 26.23 26.06 27.58 
Run3 40.00 26.76 28.88 28.24 29.38 23.29 25.72 26.21 27.57 
 
MSC 
Cord 9 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 
Run1 3.15 3.08 1.56 1.30 -1.85 -1.78 -0.26 
Run2 3.20 2.10 1.50 1.84 -1.36 -1.26 0.34 
Run3 3.47 3.16 2.03 1.81 -1.66 -1.35 -0.22 
 
MSC 
Cord 9 NTC Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 37.72 40.00 40.00 37.78 39.89 23.64 24.41 26.54 26.92 
Run2 36.90 39.49 40.00 40.00 40.00 23.66 24.22 26.04 27.00 
Run3 37.16 40.00 40.00 40.00 40.00 24.02 24.55 26.31 27.18 
 
MSC 
Cord 9 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 
Run1 16.36 15.59 11.24 12.97 -3.39 -2.62 1.73 
Run2 15.83 15.78 13.96 13.00 -2.83 -2.78 -0.96 
Run3 15.98 15.45 13.69 12.82 -3.16 -2.63 -0.87 
 
MSC 
Cord 9 NTC Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 37.72 40.00 40.00 40.00 39.39 23.64 24.41 26.54 26.92 
Run2 36.90 40.00 40.00 40.00 40.00 23.66 24.22 26.04 27.00 
Run3 37.16 40.00 40.00 40.00 40.00 24.02 24.55 26.31 27.18 
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MSC 
Cord 9 Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU 
Run1 16.36 15.59 13.46 12.47 -3.89 -3.12 -0.99 
Run2 16.34 15.78 13.96 13.00 -3.34 -2.78 -0.96 
Run3 15.98 15.45 13.69 12.82 -3.16 -2.63 -0.87 
 
 
 
MSC 
Cord 11 NTC Cqsi107 NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 40.00 32.97 40.00 33.58 28.76 23.48 28.06 27.87 
Run2 40.00 40.00 33.50 40.00 34.02 29.49 23.78 27.84 27.12 
Run3 40.00 40.00 33.33 40.00 33.97 27.91 23.60 27.95 27.34 
 
MSC 
Cord 11 Cqsi107NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi107 NES Cqsi124 NES Cqsi381 NES 
Run1 11.24 9.49 11.94 5.71 -5.53 -3.78 -6.23 
Run2 10.51 9.72 12.16 6.90 -3.61 -2.82 -5.26 
Run3 12.09 9.73 12.05 6.63 -5.46 -3.10 -5.42 
 
MSC 
Cord 11 NTC Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 35.84 31.37 28.88 32.34 28.76 23.48 28.06 27.87 
Run2 40.00 35.22 31.57 29.52 33.43 29.49 23.78 27.84 27.12 
Run3 40.00 35.03 31.99 28.85 33.10 27.91 23.60 27.95 27.34 
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MSC 
Cord 11 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 
Run1 7.08 7.89 0.82 4.47 -2.61 -3.42 3.65 
Run2 5.73 7.79 1.68 6.31 0.58 -1.48 4.63 
Run3 7.12 8.39 0.90 5.76 -1.36 -2.63 4.86 
 
MSC 
Cord 11 NTC Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 19.33 19.42 19.47 18.93 15.77 15.49 16.02 15.59 
Run2 40.00 19.05 19.70 19.32 19.01 15.87 15.79 16.05 15.68 
Run3 40.00 19.53 19.27 19.22 18.73 15.93 15.61 16.00 15.64 
 
 
 
MSC 
Cord 11 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 
Run1 3.56 3.93 3.45 3.34 -0.22 -0.59 -0.11 
Run2 3.18 3.91 3.27 3.33 0.15 -0.58 0.06 
Run3 3.60 3.66 3.22 3.09 -0.51 -0.57 -0.13 
 
MSC 
Cord 11 NTC Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 40.00 40.00 40.00 40.00 23.64 24.41 26.54 26.92 
Run2 40.00 40.00 40.00 40.00 40.00 23.66 24.22 26.04 27.00 
Run3 40.00 40.00 40.00 40.00 40.00 24.02 24.55 26.31 27.18 
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MSC 
Cord 11 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 
Run1 16.36 15.59 13.46 13.08 -3.28 -2.51 -0.38 
Run2 16.34 15.78 13.96 13.00 -3.34 -2.78 -0.96 
Run3 15.98 15.45 13.69 12.82 -3.16 -2.63 -0.87 
 
MSC 
Cord 11 NTC Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 40.00 40.00 40.00 40.00 23.64 24.41 26.54 26.92 
Run2 40.00 40.00 40.00 40.00 40.00 23.66 24.22 26.04 27.00 
Run3 40.00 40.00 40.00 40.00 40.00 24.02 24.55 26.31 27.18 
 
MSC 
Cord 11 Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU 
Run1 16.36 15.59 13.46 13.08 -3.28 -2.51 -0.38 
Run2 16.34 15.78 13.96 13.00 -3.34 -2.78 -0.96 
Run3 15.98 15.45 13.69 12.82 -3.16 -2.63 -0.87 
 
 
CC 
Cord 5 NTC Cqsi107 NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 33.80 31.59 29.28 29.38 29.90 27.68 24.04 24.62 26.29 
Run2 33.62 30.89 28.98 28.85 29.79 27.44 23.71 24.61 26.59 
Run3 33.21 30.36 28.17 29.19 31.02 27.72 23.70 24.36 26.35 
 
CC 
Cord 5 Cqsi107NES Cqsi124 NES Cqsi381 NES CqsiNEG NES ddCqsi107 NES ddCqsi124 NES Cqsi381 NES 
Run1 3.91 5.24 4.76 3.61 -0.30 -1.63 -1.15 
Run2 3.45 5.27 4.24 3.20 -0.25 -2.07 -1.04 
Run3 2.64 4.47 4.83 4.67 2.03 0.20 -0.16 
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CC 
Cord 5 NTC Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 33.80 28.92 27.17 26.93 28.20 27.68 24.04 24.62 26.29 
Run2 33.62 28.81 27.18 27.12 27.91 27.44 23.71 24.61 26.59 
Run3 33.21 28.45 27.06 27.08 28.31 27.72 23.70 24.36 26.35 
 
CC 
Cord 5 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 
Run1 1.24 3.13 2.31 1.91 0.67 -1.22 -0.40 
Run2 1.37 3.47 2.51 1.32 -0.05 -2.15 -1.19 
Run3 0.73 3.36 2.72 1.96 1.23 -1.40 -0.76 
 
CC 
Cord 5 NTC Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 31.87 29.10 26.40 30.61 28.01 23.11 21.62 24.59 24.82 
Run2 31.97 27.71 25.87 30.13 28.21 22.58 21.91 24.50 24.61 
Run3 31.93 28.38 24.60 30.70 24.28 22.63 21.82 24.70 26.43 
 
 
 
CC 
Cord 5 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 
Run1 5.99 4.78 6.02 3.19 -2.80 -1.59 -2.83 
Run2 5.13 3.96 5.63 3.60 -1.53 -0.36 -2.03 
Run3 5.75 2.78 6.00 -2.15 -7.90 -4.93 -8.15 
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CC 
Cord 5 NTC Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 33.80 29.78 27.07 28.56 29.71 27.68 24.04 24.62 26.29 
Run2 33.62 29.87 27.12 27.78 29.04 27.44 23.71 24.61 26.59 
Run3 33.21 29.81 26.76 27.76 29.81 27.72 23.70 24.36 26.35 
 
CC 
Cord 5 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 
Run1 2.10 3.03 3.94 3.42 1.32 0.39 -0.52 
Run2 2.43 3.41 3.17 2.45 0.02 -0.96 -0.72 
Run3 2.09 3.06 3.40 3.46 1.37 0.40 0.06 
 
CC 
Cord 5 NTC Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40,00 40.00 40.00 40.00 40.00 27.68 24.04 24.62 26.29 
Run2 40.00 40.00 40.00 40.00 40.00 27.44 23.71 24.61 26.59 
Run3 40.00 40.00 40.00 40.00 40.00 27.72 23.70 24.36 26.35 
 
CC 
Cord 5 Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU 
Run1 12.32 15.96 15.38 13.71 1.39 -2.25 -1.67 
Run2 12.56 16.29 15.39 13.41 0.85 -2.88 -1.98 
Run3 12.28 16.30 15.64 13.65 1.37 -2.65 -1.99 
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CC 
Cord 6 NTC Cqsi107 NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 32.95 31.83 30.59 30.03 30.25 28.82 26.06 27.23 26.54 
Run2 32.83 32.38 30.87 29.72 30.97 27.80 25.87 26.73 26.09 
Run3 32.85 32.49 30.34 29.68 31.02 28.24 26.26 26.39 27.24 
 
CC 
Cord 6 Cqsi107NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi107 NES Cqsi124 NES Cqsi381 NES 
Run1 3.01 4.53 2.80 3.71 0.70 -0.82 0.91 
Run2 4.58 5.00 2.99 4.88 0.30 -0.12 1.89 
Run3 4.25 4.08 3.29 3.78 -0.47 -0.30 0.49 
 
CC 
Cord 6 NTC Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 32.95 28.75 28.79 28.39 28.19 28.82 26.06 27.23 26.54 
Run2 32.83 28.35 28.46 28.03 28.81 27.80 25.87 26.73 26.09 
Run3 32.85 28.42 27.76 28.18 29.29 28.24 26.26 26.39 27.24 
 
CC 
Cord 6 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 
Run1 -0.07 2.73 1.16 1.65 1.72 -1.08 0.49 
Run2 0.55 2.59 1.30 2.72 2.17 0.13 1.42 
Run3 0.18 1.50 1.79 2.05 1.87 0.55 0.26 
 
CC 
Cord 6 NTC Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 31.87 28.08 30.33 30.64 30.14 23.16 25.63 25.17 26.78 
Run2 31.97 28.76 30.09 30.40 30.57 23.09 25.71 24.94 26.80 
Run3 31.93 28.91 31.12 30.57 29.52 23.08 25.59 25.06 26.80 
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CC 
Cord 6 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 
Run1 4.92 4.70 5.47 3.36 -1.56 -1.34 -2.11 
Run2 5.67 4.38 5.46 3.77 -1.90 -0.61 -1.69 
Run3 5.83 5.53 5.51 2.72 -3.11 -2.81 -2.79 
 
CC 
Cord 6 NTC Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 32.95 29.33 28.94 28.93 29.71 28.82 26.06 27.23 26.54 
Run2 32.83 30.25 29.02 29.26 29.90 27.80 25.87 26.73 26.09 
Run3 32.85 30.21 29.19 28.93 29.79 28.24 26.26 26.39 27.24 
 
CC 
Cord 6 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 
Run1 0.51 2.88 1.70 3.17 2.66 0.29 1.47 
Run2 2.45 3.15 2.53 3.81 1.36 0.66 1.28 
Run3 1.97 2.93 2.54 2.55 0.58 -0.38 0.01 
 
CC 
Cord 6 NTC Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 32.95 40.00 40.00 40.00 30.11 28.82 26.06 27.23 26.54 
Run2 32.83 40.00 40.00 40.00 30.29 27.80 25.87 26.73 26.09 
Run3 32.85 40.00 40.00 40.00 29.91 28.24 26.26 26.39 27.24 
 
CC 
Cord 6 Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU 
Run1 11.18 13.94 12.77 3.57 -7.61 -10.37 -9.20 
Run2 12.20 14.13 13.27 4.20 -8.00 -9.93 -9.07 
Run3 11.76 13.74 13.61 2.67 -9.09 -11.07 -10.94 
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CC 
Cord 13 NTC Cqsi107 NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 35.91 33.09 34.10 33.58 28.76 23.48 28.06 29.03 
Run2 40.00 36.49 33.50 33.83 32.91 29.49 23.78 27.84 28.81 
Run3 40.00 36.73 33.18 33.89 33.11 28.91 23.60 27.95 28.90 
 
CC 
Cord 13 Cqsi107NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi107 NES Cqsi124 NES Cqsi381 NES 
Run1 7.15 9.61 6.04 4.55 -2.60 -5.06 -1.49 
Run2 7.00 9.72 5.99 4.10 -2.90 -5.62 -1.89 
Run3 7.82 9.58 5.94 4.21 -3.61 -5.37 -1.73 
 
CC 
Cord 13 NTC Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 32.21 31.37 28.88 32.34 28.76 23.48 28.06 29.03 
Run2 40.00 33.02 31.57 29.52 33.43 29.49 23.78 27.84 28.81 
Run3 40.00 32.61 31.99 28.85 32.80 28.91 23.60 27.95 28.90 
 
CC 
Cord 13 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 
Run1 3.45 7.89 0.82 3.31 -0.14 -4.58 2.49 
Run2 3.53 7.79 1.68 4.62 1.09 -3.17 2.94 
Run3 3.70 8.39 0.90 3.90 0.20 -4.49 3.00 
 
CC 
Cord 13 NTC Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 39.61 40.00 35.55 40.00 36.06 29.01 25.31 30.17 27.10 
Run2 39.67 40.00 35.04 40.00 36.68 29.41 24.80 29.46 27.12 
Run3 40.00 40.00 35.70 40.00 36.33 29.84 24.82 30.41 26.89 
248 
 
 
CC 
Cord 13 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 
Run1 10.99 10.24 9.83 8.96 -2.03 -1.28 -0.87 
Run2 10.59 10.24 10.54 9.56 -1.03 -0.68 -0.98 
Run3 10.16 10.88 9.59 9.44 -0.72 -1.44 -0.15 
 
CC 
Cord 13 NTC Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 36.16 32.40 34.40 31.41 28.76 23.48 28.06 29.03 
Run2 40.00 36.21 32.71 34.02 32.02 29.49 23.78 27.84 28.81 
Run3 40.00 36.90 32.36 34.13 31.54 28.91 23.60 27.95 28.90 
 
CC 
Cord 13 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 
Run1 7.40 8.92 6.34 2.38 -5.02 -6.54 -3.96 
Run2 6.72 8.93 6.18 3.21 -3.51 -5.72 -2.97 
Run3 7.99 8.76 6.18 2.64 -5.35 -6.12 -3.54 
 
CC 
Cord 13 NTC Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 30.18 32.60 30.22 31.25 28.76 23.48 28.06 29.03 
Run2 40.00 30.70 32.31 30.71 31.48 29.49 23.78 27.84 28.81 
Run3 40.00 30.63 32.53 30.54 30.09 28.91 23.60 27.95 28.90 
 
CC 
Cord 13 Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU 
Run1 1.42 9.12 2.16 2.22 0.80 -6.90 0.06 
Run2 1.21 8.53 2.87 2.67 1.46 -5.86 -0.20 
Run3 1.72 8.93 2.59 1.19 -0.53 -7.74 -1.40 
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CC-RA 
Cord 5 NTC Cqsi107 NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 28.98 27.89 24.03 26.16 22.82 22.40 18.68 19.92 
Run2 40.00 28.78 27.99 23.98 25.63 23.40 22.15 18.71 19.96 
Run3 40.00 29.40 27.58 24.01 26.91 23.59 22.48 18.57 19.80 
 
CC-RA 
Cord 5 Cqsi107NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi107 NES Cqsi124 NES Cqsi381 NES 
Run1 6.16 5.49 5.35 6.24 0.08 0.75 0.89 
Run2 5.38 5.84 5.27 5.67 0.29 -0.17 0.40 
Run3 5.81 5.10 5.44 7.11 1.30 2.01 1.67 
 
CC-RA 
Cord 5 NTC Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 26.86 27.18 22.65 24.63 22.82 22.40 18.68 19.92 
Run2 40.00 26.90 26.90 22.56 24.32 23.40 22.15 18.71 19.96 
Run3 40.00 27.07 27.13 22.59 24.20 23.59 22.48 18.57 19.80 
 
CC-RA 
Cord 5 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 
Run1 4.04 4.78 3.97 4.71 0.67 -0.07 0.74 
Run2 3.50 4.75 3.85 4.36 0.86 -0.39 0.51 
Run3 3.48 4.65 4.02 4.40 0.92 -0.25 0.38 
 
CC-RA 
Cord 5 NTC Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 28.09 35.15 25.88 26.96 19.31 26.96 16.51 17.52 
Run2 40.00 27.95 35.32 25.86 27.56 19.25 26.57 16.60 17.53 
Run3 40.00 28.17 35.53 25.45 26.93 19.21 26.23 16.69 17.47 
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CC-RA 
Cord 5 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 
Run1 8.78 8.19 9.37 9.44 0.66 1.25 0.07 
Run2 8.70 8.75 9.26 10.03 1.33 1.28 0.77 
Run3 8.96 9.30 8.76 9.46 0.50 0.16 0.70 
 
CC-RA 
Cord 5 NTC Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 28.47 26.89 23.66 24.97 22.82 22.40 18.68 19.92 
Run2 40.00 28.11 26.95 23.65 25.22 23.40 22.15 18.71 19.96 
Run3 40.00 28.37 26.21 23.62 25.15 23.59 22.48 18.57 19.80 
 
CC-RA 
Cord 5 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 
Run1 5.65 4.49 4.98 5.05 -0.60 0.56 0.07 
Run2 4.71 4.80 4.94 5.26 0.55 0.46 0.32 
Run3 4.78 3.73 5.05 5.35 0.57 1.62 0.30 
 
CC-RA 
Cord 5 NTC Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 40.00 40.00 40.00 40.00 22.82 22.40 18.68 19.92 
Run2 40.00 40.00 40.00 40.00 40.00 23.40 22.15 18.71 19.96 
Run3 40.00 40.00 40.00 40.00 40.00 23.59 22.48 18.57 19.80 
 
CC-RA 
Cord 5 Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU 
Run1 17.18 17.60 21.32 20.08 2.90 2.48 -1.24 
Run2 16.60 17.85 21.29 20.04 3.44 2.19 -1.25 
Run3 16.41 17.52 21.43 20.20 3.79 2.68 -1.23 
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CC-RA 
Cord 6 NTC Cqsi107 NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 34.44 40.00 30.66 26.51 27.47 29.15 17.59 23.24 22.44 
Run2 34.82 40.00 33.04 27.27 25.54 27.64 17.23 22.84 22.37 
Run3 34.74 38.66 22.80 26.65 24.62 27.91 17.45 22.45 21.81 
 
CC-RA 
Cord 6 Cqsi107NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi107 NES Cqsi124 NES Cqsi381 NES 
Run1 10.85 13.07 3.27 5.03 -5.82 -8.04 1.76 
Run2 12.36 15.81 4.43 3.17 -9.19 -12.64 -1.26 
Run3 10.75 5.35 4.20 2.81 -7.94 -2.54 -1.39 
 
CC-RA 
Cord 6 NTC Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 34.44 32.55 32.80 26.95 25.25 29.15 17.59 23.24 22.44 
Run2 34.82 31.73 32.68 25.56 25.65 27.64 17.23 22.84 22.37 
Run3 34.74 31.30 33.45 25.30 24.96 27.91 17.45 22.45 21.81 
 
CC-RA 
Cord 6 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 
Run1 3.40 15.21 3.71 2.81 -0.59 -12.40 -0.90 
Run2 4.09 15.45 2.72 3.28 -0.81 -12.17 0.56 
Run3 3.39 16.00 2.85 3.15 -0.24 -12.85 0.30 
 
CC-RA 
Cord 6 NTC Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 29.45 23.87 27.77 27.76 22.84 17.28 20.08 21.15 
Run2 40.00 28.70 24.08 27.01 28.70 22.74 17.16 20.08 21.02 
Run3 40.00 30.08 23.88 27.58 28.52 22.99 17.18 20.12 21.15 
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CC-RA 
Cord 6 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 
Run1 6.61 6.59 7.69 6.61 0.00 0.02 -1.08 
Run2 5.96 6.92 6.93 7.68 1.72 0.76 0.75 
Run3 7.09 6.70 7.46 7.37 0.28 0.67 -0.09 
 
CC-RA 
Cord 6 NTC Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 34.44 34.13 34.00 25.27 25.91 29.15 17.59 23.24 22.44 
Run2 34.82 40.00 31.30 26.22 24.94 27.64 17.23 22.84 22.37 
Run3 34.74 40.00 33.83 25.69 24.29 27.91 17.45 22.45 21.81 
 
CC-RA 
Cord 6 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 
Run1 4.98 16.41 2.03 3.47 -1.51 -12.94 1.44 
Run2 12.36 14.07 3.38 2.57 -9.79 -11.50 -0.81 
Run3 12.09 16.38 3.24 2.48 -9.61 -13.90 -0.76 
 
CC-RA 
Cord 6 NTC Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 34.44 40.00 34.77 40.00 33.64 29.15 17.59 23.24 22.44 
Run2 34.82 40.00 36.38 40.00 33.45 27.64 17.23 22.84 22.37 
Run3 34.74 40.00 37.81 40.00 33.72 27.91 17.45 22.45 21.81 
 
CC-RA 
Cord 6 Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU 
Run1 10.85 17.18 16.76 11.20 0.35 -5.98 -5.56 
Run2 12.36 19.15 17.16 11.08 -1.28 -8.07 -6.08 
Run3 12.09 20.36 17.55 11.91 -0.18 -8.45 -5.64 
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CC-RA 
Cord 13 NTC Cqsi107 NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 39.25 25.94 27.03 26.87 26.47 17.55 16.78 17.41 17.41 
Run2 38.84 25.68 26.62 26.91 26.48 17.65 16.92 17.41 17.50 
Run3 40.00 25.62 26.82 27.06 26.25 17.83 16.97 17.36 17.74 
 
CC-RA 
Cord 13 Cqsi107NES Cqsi124 NES Cqsi381 NES CqsiNEG NES Cqsi107 NES Cqsi124 NES Cqsi381 NES 
Run1 8.39 10.25 9.46 9.06 0.67 -1.19 -0.40 
Run2 8.03 9.70 9.50 8.98 0.95 -0.72 -0.52 
Run3 7.79 9.85 9.70 8.51 0.72 -1.34 -1.19 
 
CC-RA 
Cord 13 NTC Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 39.25 26.41 33.92 24.82 25.96 17.55 16.78 17.41 17.41 
Run2 38.84 26.51 34.80 24.93 25.94 17.65 16.92 17.41 17.50 
Run3 40.00 26.23 35.87 24.91 26.16 17.83 16.97 17.36 17.74 
 
CC-RA 
Cord 13 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 CqsiNEG TUBB3 Cqsi107 TUBB3 Cqsi124 TUBB3 Cqsi381 TUBB3 
Run1 8.86 17.14 7.41 8.55 -0.31 -8.59 1.14 
Run2 8.86 17.88 7.52 8.44 -0.42 -9.44 0.92 
Run3 8.40 18.90 7.55 8.42 0.02 -10.48 0.87 
 
CC-RA 
Cord 13 NTC Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 40.00 18.93 18.42 19.17 18.93 15.77 15.49 16.02 15.59 
Run2 40.00 19.05 18.70 19.32 19.01 15.87 15.79 16.05 15.68 
Run3 40.00 18.83 18.27 19.02 18.73 15.93 15.61 16.00 15.64 
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CC-RA 
Cord 13 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 CqsiNEG ND1 Cqsi107 ND1 Cqsi124 ND1 Cqsi381 ND1 
Run1 3.16 2.93 3.15 3.34 0.18 0.41 0.19 
Run2 3.18 2.91 3.27 3.33 0.15 0.42 0.06 
Run3 2.90 2.66 3.02 3.09 0.19 0.43 0.07 
 
CC-RA 
Cord 13 NTC Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 39.25 25.88 30.40 25.22 25.85 17.55 16.78 17.41 17.41 
Run2 38.84 25.95 31.38 25.54 25.82 17.65 16.92 17.41 17.50 
Run3 40.00 26.22 31.09 25.18 25.90 17.83 16.97 17.36 17.74 
 
CC-RA 
Cord 13 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 CqsiNEG MAP2 Cqsi107 MAP2 Cqsi124 MAP2 Cqsi381 MAP2 
Run1 8.33 13.62 7.81 8.44 0.11 -5.18 0.63 
Run2 8.30 14.46 8.13 8.32 0.02 -6.14 0.19 
Run3 8.39 14.12 7.82 8.16 -0.23 -5.96 0.34 
 
CC-RA 
Cord 13 NTC Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi07 GAPDH Cqsi124 GAPDH Cqsi381 GAPDH CqsiNEG GAPDH 
Run1 39.25 35.16 35.09 36.47 34.38 17.55 16.78 17.41 17.41 
Run2 38.84 33.74 34.86 34.96 34.88 17.65 16.92 17.41 17.50 
Run3 40.00 33.84 36.44 35.19 36.01 17.83 16.97 17.36 17.74 
 
CC-RA 
Cord 13 Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU CqsiNEG NEU Cqsi107 NEU Cqsi124 NEU Cqsi381 NEU 
Run1 17.61 18.31 19.06 16.97 -0.64 -1.34 -2.09 
Run2 16.09 17.94 17.55 17.38 1.29 -0.56 -0.17 
Run3 16.01 19.47 17.83 18.27 2.26 -1.20 0.44 
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Neurite Length Statistical Analysis 
  
Cell Type Statistic df P-value 
CC 0.951 25 0.262 
CC-RA 0.955 25 0.319 
Sharpio-Wilk Test of Normality 
 
Cell Type Mean N Std. Deviation Std. Error Mean 
CC 3.83 25 1.55 0.31 
CC-RA 15.08 25 3.64 0.73 
Paired Sample Statistics 
 
 
Mean Std. Deviation Std. Error Mean 
95% Confidence Interval of the 
Difference 
t df Sig. (2-tailed) Lower Upper 
-11.24960 4.26542 .85308 -13.01028 -9.48892 -13.187 24 0.000 
Paired Sample T-Test 
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RT-qPCR Statistical Analysis 
 
Marker Mann-Whitney U P-value Z Score 
CD73 0.000 0.000 -3.576 
CD90 0.000 0.000 -3.576 
CD105 0.000 0.000 -3.580 
CD34 32.500 0.480 -0.707 
CD45 5.000 0.002 -3.135 
Mann-Whitney U Analysis CD Marker expression between MSC and CC 
 
 
Marker Mann-Whitney U P-value Z Score 
CD73 9.000 0.005 -2.782 
CD90 0.000 0.000 -3.576 
CD105 20.000 0.070 -1.810 
CD34 40.500 1.000 .000 
CD45 15.000 0.024 -2.252 
Mann-Whitney U Analysis CD Marker expression between CC and CC-RA  
 
 
Marker Mann-Whitney U P-value Z Score 
NES 0.000 0.000 -3.576 
SOX2 0.000 0.000 -3.576 
OCT4 0.000 0.000 -3.576 
TUBB3 0.000 0.000 -3.576 
MASH1 14.000 0.019 -2.341 
ND1 9.000 0.005 -2.782 
MAP2 0.000 0.000 -3.576 
NEU 0.000 0.000 -3.578 
Mann-Whitney U Analysis Neural Marker expression between MSC and CC 
 
 
Marker Mann-Whitney U P-value Z Score 
NES 18.000 0.047 -1.987 
SOX2 8.000 0.004 -2.870 
OCT4 9.000 0.005 -2.782 
TUBB3 11.000 0.009 -2.605 
MASH1 0.000 0.004 -2.870 
ND1 34.000 0.566 -0.574 
MAP2 28.000 0.270 -1.104 
NEU 27.000 0.233 -1.193 
Mann-Whitney U Analysis between CC and CC-RA Neural Marker expression 
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Cell 
Type 
Target Mann-Whitney U P-value Z Score 
MSC 
DICER 1.000 0.006 -2.722 
PTP1B 15.000 0.631 -0.480 
HES1 0.000 0.004 -2.882 
CC 
DICER 1.000 0.000 -3.488 
PTP1B 0.000 0.000 -3.576 
HES1 30.000 0.354 -0.927 
CC-RA 
DICER 22.000 0.102 -1.634 
PTP1B 15.000 0.024 -2.253 
HES1 30.000 0.354 -0.927 
Mann-Whitney U Analysis for target genes  
 
 
NES 
Cell 
Type 
siRNA Mann-Whitney U P-value Z Score 
MSC 
siR-107 0.000 0.004 -2.882 
siR-124 0.000 0.004 -2.882 
siR-381 0.000 0.004 -2.882 
CC 
siR-107 36.000 0.691 -0.397 
siR-124 11.00 0.009 -2.605 
siR-381 31.00 o.402 -0.839 
CC-RA 
siR-107 25.000 0.171 -1.369 
siR-124 23.000 0.122 -1.545 
siR-381 39.000 0.895 -0.132 
Mann-Whitney U Analysis for NES expression post transfection 
 
 
TUBB3 
Cell 
Type 
siRNA Mann-Whitney U P-value Z Score 
MSC 
siR-107 12.500 0.378 -0.882 
siR-124 0.000 0.004 -2.882 
siR-381 0.000 0.004 -2.882 
CC 
siR-107 22.000 0.102 -1.634 
siR-124 22.000 0.102 -1.634 
siR-381 19.500 0.064 -1.855 
CC-RA 
siR-107 39.000 0.895 -0.133 
siR-124 10.000 0.007 -2.693 
siR-381 31.000 0.402 -0.839 
Mann-Whitney U Analysis for TUBB3 expression post transfection 
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ND1 
Cell 
Type 
siRNA Mann-Whitney U P-value Z Score 
MSC 
siR-107 6.000 0.055 -1.922 
siR-124 7.000 0.078 -1.761 
siR-381 17.000 0.873 -0.160 
CC 
siR-107 18.000 0.047 -1.987 
siR-124 22.000 0.102 -1.634 
siR-381 18.000 0.047 -1.987 
CC-RA 
siR-107 30.500 0.377 -0.883 
siR-124 29.000 0.310 -1.015 
siR-381 35.000 0.627 -0.486 
Mann-Whitney U Analysis for ND1 expression post transfection 
 
 
MAP2 
Cell 
Type 
siRNA Mann-Whitney U P-value Z Score 
MSC 
siR-107 0.000 0.004 -2.903 
siR-124 0.000 0.004 -2.908 
siR-381 6.000 0.053 -1.935 
CC 
siR-107 29.500 0.331 -0.972 
siR-124 28.000 0.270 -1.104 
siR-381 30.500 0.377 -0.884 
CC-RA 
siR-107 25.000 0.171 -1.369 
siR-124 18.000 0.47 -1.987 
siR-381 31.500 0.427 -0.795 
Mann-Whitney U Analysis for MAP2 expression post transfection 
 
NEU 
Cell 
Type 
siRNA Mann-Whitney U P-value Z Score 
MSC 
siR-107 0.000 0.004 -2.908 
siR-124 0.000 0.004 -2.908 
siR-381 0.000 0.004 -2.908 
CC 
siR-107 39.000 0.895 -0.133 
siR-124 9.000 0.005 -2.783 
siR-381 28.000 0.269 -1.104 
CC-RA 
siR-107 27.000 0.233 -1.192 
siR-124 30.000 0.354 -0.927 
siR-381 26.000 0.200 -1.2381 
Mann-Whitney U Analysis for NEU expression post transfection 
